tag:blogger.com,1999:blog-36448786958466332942024-02-19T13:52:58.147-03:00TektonikeTHANK YOU FOR YOUR SUPPORT
OBRIGADO PELO APOIO !
Edificando o Homem <br>
Estudo das deformações da crosta terrestre devidas às forças internas que sobre ela operam.<br>
A Arte dos Marceneiros e Carpinteiros <br>
A Arte da Edificação do Ser Humano na Net <br>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.comBlogger210125truetag:blogger.com,1999:blog-3644878695846633294.post-58755181354622397622024-02-13T06:58:00.001-03:002024-02-13T06:58:05.963-03:00Junte-se a nós ! Excelente Plataforma ! Segura e Rápida!<center>
<p><a href="https://www.roboforex.com/?utm_source=domain&utm_medium=affbanerimg&utm_content=size250_250&utm_campaign=affconditions&a=zrmj" target="_blank" class="zrmj"><img src="http://my.roboforex.com/files/banners/38_en_rbfx_250x250__2431791955bc1790c6214431f7f3d082.jpg" /></a></p>
</center>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>HiTekhttp://www.blogger.com/profile/13927380657702149848noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-31613428387938275322023-08-18T21:46:00.007-03:002023-08-19T03:59:23.838-03:00A True Father of Faith ! Fr. Mark Beard. Louisiana RIP🙏🏼♥️❤️♥️🙏🏼<p>A True Father of Faith, eager to transmit to the children entrusted to him by God the simple Path of Salvation and Eternal Life</p><p><a href="https://www.tiktok.com/@altarboy33ad/video/7263692979163155758?refer=embed" target="_blank">A True and authentic father of faith</a><br /></p>
<blockquote cite="https://www.tiktok.com/@altarboy33ad/video/7263692979163155758" class="tiktok-embed" data-video-id="7263692979163155758" style="max-width: 605px; min-width: 325px;"> <section> <a href="https://www.tiktok.com/@altarboy33ad?refer=embed" target="_blank" title="@altarboy33ad">@altarboy33ad</a> <p></p> <a href="https://www.tiktok.com/music/original-sound-7263692996405840686?refer=embed" target="_blank" title="♬ original sound - altarboy33ad">♬ original sound - altarboy33ad</a></section></blockquote><p> </p><h4 style="text-align: left;">Traduzindo o que disse o Pregador ! (<span>Fr. Mark Beard. Louisiana RIP🙏🏼♥️❤️♥️🙏🏼)</span></h4><h4 style="text-align: left;">Ouça o que estou lhe dizendo<br />Eu não me importo onde você vai para o serviço, <br />mas se você não está na Igreja Católica como católico, <br />você não está recebendo a Eucaristia, <br />então suas chances de vida eterna tornam-se extremamente mitigadas.</h4><h4 style="text-align: left;">O que estou tentando fazer você entender <br />é que você não pode escolher os mandamentos,<br />você não pode escolher se está dentro ou fora<br />se você é católico ou não<br />ou você está caminhando em direção a Ele ou está se afastando d'Ele, especialmente a missa e a eucaristia é tudo. </h4><h4 style="text-align: left;">Ele está lhe dizendo: "- se Eu não estiver em você e você não estiver em Mim, você não terá a vida eterna". </h4><h4 style="text-align: center;"> ADORAÇÂO AO SANTISSIMO SACRAMENTO</h4><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQTknCQTC3uFPgQCK432r9nqbBdUIhJveqOVl4zTsCyIkje6wtC-WbUhu13_qd4znNahnHK4MLNW29ZZHUm48XzfWbDZeDS3GdYJG3ASjAIE4Dl3GCPcajMfYRsHQhpPugXDr2KDTm_ttP3t9MGvjtQ2DD8t4ws8hzYW7kuG_QSpWXBZ7ye38K1FyS6vU/s740/Adoradores.jpg" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="492" data-original-width="740" height="359" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQTknCQTC3uFPgQCK432r9nqbBdUIhJveqOVl4zTsCyIkje6wtC-WbUhu13_qd4znNahnHK4MLNW29ZZHUm48XzfWbDZeDS3GdYJG3ASjAIE4Dl3GCPcajMfYRsHQhpPugXDr2KDTm_ttP3t9MGvjtQ2DD8t4ws8hzYW7kuG_QSpWXBZ7ye38K1FyS6vU/w541-h359/Adoradores.jpg" width="541" /></a></div><br /><h4 style="text-align: center;">CRISTO EUCARISTICO, ESSÊNCIA DA FÉ CATÓLICA</h4><h4 style="text-align: center;">LOUVADO SEJA !</h4><div class="separator" style="clear: both; text-align: center;"></div><div class="separator" style="clear: both; text-align: center;"><iframe allowfullscreen="" class="BLOG_video_class" height="266" src="https://www.youtube.com/embed/M4NDI15UQhU" width="320" youtube-src-id="M4NDI15UQhU"></iframe></div><br /><h4 style="text-align: center;">ADOREMOS !<br /></h4><h4 style="text-align: center;"> </h4> <script async="" src="https://www.tiktok.com/embed.js"></script><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>HiTekhttp://www.blogger.com/profile/13927380657702149848noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-80058690511661001902023-07-30T10:51:00.002-03:002023-07-30T10:51:37.863-03:00Atualizações: E AGORA ÇIENTISTAS EMPIRISTAS NAS MASSAS ???<div class="separator" style="clear: both; text-align: center;"><iframe allowfullscreen='allowfullscreen' webkitallowfullscreen='webkitallowfullscreen' mozallowfullscreen='mozallowfullscreen' width='400' height='322' src='https://www.blogger.com/video.g?token=AD6v5dxbOee3ehjVSM_Q1Bf3azPR3Htu4z27-5Bk3FarDxZy2f-2Shxj0sM4QvaeinFGLYapMpaYYcy0_kkl1eLTcw' class='b-hbp-video b-uploaded' frameborder='0'></iframe></div><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-16871183223107999332022-04-15T23:37:00.001-03:002022-04-15T23:39:10.427-03:00<h2 style="text-align: center;"><b> <span data-offset-key="fges4-0-0"><span data-text="true">A Providencia está lhe alcançando</span></span></b></h2><p style="text-align: center;"></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiiDi9cpOutyeIIUb-u0TXGQucV1oWHPgdKXdVJPnCLmRBzrSCIryh_uoo26beVvarhVrZQwv32Nr_Hk6-tWo06VfxDw4vBwK24ak6TBGcpM9IBzqhS-vhjH0gKmjDW4imhKf9vwBQUw_yfV_HivzW6kRKwmDzyhr0FftHxd6ZnfkLv2cA2Mo7Aplzy/s490/image008.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="490" data-original-width="381" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiiDi9cpOutyeIIUb-u0TXGQucV1oWHPgdKXdVJPnCLmRBzrSCIryh_uoo26beVvarhVrZQwv32Nr_Hk6-tWo06VfxDw4vBwK24ak6TBGcpM9IBzqhS-vhjH0gKmjDW4imhKf9vwBQUw_yfV_HivzW6kRKwmDzyhr0FftHxd6ZnfkLv2cA2Mo7Aplzy/s320/image008.jpg" width="249" /></a></div><br /><p></p><p>Não deixe de assistir esse video ! IMPORTANTISSIMO !<br />
PEDIMOS A DEUS QUE NOS LIVRE DO MAL !<br />
SE VOCE CHEGOU AQUI É PORQUE ESTA MENSAGEM É PARA VOCE !<br />
DIVULGUE E COMPARTILHE PARA ALCANÇAR AQUELES QUE MERECEM ASSISTI-LO !<br />
<a aria-label="https://youhitek.blogspot.com/2022/04/pedimos-deus-que-nos-livre-do-mal.html?spref=tw" class="button button--link button--external-link" href="https://youhitek.blogspot.com/2022/04/pedimos-deus-que-nos-livre-do-mal.html?spref=tw" rel="noopener noreferrer" target="_blank" title="https://youhitek.blogspot.com/2022/04/pedimos-deus-que-nos-livre-do-mal.html?spref=tw"><span class="button__content"><span class="button__label" dir="auto">https://youhitek.blogspot.com/2022/04/pedimos-deus-que-nos-livre-do-mal.html?spref=tw</span></span></a><a aria-label="https://youhitek.blogspot.com/2022/04/pedimos-deus-que-nos-livre-do-mal.html?spref=tw" class="button button--link button--external-link" href="https://youhitek.blogspot.com/2022/04/pedimos-deus-que-nos-livre-do-mal.html?spref=tw" rel="noopener noreferrer" target="_blank" title="https://youhitek.blogspot.com/2022/04/pedimos-deus-que-nos-livre-do-mal.html?spref=tw"><span class="button__content"><svg aria-hidden="true" class="icon icon--ExternalLink" fill="none" height="16" stroke-linecap="round" stroke-linejoin="round" stroke-width="2" stroke="currentColor" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"><g></g></svg></span></a></p><div data-contents="true"><div data-block="true" data-editor="bnomv" data-offset-key="fges4-0-0"><div class="public-DraftStyleDefault-block public-DraftStyleDefault-ltr" data-offset-key="fges4-0-0"><span data-offset-key="fges4-0-0"><span data-text="true">A Providencia está lhe alcançando</span></span></div><div class="public-DraftStyleDefault-block public-DraftStyleDefault-ltr" data-offset-key="fges4-0-0"><span data-offset-key="fges4-0-0"><span data-text="true"> </span></span><span style="color: #1d9bf0;"><span data-offset-key="fges4-1-0"><span data-text="true">https://odysee.com/@TEKTONIKE:b/Providencia:c?r=Lo9tnMEFCL1RKEA3HgNdPSDdg6JimhUT</span></span></span><span data-offset-key="fges4-2-0"><span data-text="true"> </span></span><span style="color: #1d9bf0;"><span data-offset-key="fges4-3-0"><span data-text="true">#Odysee</span></span></span><span data-offset-key="fges4-4-0"><span data-text="true"> via </span></span><span style="color: #1d9bf0;"><span data-offset-key="fges4-5-0"><span data-text="true">@OdyseeTeam</span></span></span><span data-offset-key="fges4-6-0"><span data-text="true"> </span></span></div></div></div><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-81217717923262212672022-01-22T13:07:00.004-03:002022-01-22T13:40:32.632-03:00Covid Vaccine Scientific Proof Lethal!<h2 style="text-align: center;"> LUGAR DE NAZISTA É NA FORCA ! <br /></h2><div style="text-align: center;"><span style="font-size: medium;"><span style="font-family: arial;"> (...assim muitos foram sentenciados em Nuremberg!)</span></span></div><div style="text-align: center;"><span style="font-size: medium;"><span style="font-family: arial;"><br /></span></span></div><div style="text-align: left;"><span style="font-size: medium;"><span style="font-family: arial;">Voce não tem recebido noticias deste caso Judicial Monumental porque os governos deles com Ministros, servidores civis e as redes da Grande Midia são controladas por eles ! </span></span></div><div style="text-align: left;"><span style="font-size: medium;"><span style="font-family: arial;">Mas siga os Links dos Tribunais Criminais Internacionais !</span></span></div><div style="text-align: left;"><span style="font-size: medium;"><span style="font-family: arial;"> Links no QR Code !</span></span></div><div style="text-align: left;"><span style="font-size: medium;"><span style="font-family: arial;">Abra em seu celular o Leitor de QR Code aponte para estes Codigos e siga o Link na WWW !<span style="font-weight: normal;"><span><span><a class="oajrlxb2 g5ia77u1 qu0x051f esr5mh6w e9989ue4 r7d6kgcz rq0escxv nhd2j8a9 nc684nl6 p7hjln8o kvgmc6g5 cxmmr5t8 oygrvhab hcukyx3x jb3vyjys rz4wbd8a qt6c0cv9 a8nywdso i1ao9s8h esuyzwwr f1sip0of lzcic4wl gpro0wi8 q66pz984 b1v8xokw" href="https://www.facebook.com/hashtag/usa?__eep__=6&__cft__[0]=AZXhl0iLAHtU3qbA2tka28qQOzaySpQD_fJWIkVdccBy1G3P8zXBuewjt-yd5atvgIolH_E_9lW1jGCwAq1F9xwRtWseRLtCIqD3R-qIBV1sUErlYZDJ5gvfSx46q-b0iP8vpZcpQQDuQQ3PGTPQwEzFoAsfvUIfsr0qG4Wh44CXHFk7hXSWfOVlWfOin2I17X4&__tn__=*NK-R" role="link" tabindex="0">#USA</a></span> <span><a class="oajrlxb2 g5ia77u1 qu0x051f esr5mh6w e9989ue4 r7d6kgcz rq0escxv nhd2j8a9 nc684nl6 p7hjln8o kvgmc6g5 cxmmr5t8 oygrvhab hcukyx3x jb3vyjys rz4wbd8a qt6c0cv9 a8nywdso i1ao9s8h esuyzwwr f1sip0of lzcic4wl gpro0wi8 q66pz984 b1v8xokw" href="https://www.facebook.com/hashtag/world?__eep__=6&__cft__[0]=AZXhl0iLAHtU3qbA2tka28qQOzaySpQD_fJWIkVdccBy1G3P8zXBuewjt-yd5atvgIolH_E_9lW1jGCwAq1F9xwRtWseRLtCIqD3R-qIBV1sUErlYZDJ5gvfSx46q-b0iP8vpZcpQQDuQQ3PGTPQwEzFoAsfvUIfsr0qG4Wh44CXHFk7hXSWfOVlWfOin2I17X4&__tn__=*NK-R" role="link" tabindex="0">#world</a></span> <span><a class="oajrlxb2 g5ia77u1 qu0x051f esr5mh6w e9989ue4 r7d6kgcz rq0escxv nhd2j8a9 nc684nl6 p7hjln8o kvgmc6g5 cxmmr5t8 oygrvhab hcukyx3x jb3vyjys rz4wbd8a qt6c0cv9 a8nywdso i1ao9s8h esuyzwwr f1sip0of lzcic4wl gpro0wi8 q66pz984 b1v8xokw" href="https://www.facebook.com/hashtag/heyjudge?__eep__=6&__cft__[0]=AZXhl0iLAHtU3qbA2tka28qQOzaySpQD_fJWIkVdccBy1G3P8zXBuewjt-yd5atvgIolH_E_9lW1jGCwAq1F9xwRtWseRLtCIqD3R-qIBV1sUErlYZDJ5gvfSx46q-b0iP8vpZcpQQDuQQ3PGTPQwEzFoAsfvUIfsr0qG4Wh44CXHFk7hXSWfOVlWfOin2I17X4&__tn__=*NK-R" role="link" tabindex="0">#heyJudge</a></span> <span><a class="oajrlxb2 g5ia77u1 qu0x051f esr5mh6w e9989ue4 r7d6kgcz rq0escxv nhd2j8a9 nc684nl6 p7hjln8o kvgmc6g5 cxmmr5t8 oygrvhab hcukyx3x jb3vyjys rz4wbd8a qt6c0cv9 a8nywdso i1ao9s8h esuyzwwr f1sip0of lzcic4wl gpro0wi8 q66pz984 b1v8xokw" href="https://www.facebook.com/hashtag/intlcriminalcourt?__eep__=6&__cft__[0]=AZXhl0iLAHtU3qbA2tka28qQOzaySpQD_fJWIkVdccBy1G3P8zXBuewjt-yd5atvgIolH_E_9lW1jGCwAq1F9xwRtWseRLtCIqD3R-qIBV1sUErlYZDJ5gvfSx46q-b0iP8vpZcpQQDuQQ3PGTPQwEzFoAsfvUIfsr0qG4Wh44CXHFk7hXSWfOVlWfOin2I17X4&__tn__=*NK-R" role="link" tabindex="0">#intlcriminalcourt</a></span></span></span></span></span></div><h1 style="text-align: left;"><span class="d2edcug0 hpfvmrgz qv66sw1b c1et5uql lr9zc1uh a8c37x1j fe6kdd0r mau55g9w c8b282yb keod5gw0 nxhoafnm aigsh9s9 d3f4x2em iv3no6db jq4qci2q a3bd9o3v b1v8xokw oo9gr5id hzawbc8m" dir="auto"><div dir="auto"><div class="ecm0bbzt hv4rvrfc ihqw7lf3 dati1w0a" data-ad-comet-preview="message" data-ad-preview="message" id="jsc_c_h2"><div class="j83agx80 cbu4d94t ew0dbk1b irj2b8pg"><div class="qzhwtbm6 knvmm38d"><span class="d2edcug0 hpfvmrgz qv66sw1b c1et5uql lr9zc1uh a8c37x1j fe6kdd0r mau55g9w c8b282yb keod5gw0 nxhoafnm aigsh9s9 d3f4x2em iv3no6db jq4qci2q a3bd9o3v b1v8xokw oo9gr5id hzawbc8m" dir="auto"><div class="kvgmc6g5 cxmmr5t8 oygrvhab hcukyx3x c1et5uql ii04i59q"><div class="separator" style="clear: both; text-align: left;"><span style="margin-left: 1em; margin-right: 1em;"><img alt="https://blogger.googleusercontent.com/img/a/AVvXsEgJ-yaHTHxGKuwC3aEVI_NgtiVJ7AcZivFW7LWDT4QoR5LMOdYJpiAyfbDMIdClqiGhBK_H6bJ2zCmAqIpC0gREtOJjoTwF86mo82Um1Sxkb9yaIYOvsMsIYXv5iJpAr4yip9vn-2PBk4ETEA0yP1DNT8f-XjhEvHV96fxCHb-_BdP5juif8luxDJT9ZQ=s844" class="shrinkToFit" height="213" src="https://blogger.googleusercontent.com/img/a/AVvXsEgJ-yaHTHxGKuwC3aEVI_NgtiVJ7AcZivFW7LWDT4QoR5LMOdYJpiAyfbDMIdClqiGhBK_H6bJ2zCmAqIpC0gREtOJjoTwF86mo82Um1Sxkb9yaIYOvsMsIYXv5iJpAr4yip9vn-2PBk4ETEA0yP1DNT8f-XjhEvHV96fxCHb-_BdP5juif8luxDJT9ZQ=w507-h213" width="507" /> </span></div><div style="text-align: center;"><span style="font-weight: normal;"><span style="font-size: medium;"></span></span></div><div style="text-align: left;"><span style="font-weight: normal;"><span style="font-size: medium;"><span> </span></span><span style="font-size: medium;"><span class="d2edcug0 hpfvmrgz qv66sw1b c1et5uql lr9zc1uh a8c37x1j fe6kdd0r mau55g9w c8b282yb keod5gw0 nxhoafnm aigsh9s9 d3f4x2em iv3no6db jq4qci2q a3bd9o3v b1v8xokw oo9gr5id hzawbc8m" dir="auto"><div dir="auto" style="text-align: start;"><span><a class="oajrlxb2 g5ia77u1 qu0x051f esr5mh6w e9989ue4 r7d6kgcz rq0escxv nhd2j8a9 nc684nl6 p7hjln8o kvgmc6g5 cxmmr5t8 oygrvhab hcukyx3x jb3vyjys rz4wbd8a qt6c0cv9 a8nywdso i1ao9s8h esuyzwwr f1sip0of lzcic4wl gpro0wi8 q66pz984 b1v8xokw" href="https://www.facebook.com/hashtag/lugardenazista%C3%A9naforca?__eep__=6&__cft__[0]=AZXmMs37G6MhGqY_pggpJWGe3o5amUuXn2-mTRoy3XsTuvACAOHbxgTE0VpulD3Psby6bHv29oHA14IyaRjc0AyonMhSYyX6T_YdZEgW5fyOZ1TTCj3CnUrO5osvVeiX15zrBatx2rPlA-93OofdBzR9&__tn__=*NK-R" role="link" tabindex="0">#LugarDeNazistaÉNaForca</a></span></div><div dir="auto" style="text-align: start;">MAIS DE MIL LINKS DOS PRINCIPAIS ESTUDOS CIENTIFICOS RECENTES SOBRE O QUE ESTAMOS PUBLICANDO !</div><div dir="auto" style="text-align: start;">SÃO
FONTES DE FORMAÇÃO DE PROVAS PARA O TRIBUNAL ESPECIAL DE NUREMBERG QUE
JULGARA A TODOS OS CONDUTORES DESTA AÇÃO HEDIONDA CONTRA A HUMANIDADE E
SEUS COOPERADORES, CENSORES, POLITICOS, SERVIDORES PUBLICOS E CIVIS
ENVOLVIDOS NA DESINFORMAÇÂAO NA IMPRENSA E MEIOS DE COMUNICAÇÃO !</div><div dir="auto" style="text-align: start;">GAME OVER PRA VOCES !</div><div dir="auto" style="text-align: start;">THE END !</div><div dir="auto" style="text-align: start;"><span><a class="oajrlxb2 g5ia77u1 qu0x051f esr5mh6w e9989ue4 r7d6kgcz rq0escxv nhd2j8a9 nc684nl6 p7hjln8o kvgmc6g5 cxmmr5t8 oygrvhab hcukyx3x jb3vyjys rz4wbd8a qt6c0cv9 a8nywdso i1ao9s8h esuyzwwr f1sip0of lzcic4wl gpro0wi8 q66pz984 b1v8xokw" href="https://www.facebook.com/hashtag/lugardenazista%C3%A9naforca?__eep__=6&__cft__[0]=AZXmMs37G6MhGqY_pggpJWGe3o5amUuXn2-mTRoy3XsTuvACAOHbxgTE0VpulD3Psby6bHv29oHA14IyaRjc0AyonMhSYyX6T_YdZEgW5fyOZ1TTCj3CnUrO5osvVeiX15zrBatx2rPlA-93OofdBzR9&__tn__=*NK-R" role="link" tabindex="0">#LugarDeNazistaÉNaForca</a></span></div><div dir="auto" style="text-align: start;"><span> </span></div><div dir="auto" style="text-align: start;"><header class="entry-header clr" style="text-align: left;">
<h2 class="single-post-title entry-title" itemprop="headline" style="text-align: center;">Covid Vaccine Scientific Proof Lethal</h2>
</header>
<ul class="meta ospm-default clr" style="text-align: center;"><li class="meta-date" itemprop="datePublished"><span class="screen-reader-text">Post published:</span>5 January 2022</li></ul>
<p style="text-align: center;"><b>COVID-19 Vaccines: Scientific Proof of Lethality</b></p><p>Post published: 5 January 2022 at https://www.saveusnow.org.uk/covid-vaccine-scientific-proof-lethal</p><p><b><i> </i></b></p><p><b>Over
One Thousand Scientific Studies Prove That the COVID-19 Vaccines Are
Dangerous, and All Those Pushing This Agenda Are Committing the
Indictable Crime of Gross Misconduct in Public Office </b></p><p>Just
over 12 months from deployment of the COVID 19 emergency use
experimental vaccines, scientific studies in the thousands, and reports
of criminal complaints of assault and murder from the illegal, unlawful
use of biochemical poisons made to police forces around the country,
verify an assault on an unsuspecting UK population. Irrefutable science
shows that the COVID 19 vaccine is not safe and not effective in
limiting transmission or infection from the SARS-CoV-2, coronavirus
pathogens.</p><p>The “safe and effective” false propaganda, put out by
public officials who now are continuing to push this vaccine, is a clear
breach of duty. A public office holder is subject to, and aware of, a
duty to prevent death or serious injury that arises only by virtue of
the functions of the public office.</p><p>Many have breached that duty
and, in doing so, are recklessly causing a risk of death or serious
injury, by carrying on regardless of the now-confirmed dangers
associated with COVID 19 injections. Some of these risks are <b>blood
clotting, myocarditis, pericarditis, thrombosis, thrombocytopenia,
anaphylaxis, Bell’s palsy, Guillain-Barre, cancer including deaths, </b>etc.</p><p>All
of these are confirmed in the following science-and-government-gathered
data from the UK Health and Security agency on COVID 19 regarding
vaccine damage.</p><p>The term “vaccine” was changed recently to
incorporate this illegal, unlawful medical experiment to facilitate
usage of mRNA technology that is demonstrably not a vaccine, and which
contains biologically toxic nano-metamaterials associated with 5G urban
data gathering capability.</p><p>Metal nanoparticulates are known in
science to be genotoxic—a poison that can also cause sterilization. The
dangers posed to the victims in the near term from this medical battery
are now known. However, the long term lethality of this weapon is not as
yet realized due to the debilitating effects it has on the immune
system, causing Acquired Immunodeficiency Syndrome(AIDS).</p><p>We can
now confirm the 2017 depopulation defence-intelligence documents,
showing the planned murder of over 55 million across the United Kingdom
by 2025 using this biochemical weapon.</p><p>The Medicines and
Healthcare (products) Regulatory Agency (MHRA) had prior warning of the
expected large numbers of adverse reactions before the
deployment—confirming the premeditated nature of the crime and public
conduct offences then and now.</p><ol><li>Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre cohort study: <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01608-1/</a></li><li>Vaccine-induced
immune thrombotic thrombocytopenia with disseminated intravascular
coagulation and death after ChAdOx1 nCoV-19 vaccination: <u>https://www.sciencedirect.com/science/article/pii/S1052305721003414</u></li><li>Fatal cerebral hemorrhage after COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33928772/">https://pubmed.ncbi.nlm.nih.gov/33928772/</a></li><li>Myocarditis after mRNA vaccination against SARS-CoV-2, a case series: <a href="https://www.sciencedirect.com/science/article/pii/S2666602221000409">https://www.sciencedirect.com/science/article/pii/S2666602221000409</a></li><li>Three cases of acute venous thromboembolism in women after vaccination against COVID-19: <a href="https://www.sciencedirect.com/science/article/pii/S2213333X21003929">https://www.sciencedirect.com/science/article/pii/S2213333X21003929</a></li><li>Acute thrombosis of the coronary tree after vaccination against COVID-19: <a href="https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988">https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988</a></li><li>US
case reports of cerebral venous sinus thrombosis with thrombocytopenia
after vaccination with Ad26.COV2.S (against covid-19), March 2 to April
21, 2020: <a href="https://pubmed.ncbi.nlm.nih.gov/33929487/">https://pubmed.ncbi.nlm.nih.gov/33929487/</a></li><li>Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccine: <a href="https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/">https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-7/</a></li><li>Management
of cerebral and splanchnic vein thrombosis associated with
thrombocytopenia in subjects previously vaccinated with Vaxzevria
(AstraZeneca): position statement of the Italian Society for the Study
of Hemostasis and Thrombosis (SISET): <a href="https://pubmed.ncbi.nlm.nih.gov/33871350/">https://pubmed.ncbi.nlm.nih.gov/33871350/</a></li><li>Vaccine-induced
immune immune thrombotic thrombocytopenia and cerebral venous sinus
thrombosis after vaccination with COVID-19; a systematic review: <a href="https://www.sciencedirect.com/science/article/pii/S0022510X21003014">https://www.sciencedirect.com/science/article/pii/S0022510X21003014</a></li><li>Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines: <a href="https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381">https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381</a></li><li>Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an important and practical clinical dilemma: <a href="https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505">https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505</a></li><li>Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: <a href="https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904">https://www.sciencedirect.com/science/article/abs/pii/S0953620521001904</a></li><li>COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an emerging cause of splanchnic vein thrombosis: <a href="https://www.sciencedirect.com/science/article/pii/S1665268121000557">https://www.sciencedirect.com/science/article/pii/S1665268121000557</a></li><li>The
roles of platelets in COVID-19-associated coagulopathy and
vaccine-induced immune thrombotic immune thrombocytopenia (covid): <a href="https://www.sciencedirect.com/science/article/pii/S1050173821000967">https://www.sciencedirect.com/science/article/pii/S1050173821000967</a></li><li>Roots of autoimmunity of thrombotic events after COVID-19 vaccination: <a href="https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160">https://www.sciencedirect.com/science/article/abs/pii/S1568997221002160</a></li><li>Cerebral venous sinus thrombosis after vaccination: the United Kingdom experience: <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01788-8/fulltext</a></li><li>Thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: <a href="https://www.nejm.org/doi/full/10.1056/nejme2106315">https://www.nejm.org/doi/full/10.1056/nejme2106315</a></li><li>Myocarditis
after immunization with COVID-19 mRNA vaccines in members of the US
military. This article reports that in “23 male patients, including 22
previously healthy military members, myocarditis was identified within 4
days after receipt of the vaccine”: <a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601">https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601</a></li><li>Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article">https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRelated_article</a></li><li>Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children: <a href="https://pubmed.ncbi.nlm.nih.gov/34374740/">https://pubmed.ncbi.nlm.nih.gov/34374740/</a></li><li>Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-19: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article">https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article</a></li><li>Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-19): <a href="https://haematologica.org/article/view/haematol.2021.279075">https://haematologica.org/article/view/haematol.2021.279075</a></li><li>Thrombocytopenia,
including immune thrombocytopenia after receiving COVID-19 mRNA
vaccines reported to the Vaccine Adverse Event Reporting System (VAERS):
<a href="https://www.sciencedirect.com/science/article/pii/S0264410X21005247">https://www.sciencedirect.com/science/article/pii/S0264410X21005247</a></li><li>Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination: <a href="https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478">https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021-052478</a></li><li>Aphasia
seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine.
Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left
temporal lobe in a 52-year-old man. <a href="https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005">https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005</a></li><li>Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: <a href="https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895">https://www.sciencedirect.com/science/article/abs/pii/S0896841121000895</a></li><li>Hypothesis behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination: <a href="https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315">https://www.sciencedirect.com/science/article/abs/pii/S0049384821003315</a></li><li>Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19 vaccination: analysis of European data: <a href="https://www.sciencedirect.com/science/article/pii/S0896841121000937">https://www.sciencedirect.com/science/article/pii/S0896841121000937</a></li><li>Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine: <a href="https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098">https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098</a></li><li>Primary
adrenal insufficiency associated with thrombotic immune
thrombocytopenia induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19
vaccine (VITT): <a href="https://www.sciencedirect.com/science/article/pii/S0953620521002363">https://www.sciencedirect.com/science/article/pii/S0953620521002363</a></li><li>Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers: <a href="https://www.sciencedirect.com/science/article/pii/S0828282X21006243">https://www.sciencedirect.com/science/article/pii/S0828282X21006243</a></li><li>“Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine in a patient with antiphospholipid syndrome”: <a href="https://www.sciencedirect.com/science/article/pii/S2666572721000389">https://www.sciencedirect.com/science/article/pii/S2666572721000389</a></li><li>Early
results of bivalirudin treatment for thrombotic thrombocytopenia and
cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: <a href="https://www.sciencedirect.com/science/article/pii/S0196064421003425">https://www.sciencedirect.com/science/article/pii/S0196064421003425</a></li><li>Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination: <a href="https://www.sciencedirect.com/science/article/pii/S1443950621011562">https://www.sciencedirect.com/science/article/pii/S1443950621011562</a></li><li>Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection: <a href="https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706">https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706</a></li><li>Prothrombotic immune thrombocytopenia after COVID-19 vaccination: <a href="https://www.sciencedirect.com/science/article/pii/S0006497121009411">https://www.sciencedirect.com/science/article/pii/S0006497121009411</a></li><li>Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success story: <a href="https://www.sciencedirect.com/science/article/pii/S2589936821000256">https://www.sciencedirect.com/science/article/pii/S2589936821000256</a></li><li>Cerebral
venous sinus thrombosis negative for anti-PF4 antibody without
thrombocytopenia after immunization with COVID-19 vaccine in a
non-comorbid elderly Indian male treated with conventional
heparin-warfarin based anticoagulation: <a href="https://www.sciencedirect.com/science/article/pii/S1871402121002046">https://www.sciencedirect.com/science/article/pii/S1871402121002046</a></li><li>Thrombosis after COVID-19 vaccination: possible link to ACE pathways: <a href="https://www.sciencedirect.com/science/article/pii/S0049384821004369">https://www.sciencedirect.com/science/article/pii/S0049384821004369</a></li><li>Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2 vaccination with adenovirus and after COVID-19: <a href="https://www.sciencedirect.com/science/article/pii/S0735109721051949">https://www.sciencedirect.com/science/article/pii/S0735109721051949</a></li><li>A rare case of a middle-aged Asian male with cerebral venous thrombosis after AstraZeneca COVID-19 vaccination: <a href="https://www.sciencedirect.com/science/article/pii/S0735675721005714">https://www.sciencedirect.com/science/article/pii/S0735675721005714</a></li><li>Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: <a href="https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X">https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X</a></li><li>Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19): <a href="https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963">https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963</a>.</li><li>Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination: the straw that breaks the camel’s back?: <a href="https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ">https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLXFQ</a></li><li>Vaccine-induced
thrombotic thrombocytopenia, a rare but severe case of friendly fire in
the battle against the COVID-19 pandemic: What pathogenesis?: <a href="https://www.sciencedirect.com/science/article/pii/S0953620521002314">https://www.sciencedirect.com/science/article/pii/S0953620521002314</a></li><li>Diagnostic-therapeutic
recommendations of the ad-hoc FACME expert working group on the
management of cerebral venous thrombosis related to COVID-19
vaccination: <a href="https://www.sciencedirect.com/science/article/pii/S0213485321000839">https://www.sciencedirect.com/science/article/pii/S0213485321000839</a></li><li>Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the “AstraZeneca COVID-19 vaccine”: <a href="https://pubmed.ncbi.nlm.nih.gov/33918932/">https://pubmed.ncbi.nlm.nih.gov/33918932/</a></li><li>Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33606296/">https://pubmed.ncbi.nlm.nih.gov/33606296/</a></li><li>Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33854395/">https://pubmed.ncbi.nlm.nih.gov/33854395/</a></li><li>Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19 vaccine: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/</a></li><li>COVID-19 vaccination: information on the occurrence of arterial and venous thrombosis using data from VigiBase: <a href="https://pubmed.ncbi.nlm.nih.gov/33863748/">https://pubmed.ncbi.nlm.nih.gov/33863748/</a></li><li>Cerebral venous thrombosis associated with the covid-19 vaccine in Germany: <a href="https://onlinelibrary.wiley.com/doi/10.1002/ana.26172">https://onlinelibrary.wiley.com/doi/10.1002/ana.26172</a></li><li>Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2 against SARS-CoV-2: a black swan event: <a href="https://pubmed.ncbi.nlm.nih.gov/34133027/">https://pubmed.ncbi.nlm.nih.gov/34133027/</a></li><li>The importance of recognizing cerebral venous thrombosis following anti-COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34001390/">https://pubmed.ncbi.nlm.nih.gov/34001390/</a></li><li>Thrombosis with thrombocytopenia after messenger RNA vaccine -1273: <a href="https://pubmed.ncbi.nlm.nih.gov/34181446/">https://pubmed.ncbi.nlm.nih.gov/34181446/</a></li><li>Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: <a href="https://pubmed.ncbi.nlm.nih.gov/34174723/">https://pubmed.ncbi.nlm.nih.gov/34174723/</a></li><li>First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: <a href="https://www.nature.com/articles/s41591-021-01408-4">https://www.nature.com/articles/s41591-021-01408-4</a></li><li>Exacerbation of immune thrombocytopenia after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34075578/">https://pubmed.ncbi.nlm.nih.gov/34075578/</a></li><li>First report of a de novo iTTP episode associated with a COVID-19 mRNA-based anti-COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34105244/">https://pubmed.ncbi.nlm.nih.gov/34105244/</a></li><li>PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia: <a href="https://www.nejm.org/doi/full/10.1056/NEJMc2106383">https://www.nejm.org/doi/full/10.1056/NEJMc2106383</a></li><li>Antibody epitopes in vaccine-induced immune immune thrombotic thrombocytopenia: <a href="https://www.nature.com/articles/s41586-021-03744-4">https://www.nature.com/articles/s41586-021-03744-4</a></li><li>Myocarditis with COVID-19 mRNA vaccines: <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135">https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.056135</a></li><li>Myocarditis and pericarditis after COVID-19 vaccination: <a href="https://jamanetwork.com/journals/jama/fullarticle/2782900">https://jamanetwork.com/journals/jama/fullarticle/2782900</a></li><li>Myocarditis temporally associated with COVID-19 vaccination: <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891">https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055891</a>.</li><li>COVID-19 Vaccination Associated with Myocarditis in Adolescents: <a href="https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf">https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12/peds.2021-053427.full.pdf</a></li><li>Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/33994339/">https://pubmed.ncbi.nlm.nih.gov/33994339/</a></li><li>Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature: <a href="https://www.sciencedirect.com/science/article/pii/S1553838921005789">https://www.sciencedirect.com/science/article/pii/S1553838921005789</a></li><li>COVID-19 vaccine-induced myocarditis: a case report with review of the literature: <a href="https://www.sciencedirect.com/science/article/pii/S1871402121002253">https://www.sciencedirect.com/science/article/pii/S1871402121002253</a></li><li>Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings: <a href="https://www.sciencedirect.com/science/article/pii/S1936878X2100485X">https://www.sciencedirect.com/science/article/pii/S1936878X2100485X</a></li><li>Recurrence
of acute myocarditis temporally associated with receipt of coronavirus
mRNA disease vaccine 2019 (COVID-19) in a male adolescent: <a href="https://www.sciencedirect.com/science/article/pii/S002234762100617X">https://www.sciencedirect.com/science/article/pii/S002234762100617X</a></li><li>Fulminant
myocarditis and systemic hyper inflammation temporally associated with
BNT162b2 COVID-19 mRNA vaccination in two patients: <a href="https://www.sciencedirect.com/science/article/pii/S0167527321012286">https://www.sciencedirect.com/science/article/pii/S0167527321012286</a>.</li><li>Acute myocarditis after administration of BNT162b2 vaccine: <a href="https://www.sciencedirect.com/science/article/pii/S2214250921001530">https://www.sciencedirect.com/science/article/pii/S2214250921001530</a></li><li>Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector: <a href="https://www.sciencedirect.com/science/article/pii/S2352906721001573">https://www.sciencedirect.com/science/article/pii/S2352906721001573</a></li><li>Myocarditis following vaccination with BNT162b2 in a healthy male: <a href="https://www.sciencedirect.com/science/article/pii/S0735675721005362">https://www.sciencedirect.com/science/article/pii/S0735675721005362</a></li><li>Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection: <a href="https://www.sciencedirect.com/science/article/pii/S1930043321005549">https://www.sciencedirect.com/science/article/pii/S1930043321005549</a></li><li>Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents: <a href="https://www.sciencedirect.com/science/article/pii/S002234762100665X">https://www.sciencedirect.com/science/article/pii/S002234762100665X</a></li><li>Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA vaccine: <a href="https://www.sciencedirect.com/science/article/pii/S1885585721002218">https://www.sciencedirect.com/science/article/pii/S1885585721002218</a></li><li>Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA: <a href="https://www.sciencedirect.com/science/article/pii/S2589790X21001931">https://www.sciencedirect.com/science/article/pii/S2589790X21001931</a></li><li>Temporal
relationship between the second dose of BNT162b2 mRNA Covid-19 vaccine
and cardiac involvement in a patient with previous SARS-COV-2 infection:
<a href="https://www.sciencedirect.com/science/article/pii/S2352906721000622">https://www.sciencedirect.com/science/article/pii/S2352906721000622</a></li><li>Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age: <a href="https://www.sciencedirect.com/science/article/pii/S0022347621007368">https://www.sciencedirect.com/science/article/pii/S0022347621007368</a></li><li>Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man: <a href="https://www.sciencedirect.com/science/article/pii/S0870255121003243">https://www.sciencedirect.com/science/article/pii/S0870255121003243</a></li><li>Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents: <a href="https://www.sciencedirect.com/science/article/pii/S0022347621007496">https://www.sciencedirect.com/science/article/pii/S0022347621007496</a></li><li>A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: <a href="https://www.sciencedirect.com/science/article/pii/S1936878X21004861">https://www.sciencedirect.com/science/article/pii/S1936878X21004861</a></li><li>Takotsubo cardiomyopathy after vaccination with mRNA COVID-19: <a href="https://www.sciencedirect.com/science/article/pii/S1443950621011331">https://www.sciencedirect.com/science/article/pii/S1443950621011331</a></li><li>COVID-19 mRNA vaccination and myocarditis: <a href="https://pubmed.ncbi.nlm.nih.gov/34268277/">https://pubmed.ncbi.nlm.nih.gov/34268277/</a></li><li>COVID-19 vaccine and myocarditis: <a href="https://pubmed.ncbi.nlm.nih.gov/34399967/">https://pubmed.ncbi.nlm.nih.gov/34399967/</a></li><li>Epidemiology
and clinical features of myocarditis/pericarditis before the
introduction of COVID-19 mRNA vaccine in Korean children: a multicenter
study <a href="https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc%20e/en/covidwho-1360706">https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resourc e/en/covidwho-1360706</a>.</li><li>COVID-19 vaccines and myocarditis: <a href="https://pubmed.ncbi.nlm.nih.gov/34246566/">https://pubmed.ncbi.nlm.nih.gov/34246566/</a></li><li>Myocarditis
and other cardiovascular complications of COVID-19 mRNA-based COVID-19
vaccines
https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-comp
lications-of-the-mrna-based-covid-19-vaccines <a href="https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines">https://www.cureus.com/articles/61030-myocarditis-and-other-cardiovascular-complications-of-the-mrna-based-covid-19-vaccines</a></li><li>Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34340927/">https://pubmed.ncbi.nlm.nih.gov/34340927/</a></li><li>Myocarditis with covid-19 mRNA vaccines: <a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135">https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135</a></li><li>Association of myocarditis with COVID-19 mRNA vaccine in children: <a href="https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co%20vid-19-vaccine-in-children/">https://media.jamanetwork.com/news-item/association-of-myocarditis-with-mrna-co vid-19-vaccine-in-children/</a></li><li>Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children: <a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052">https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052</a></li><li>Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military: <a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C">https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C</a></li><li>Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines: <a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600">https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600</a></li><li>Myocarditis following immunization with Covid-19 mRNA: <a href="https://www.nejm.org/doi/full/10.1056/NEJMc2109975">https://www.nejm.org/doi/full/10.1056/NEJMc2109975</a></li><li>Patients with acute myocarditis after vaccination withCOVID-19 mRNA: <a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602">https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602</a></li><li>Myocarditis associated with vaccination with COVID-19 mRNA: <a href="https://pubs.rsna.org/doi/10.1148/radiol.2021211430">https://pubs.rsna.org/doi/10.1148/radiol.2021211430</a></li><li>Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination: <a href="https://pediatrics.aappublications.org/content/148/3/e2021052478">https://pediatrics.aappublications.org/content/148/3/e2021052478</a></li><li>Cardiovascular
magnetic resonance imaging findings in young adult patients with acute
myocarditis after COVID-19 mRNA vaccination: a case series: <a href="https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4">https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-021-00795-4</a></li><li>Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA: <a href="https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis">https://www.cps.ca/en/documents/position/clinical-guidance-for-youth-with-myocarditis-and-pericarditis</a></li><li>Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: <a href="https://pubmed.ncbi.nlm.nih.gov/34402228/">https://pubmed.ncbi.nlm.nih.gov/34402228/</a></li><li>Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine: <a href="https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567">https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567</a></li><li>Myocarditis / pericarditis associated with COVID-19 vaccine: <a href="https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html">https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html</a></li><li>Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: <a href="https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce%20nts_Receiving.95800.aspx">https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx</a></li><li>Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: <a href="https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543">https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543</a></li><li>The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism: <a href="https://pubmed.ncbi.nlm.nih.gov/34312010/">https://pubmed.ncbi.nlm.nih.gov/34312010/</a></li><li>Acute
myocardial injury after COVID-19 vaccination: a case report and review
of current evidence from the Vaccine Adverse Event Reporting System
database: <a href="https://pubmed.ncbi.nlm.nih.gov/34219532/">https://pubmed.ncbi.nlm.nih.gov/34219532/</a></li><li>Be alert to the risk of adverse cardiovascular events after COVID-19 vaccination: <a href="https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033">https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033</a></li><li>Myocarditis
associated with COVID-19 vaccination: echocardiographic, cardiac
tomography, and magnetic resonance imaging findings: <a href="https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236">https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236</a></li><li>In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine: <a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038">https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038</a></li><li>Occurrence
of acute infarct-like myocarditis after COVID-19 vaccination: just an
accidental coincidence or rather a vaccination-associated autoimmune
myocarditis?: <a href="https://pubmed.ncbi.nlm.nih.gov/34333695/">https://pubmed.ncbi.nlm.nih.gov/34333695/</a></li><li>Recurrence
of acute myocarditis temporally associated with receipt of coronavirus
mRNA disease vaccine 2019 (COVID-19) in a male adolescent: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/</a></li><li>Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?: <a href="https://pubmed.ncbi.nlm.nih.gov/34118375/">https://pubmed.ncbi.nlm.nih.gov/34118375/</a></li><li>Self-limited
myocarditis presenting with chest pain and ST-segment elevation in
adolescents after vaccination with the BNT162b2 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34180390/">https://pubmed.ncbi.nlm.nih.gov/34180390/</a></li><li>Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34133825/">https://pubmed.ncbi.nlm.nih.gov/34133825/</a></li><li>Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a 40-year-old man: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34487236/">https://pubmed.ncbi.nlm.nih.gov/34487236/</a></li><li>Insights
from a murine model of COVID-19 mRNA vaccine-induced myopericarditis:
could accidental intravenous injection of a vaccine induce
myopericarditis <a href="https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059">https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059</a></li><li>Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34447639/">https://pubmed.ncbi.nlm.nih.gov/34447639/</a></li><li>Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report: <a href="https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183">https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183</a></li><li>Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or causal relationship: <a href="https://pubmed.ncbi.nlm.nih.gov/34236331/">https://pubmed.ncbi.nlm.nih.gov/34236331/</a></li><li>Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34435250/">https://pubmed.ncbi.nlm.nih.gov/34435250/</a></li><li>COVID-19 vaccine-induced rhabdomyolysis: case report with literature review: <a href="https://pubmed.ncbi.nlm.nih.gov/34186348/">https://pubmed.ncbi.nlm.nih.gov/34186348/</a>.</li><li>GM1
ganglioside antibody and COVID-19-related Guillain Barre syndrome: case
report, systemic review, and implications for vaccine development: <a href="https://www.sciencedirect.com/science/article/pii/S2666354621000065">https://www.sciencedirect.com/science/article/pii/S2666354621000065</a></li><li>Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual association: <a href="https://www.sciencedirect.com/science/article/pii/S0303846721004169">https://www.sciencedirect.com/science/article/pii/S0303846721004169</a></li><li>Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: <a href="https://www.sciencedirect.com/science/article/pii/S0165572821002186">https://www.sciencedirect.com/science/article/pii/S0165572821002186</a></li><li>Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: <a href="https://www.sciencedirect.com/science/article/pii/S2214250921000998">https://www.sciencedirect.com/science/article/pii/S2214250921000998</a>.</li><li>Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-19: a case report: <a href="https://www.sciencedirect.com/science/article/pii/S0736467921006442">https://www.sciencedirect.com/science/article/pii/S0736467921006442</a></li><li>Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: <a href="https://www.sciencedirect.com/science/article/pii/S0035378721005853">https://www.sciencedirect.com/science/article/pii/S0035378721005853</a>.</li><li>SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following vaccination: <a href="https://www.sciencedirect.com/science/article/pii/S2049080121005343">https://www.sciencedirect.com/science/article/pii/S2049080121005343</a></li><li>Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: a case report: <a href="https://www.sciencedirect.com/science/article/pii/S2049080121007536">https://www.sciencedirect.com/science/article/pii/S2049080121007536</a></li><li>Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of self-report database: <a href="https://www.sciencedirect.com/science/article/pii/S1201971221007049">https://www.sciencedirect.com/science/article/pii/S1201971221007049</a></li><li>Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence: <a href="https://www.sciencedirect.com/science/article/pii/S0899707121003557">https://www.sciencedirect.com/science/article/pii/S0899707121003557</a>.</li><li>New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccination: <a href="https://www.sciencedirect.com/science/article/pii/S0165572821001569">https://www.sciencedirect.com/science/article/pii/S0165572821001569</a></li><li>Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal association: <a href="https://www.sciencedirect.com/science/article/pii/S0165572821002137">https://www.sciencedirect.com/science/article/pii/S0165572821002137</a></li><li>Bell’s palsy and SARS-CoV-2 vaccines: an unfolding story: <a href="https://www.sciencedirect.com/science/article/pii/S1473309921002735">https://www.sciencedirect.com/science/article/pii/S1473309921002735</a></li><li>Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a history of recurrent Bell’s palsy: <a href="https://www.sciencedirect.com/science/article/pii/S266635462100020X">https://www.sciencedirect.com/science/article/pii/S266635462100020X</a></li><li>Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine:. <a href="https://www.sciencedirect.com/science/article/pii/S2451993621001456">https://www.sciencedirect.com/science/article/pii/S2451993621001456</a>.</li><li>Bell’s palsy after COVID-19 vaccination: case report: <a href="https://www.sciencedirect.com/science/article/pii/S217358082100122X">https://www.sciencedirect.com/science/article/pii/S217358082100122X</a>.</li><li>An academic hospital experience assessing the risk of COVID-19 mRNA vaccine using patient’s allergy history: <a href="https://www.sciencedirect.com/science/article/pii/S2213219821007972">https://www.sciencedirect.com/science/article/pii/S2213219821007972</a></li><li>COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in PET: <a href="https://www.sciencedirect.com/science/article/pii/S1930043321002612">https://www.sciencedirect.com/science/article/pii/S1930043321002612</a></li><li>ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: <a href="https://www.sciencedirect.com/science/article/pii/S0272638621007423">https://www.sciencedirect.com/science/article/pii/S0272638621007423</a></li><li>Late cutaneous reactions after administration of COVID-19 mRNA vaccines: <a href="https://www.sciencedirect.com/science/article/pii/S2213219821007996">https://www.sciencedirect.com/science/article/pii/S2213219821007996</a></li><li>COVID-19 vaccine-induced rhabdomyolysis: case report with review of the literature: <a href="https://www.sciencedirect.com/science/article/pii/S1871402121001880">https://www.sciencedirect.com/science/article/pii/S1871402121001880</a></li><li>Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: <a href="https://www.sciencedirect.com/science/article/pii/S0190962221024427">https://www.sciencedirect.com/science/article/pii/S0190962221024427</a></li><li>Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines:. <a href="https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381">https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381</a>.</li><li>COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization:. <a href="https://www.sciencedirect.com/science/article/pii/S1939455121000119">https://www.sciencedirect.com/science/article/pii/S1939455121000119</a>.</li><li>Cerebral
venous sinus thrombosis negative for anti-PF4 antibody without
thrombocytopenia after immunization with COVID-19 vaccine in an elderly,
non-comorbid Indian male treated with conventional
heparin-warfarin-based anticoagulation:. <a href="https://www.sciencedirect.com/science/article/pii/S1871402121002046">https://www.sciencedirect.com/science/article/pii/S1871402121002046</a>.</li><li>Acute myocarditis after administration of BNT162b2 vaccine against COVID-19:. <a href="https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X">https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X</a></li><li>Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data:. <a href="https://www.sciencedirect.com/science/article/pii/S0896841121000937">https://www.sciencedirect.com/science/article/pii/S0896841121000937</a>.</li><li>immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA vaccine:. <a href="https://www.sciencedirect.com/science/article/pii/S2214250921002018">https://www.sciencedirect.com/science/article/pii/S2214250921002018</a>.</li><li>Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna) vaccine: Case report: <a href="https://www.sciencedirect.com/science/article/pii/S1876034121001878">https://www.sciencedirect.com/science/article/pii/S1876034121001878</a>.</li><li>COVID-19
RNA-based vaccines and the risk of prion disease:
https://scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion-dis
ease-1503.pdf</li><li>This study notes that 115 pregnant women lost
their babies, out of 827 who participated in a study on the safety of
covid-19 vaccines: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2104983">https://www.nejm.org/doi/full/10.1056/NEJMoa2104983</a>.</li><li>Process-related impurities in the ChAdOx1 nCov-19 vaccine: <a href="https://www.researchsquare.com/article/rs-477964/v1">https://www.researchsquare.com/article/rs-477964/v1</a></li><li>COVID-19 mRNA vaccine causing CNS inflammation: a case series: <a href="https://link.springer.com/article/10.1007/s00415-021-10780-7">https://link.springer.com/article/10.1007/s00415-021-10780-7</a></li><li>Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33475702/">https://pubmed.ncbi.nlm.nih.gov/33475702/</a></li><li>Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol: <a href="https://pubmed.ncbi.nlm.nih.gov/33320974/">https://pubmed.ncbi.nlm.nih.gov/33320974/</a></li><li>Pfizer Vaccine Raises Allergy Concerns: <a href="https://pubmed.ncbi.nlm.nih.gov/33384356/">https://pubmed.ncbi.nlm.nih.gov/33384356/</a></li><li>Allergic
reactions, including anaphylaxis, after receiving the first dose of
Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020: <a href="https://pubmed.ncbi.nlm.nih.gov/33444297/">https://pubmed.ncbi.nlm.nih.gov/33444297/</a></li><li>Allergic
reactions, including anaphylaxis, after receiving first dose of Modern
COVID-19 vaccine – United States, December 21, 2020-January 10, 2021: <a href="https://pubmed.ncbi.nlm.nih.gov/33507892/">https://pubmed.ncbi.nlm.nih.gov/33507892/</a></li><li>Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021: <a href="https://pubmed.ncbi.nlm.nih.gov/34414880/">https://pubmed.ncbi.nlm.nih.gov/34414880/</a></li><li>Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021: <a href="https://pubmed.ncbi.nlm.nih.gov/33576785/">https://pubmed.ncbi.nlm.nih.gov/33576785/</a></li><li>Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data: <a href="https://pubmed.ncbi.nlm.nih.gov/34269740/">https://pubmed.ncbi.nlm.nih.gov/34269740/</a></li><li>Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34215453/">https://pubmed.ncbi.nlm.nih.gov/34215453/</a></li><li>Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research: <a href="https://pubmed.ncbi.nlm.nih.gov/33932618/">https://pubmed.ncbi.nlm.nih.gov/33932618/</a></li><li>Severe
Allergic Reactions after COVID-19 Vaccination with the Pfizer /
BioNTech Vaccine in Great Britain and the USA: Position Statement of the
German Allergy Societies: German Medical Association of Allergologists
(AeDA), German Society for Allergology and Clinical Immunology (DGAKI)
and Society for Pediatric Allergology and Environmental Medicine (GPA): <a href="https://pubmed.ncbi.nlm.nih.gov/33643776/">https://pubmed.ncbi.nlm.nih.gov/33643776/</a></li><li>Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/33571463/">https://pubmed.ncbi.nlm.nih.gov/33571463/</a></li><li>Reported orofacial adverse effects from COVID-19 vaccines: the known and the unknown: <a href="https://pubmed.ncbi.nlm.nih.gov/33527524/">https://pubmed.ncbi.nlm.nih.gov/33527524/</a></li><li>Cutaneous adverse effects of available COVID-19 vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34518015/">https://pubmed.ncbi.nlm.nih.gov/34518015/</a></li><li>Cumulative
adverse event report of anaphylaxis following injections of COVID-19
mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report: <a href="https://pubmed.ncbi.nlm.nih.gov/34347278/">https://pubmed.ncbi.nlm.nih.gov/34347278/</a></li><li>COVID-19 vaccines increase the risk of anaphylaxis: <a href="https://pubmed.ncbi.nlm.nih.gov/33685103/">https://pubmed.ncbi.nlm.nih.gov/33685103/</a></li><li>Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34050949/">https://pubmed.ncbi.nlm.nih.gov/34050949/</a></li><li>Allergenic
components of the mRNA-1273 vaccine for COVID-19: possible involvement
of polyethylene glycol and IgG-mediated complement activation: <a href="https://pubmed.ncbi.nlm.nih.gov/33657648/">https://pubmed.ncbi.nlm.nih.gov/33657648/</a></li><li>Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33825239/">https://pubmed.ncbi.nlm.nih.gov/33825239/</a></li><li>Acute allergic reactions to COVID-19 mRNA vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/33683290/">https://pubmed.ncbi.nlm.nih.gov/33683290/</a></li><li>Polyethylene
glycole allergy of the SARS CoV2 vaccine recipient: case report of a
young adult recipient and management of future exposure to SARS-CoV2: <a href="https://pubmed.ncbi.nlm.nih.gov/33919151/">https://pubmed.ncbi.nlm.nih.gov/33919151/</a></li><li>Elevated
rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA
vaccine against COVID-19 in Japanese healthcare workers; a secondary
analysis of initial post-approval safety data: <a href="https://pubmed.ncbi.nlm.nih.gov/34128049/">https://pubmed.ncbi.nlm.nih.gov/34128049/</a></li><li>Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health system experience: <a href="https://pubmed.ncbi.nlm.nih.gov/34474708/">https://pubmed.ncbi.nlm.nih.gov/34474708/</a></li><li>Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI): <a href="https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447">https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447</a></li><li>.IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34318537/">https://pubmed.ncbi.nlm.nih.gov/34318537/</a></li><li>Allergic reactions after COVID-19 vaccination: putting the risk in perspective: <a href="https://pubmed.ncbi.nlm.nih.gov/34463751/">https://pubmed.ncbi.nlm.nih.gov/34463751/</a></li><li>Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies: https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.</li><li>Risk
of severe allergic reactions to COVID-19 vaccines among patients with
allergic skin disease: practical recommendations. An ETFAD position
statement with external experts: <a href="https://pubmed.ncbi.nlm.nih.gov/33752263/">https://pubmed.ncbi.nlm.nih.gov/33752263/</a></li><li>COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34073536/">https://pubmed.ncbi.nlm.nih.gov/34073536/</a></li><li>Fatal brain hemorrhage after COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33928772/">https://pubmed.ncbi.nlm.nih.gov/33928772/</a></li><li>A case series of skin reactions to COVID-19 vaccine in the Department of Dermatology at Loma Linda University: <a href="https://pubmed.ncbi.nlm.nih.gov/34423106/">https://pubmed.ncbi.nlm.nih.gov/34423106/</a></li><li>Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study based on a registry of 414 cases: <a href="https://pubmed.ncbi.nlm.nih.gov/33838206/">https://pubmed.ncbi.nlm.nih.gov/33838206/</a></li><li>Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-REPP: a registry-based study: <a href="https://pubmed.ncbi.nlm.nih.gov/34517079/">https://pubmed.ncbi.nlm.nih.gov/34517079/</a></li><li>Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-sectional study of 405 cases: <a href="https://pubmed.ncbi.nlm.nih.gov/34254291/">https://pubmed.ncbi.nlm.nih.gov/34254291/</a></li><li>Varicella
zoster virus and herpes simplex virus reactivation after vaccination
with COVID-19: review of 40 cases in an international dermatologic
registry: <a href="https://pubmed.ncbi.nlm.nih.gov/34487581/">https://pubmed.ncbi.nlm.nih.gov/34487581/</a></li><li>Immune
thrombosis and thrombocytopenia (VITT) associated with the COVID-19
vaccine: diagnostic and therapeutic recommendations for a new syndrome: <a href="https://pubmed.ncbi.nlm.nih.gov/33987882/">https://pubmed.ncbi.nlm.nih.gov/33987882/</a></li><li>Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune) thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34138513/">https://pubmed.ncbi.nlm.nih.gov/34138513/</a></li><li>Intracerebral
hemorrhage due to thrombosis with thrombocytopenia syndrome after
COVID-19 vaccination: the first fatal case in Korea: <a href="https://pubmed.ncbi.nlm.nih.gov/34402235/">https://pubmed.ncbi.nlm.nih.gov/34402235/</a></li><li>Risk
of thrombocytopenia and thromboembolism after covid-19 vaccination and
positive SARS-CoV-2 tests: self-controlled case series study: <a href="https://pubmed.ncbi.nlm.nih.gov/34446426/">https://pubmed.ncbi.nlm.nih.gov/34446426/</a></li><li>Vaccine-induced
immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis
after covid-19 vaccination; a systematic review: <a href="https://pubmed.ncbi.nlm.nih.gov/34365148/">https://pubmed.ncbi.nlm.nih.gov/34365148/</a>.</li><li>Nerve and muscle adverse events after vaccination with COVID-19: a systematic review and meta-analysis of clinical trials: <a href="https://pubmed.ncbi.nlm.nih.gov/34452064/">https://pubmed.ncbi.nlm.nih.gov/34452064/</a>.</li><li>A
rare case of cerebral venous thrombosis and disseminated intravascular
coagulation temporally associated with administration of COVID-19
vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33917902/">https://pubmed.ncbi.nlm.nih.gov/33917902/</a></li><li>Primary
adrenal insufficiency associated with thrombotic immune
thrombocytopenia induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine
(VITT): <a href="https://pubmed.ncbi.nlm.nih.gov/34256983/">https://pubmed.ncbi.nlm.nih.gov/34256983/</a></li><li>Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34247246/">https://pubmed.ncbi.nlm.nih.gov/34247246/</a>.</li><li>Thromboaspiration
infusion and fibrinolysis for portomesenteric thrombosis after
administration of AstraZeneca COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34132839/">https://pubmed.ncbi.nlm.nih.gov/34132839/</a></li><li>59-year-old
woman with extensive deep venous thrombosis and pulmonary
thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2
mRNA vaccine COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34117206/">https://pubmed.ncbi.nlm.nih.gov/34117206/</a></li><li>Cerebral
venous thrombosis and vaccine-induced thrombocytopenia.a.
Oxford-AstraZeneca COVID-19: a missed opportunity for a rapid return on
experience: <a href="https://pubmed.ncbi.nlm.nih.gov/34033927/">https://pubmed.ncbi.nlm.nih.gov/34033927/</a></li><li>Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34277198/">https://pubmed.ncbi.nlm.nih.gov/34277198/</a></li><li>Pericarditis after administration of COVID-19 mRNA BNT162b2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34364831/">https://pubmed.ncbi.nlm.nih.gov/34364831/</a></li><li>Unusual presentation of acute pericarditis after vaccination against SARS-COV-2 mRNA-1237 Modern: <a href="https://pubmed.ncbi.nlm.nih.gov/34447639/">https://pubmed.ncbi.nlm.nih.gov/34447639/</a></li><li>Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273: <a href="https://pubmed.ncbi.nlm.nih.gov/34514306/">https://pubmed.ncbi.nlm.nih.gov/34514306/</a></li><li>Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/33946748/">https://pubmed.ncbi.nlm.nih.gov/33946748/</a></li><li>Insights
from a murine model of myopericarditis induced by COVID-19 mRNA
vaccine: could accidental intravenous injection of a vaccine induce
myopericarditis: <a href="https://pubmed.ncbi.nlm.nih.gov/34453510/">https://pubmed.ncbi.nlm.nih.gov/34453510/</a></li><li>Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33476455/">https://pubmed.ncbi.nlm.nih.gov/33476455/</a></li><li>propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34451967/">https://pubmed.ncbi.nlm.nih.gov/34451967/</a></li><li>Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19 vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34377889/">https://pubmed.ncbi.nlm.nih.gov/34377889/</a></li><li>Thrombosis
with thrombocytopenia syndrome (TTS) following AstraZeneca ChAdOx1
nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for
persons <60 years in Australia: <a href="https://pubmed.ncbi.nlm.nih.gov/34272095/">https://pubmed.ncbi.nlm.nih.gov/34272095/</a></li><li>COVID-19 vaccination association and facial nerve palsy: A case-control study: <a href="https://pubmed.ncbi.nlm.nih.gov/34165512/">https://pubmed.ncbi.nlm.nih.gov/34165512/</a></li><li>The association between COVID-19 vaccination and Bell’s palsy: <a href="https://pubmed.ncbi.nlm.nih.gov/34411533/">https://pubmed.ncbi.nlm.nih.gov/34411533/</a></li><li>Bell’s palsy after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33611630/">https://pubmed.ncbi.nlm.nih.gov/33611630/</a></li><li>Acute
transverse myelitis (ATM): clinical review of 43 patients with
COVID-19-associated ATM and 3 serious adverse events of post-vaccination
ATM with ChAdOx1 nCoV-19 vaccine (AZD1222): <a href="https://pubmed.ncbi.nlm.nih.gov/33981305/">https://pubmed.ncbi.nlm.nih.gov/33981305/</a></li><li>Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34336436/">https://pubmed.ncbi.nlm.nih.gov/34336436/</a></li><li>Sequential contralateral facial nerve palsy after first and second doses of COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34281950/">https://pubmed.ncbi.nlm.nih.gov/34281950/</a>.</li><li>Transverse myelitis induced by SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34458035/">https://pubmed.ncbi.nlm.nih.gov/34458035/</a></li><li>Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-19): <a href="https://pubmed.ncbi.nlm.nih.gov/33734623/">https://pubmed.ncbi.nlm.nih.gov/33734623/</a></li><li>Acute abducens nerve palsy after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34044114/">https://pubmed.ncbi.nlm.nih.gov/34044114/</a>.</li><li>Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of self-report database: <a href="https://pubmed.ncbi.nlm.nih.gov/34492394/">https://pubmed.ncbi.nlm.nih.gov/34492394/</a></li><li>Transient
oculomotor paralysis after administration of RNA-1273 messenger vaccine
for SARS-CoV-2 diplopia after COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34369471/">https://pubmed.ncbi.nlm.nih.gov/34369471/</a></li><li>Bell’s palsy after Ad26.COV2.S COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34014316/">https://pubmed.ncbi.nlm.nih.gov/34014316/</a></li><li>Bell’s palsy after COVID-19 vaccination: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34330676/">https://pubmed.ncbi.nlm.nih.gov/34330676/</a></li><li>A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy following ChAdOx1 nCoV-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34272622/">https://pubmed.ncbi.nlm.nih.gov/34272622/</a></li><li>Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34477091/">https://pubmed.ncbi.nlm.nih.gov/34477091/</a></li><li>Acute facial paralysis as a possible complication of SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33975372/">https://pubmed.ncbi.nlm.nih.gov/33975372/</a>.</li><li>Bell’s palsy after COVID-19 vaccination with high antibody response in CSF: <a href="https://pubmed.ncbi.nlm.nih.gov/34322761/">https://pubmed.ncbi.nlm.nih.gov/34322761/</a>.</li><li>Parsonage-Turner
syndrome associated with SARS-CoV-2 or SARS-CoV-2 vaccination. Comment
on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of accessory
spinal nerve palsy” by Coll et al. Articular Spine 2021; 88: 10519: <a href="https://pubmed.ncbi.nlm.nih.gov/34139321/">https://pubmed.ncbi.nlm.nih.gov/34139321/</a>.</li><li>Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34032902/">https://pubmed.ncbi.nlm.nih.gov/34032902/</a>.</li><li>Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-19): causality or victim?: <a href="https://pubmed.ncbi.nlm.nih.gov/33862041/">https://pubmed.ncbi.nlm.nih.gov/33862041/</a></li><li>Autoimmune hepatitis triggered by vaccination against SARS-CoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/34332438/">https://pubmed.ncbi.nlm.nih.gov/34332438/</a></li><li>Acute
autoimmune-like hepatitis with atypical antimitochondrial antibody
after vaccination with COVID-19 mRNA: a new clinical entity: <a href="https://pubmed.ncbi.nlm.nih.gov/34293683/">https://pubmed.ncbi.nlm.nih.gov/34293683/</a>.</li><li>Autoimmune hepatitis after COVID vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34225251/">https://pubmed.ncbi.nlm.nih.gov/34225251/</a></li><li>A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination with Janssen COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34449715/">https://pubmed.ncbi.nlm.nih.gov/34449715/</a></li><li>Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34139631/">https://pubmed.ncbi.nlm.nih.gov/34139631/</a>.</li><li>Bilateral
superior ophthalmic vein thrombosis, ischemic stroke and immune
thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/33864750/">https://pubmed.ncbi.nlm.nih.gov/33864750/</a></li><li>Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced immune-immune thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/33914590/">https://pubmed.ncbi.nlm.nih.gov/33914590/</a></li><li>Venous sinus thrombosis after vaccination with ChAdOx1 nCov-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34420802/">https://pubmed.ncbi.nlm.nih.gov/34420802/</a></li><li>Cerebral
venous sinus thrombosis following vaccination against SARS-CoV-2: an
analysis of cases reported to the European Medicines Agency: <a href="https://pubmed.ncbi.nlm.nih.gov/34293217/">https://pubmed.ncbi.nlm.nih.gov/34293217/</a></li><li>Risk
of thrombocytopenia and thromboembolism after covid-19 vaccination and
positive SARS-CoV-2 tests: self-controlled case series study: <a href="https://pubmed.ncbi.nlm.nih.gov/34446426/">https://pubmed.ncbi.nlm.nih.gov/34446426/</a></li><li>Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an analysis of European data: <a href="https://pubmed.ncbi.nlm.nih.gov/34174723/">https://pubmed.ncbi.nlm.nih.gov/34174723/</a></li><li>Arterial
events, venous thromboembolism, thrombocytopenia and bleeding after
vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway:
population-based cohort study: <a href="https://pubmed.ncbi.nlm.nih.gov/33952445/">https://pubmed.ncbi.nlm.nih.gov/33952445/</a></li><li>First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland: <a href="https://pubmed.ncbi.nlm.nih.gov/34108714/">https://pubmed.ncbi.nlm.nih.gov/34108714/</a></li><li>Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: <a href="https://pubmed.ncbi.nlm.nih.gov/34288044/">https://pubmed.ncbi.nlm.nih.gov/34288044/</a></li><li>Malignant
cerebral infarction after vaccination with ChAdOx1 nCov-19: a
catastrophic variant of vaccine-induced immune-mediated thrombotic
thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34341358/">https://pubmed.ncbi.nlm.nih.gov/34341358/</a></li><li>celiac
artery and splenic artery thrombosis complicated by splenic infarction 7
days after the first dose of Oxford vaccine, causal relationship or
coincidence: <a href="https://pubmed.ncbi.nlm.nih.gov/34261633/">https://pubmed.ncbi.nlm.nih.gov/34261633/</a>.</li><li>Primary
adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1
nCoV-19 (VITT) vaccine-induced immune thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34256983/">https://pubmed.ncbi.nlm.nih.gov/34256983/</a></li><li>Thrombocytopenia after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34332437/">https://pubmed.ncbi.nlm.nih.gov/34332437/</a>.</li><li>Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33845870/">https://pubmed.ncbi.nlm.nih.gov/33845870/</a>.</li><li>Thrombosis with thrombocytopenia syndrome after COVID-19 immunization: <a href="https://pubmed.ncbi.nlm.nih.gov/34236343/">https://pubmed.ncbi.nlm.nih.gov/34236343/</a></li><li>Acute myocardial infarction within 24 hours after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34364657/">https://pubmed.ncbi.nlm.nih.gov/34364657/</a>.</li><li>Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34287612/">https://pubmed.ncbi.nlm.nih.gov/34287612/</a></li><li>central
venous sinus thrombosis with subarachnoid hemorrhage after COVID-19
mRNA vaccination: are these reports merely coincidental: <a href="https://pubmed.ncbi.nlm.nih.gov/34478433/">https://pubmed.ncbi.nlm.nih.gov/34478433/</a></li><li>Intracerebral
hemorrhage due to thrombosis with thrombocytopenia syndrome after
COVID-19 vaccination: the first fatal case in Korea: <a href="https://pubmed.ncbi.nlm.nih.gov/34402235/">https://pubmed.ncbi.nlm.nih.gov/34402235/</a></li><li>Cerebral
venous sinus thrombosis negative for anti-PF4 antibody without
thrombocytopenia after immunization with COVID-19 vaccine in a
non-comorbid elderly Indian male treated with conventional
heparin-warfarin-based anticoagulation: <a href="https://pubmed.ncbi.nlm.nih.gov/34186376/">https://pubmed.ncbi.nlm.nih.gov/34186376/</a></li><li>Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34101024/">https://pubmed.ncbi.nlm.nih.gov/34101024/</a></li><li>A case of multiple thrombocytopenia and thrombosis following vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/34137813/">https://pubmed.ncbi.nlm.nih.gov/34137813/</a></li><li>Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34191218/">https://pubmed.ncbi.nlm.nih.gov/34191218/</a></li><li>Acute
ischemic stroke revealing immune thrombotic thrombocytopenia induced by
ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: <a href="https://pubmed.ncbi.nlm.nih.gov/34175640/">https://pubmed.ncbi.nlm.nih.gov/34175640/</a></li><li>New-onset refractory status epilepticus after ChAdOx1 nCoV-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34153802/">https://pubmed.ncbi.nlm.nih.gov/34153802/</a></li><li>Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34092488/">https://pubmed.ncbi.nlm.nih.gov/34092488/</a></li><li>Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34261635/">https://pubmed.ncbi.nlm.nih.gov/34261635/</a></li><li>Thromboaspiration
infusion and fibrinolysis for portomesenteric thrombosis after
administration of the AstraZeneca COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34132839/">https://pubmed.ncbi.nlm.nih.gov/34132839/</a>.</li><li>Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34144250/">https://pubmed.ncbi.nlm.nih.gov/34144250/</a></li><li>Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33687691/">https://pubmed.ncbi.nlm.nih.gov/33687691/</a></li><li>Procoagulant
antibody-mediated procoagulant platelets in immune thrombotic
thrombocytopenia associated with SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34011137/">https://pubmed.ncbi.nlm.nih.gov/34011137/</a>.</li><li>Vaccine-induced
immune thrombotic thrombocytopenia causing a severe form of cerebral
venous thrombosis with high mortality rate: a case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34393988/">https://pubmed.ncbi.nlm.nih.gov/34393988/</a>.</li><li>Procoagulant
microparticles: a possible link between vaccine-induced immune
thrombocytopenia (VITT) and cerebral sinus venous thrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34129181/">https://pubmed.ncbi.nlm.nih.gov/34129181/</a>.</li><li>Atypical
thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data
from the French network of regional pharmacovigilance centers: <a href="https://pubmed.ncbi.nlm.nih.gov/34083026/">https://pubmed.ncbi.nlm.nih.gov/34083026/</a>.</li><li>Acute cerebral venous thrombosis and pulmonary artery embolism associated with the COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34247246/">https://pubmed.ncbi.nlm.nih.gov/34247246/</a>.</li><li>Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage: <a href="https://pubmed.ncbi.nlm.nih.gov/34235757/">https://pubmed.ncbi.nlm.nih.gov/34235757/</a>.</li><li>Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34473841/">https://pubmed.ncbi.nlm.nih.gov/34473841/</a>.</li><li>Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34189756/">https://pubmed.ncbi.nlm.nih.gov/34189756/</a></li><li>Cerebral venous thrombosis following COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34045111/">https://pubmed.ncbi.nlm.nih.gov/34045111/</a>.</li><li>Lipschütz ulcers after AstraZeneca COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34366434/">https://pubmed.ncbi.nlm.nih.gov/34366434/</a>.</li><li>Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34330677/">https://pubmed.ncbi.nlm.nih.gov/34330677/</a></li><li>Thrombosis with thrombocytopenia after Messenger vaccine RNA-1273: <a href="https://pubmed.ncbi.nlm.nih.gov/34181446/">https://pubmed.ncbi.nlm.nih.gov/34181446/</a></li><li>Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34477089/">https://pubmed.ncbi.nlm.nih.gov/34477089/</a></li><li>Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the underlying mechanism: <a href="https://pubmed.ncbi.nlm.nih.gov/34071883/">https://pubmed.ncbi.nlm.nih.gov/34071883/</a></li><li>Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia (VITT): <a href="https://pubmed.ncbi.nlm.nih.gov/34033367/">https://pubmed.ncbi.nlm.nih.gov/34033367/</a></li><li>Comparison
of adverse drug reactions among four COVID-19 vaccines in Europe using
the EudraVigilance database: Thrombosis in unusual sites: <a href="https://pubmed.ncbi.nlm.nih.gov/34375510/">https://pubmed.ncbi.nlm.nih.gov/34375510/</a></li><li>Immunoglobulin adjuvant for vaccine-induced immune thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34107198/">https://pubmed.ncbi.nlm.nih.gov/34107198/</a></li><li>Severe
vaccine-induced thrombotic thrombocytopenia following vaccination with
COVID-19: an autopsy case report and review of the literature: <a href="https://pubmed.ncbi.nlm.nih.gov/34355379/">https://pubmed.ncbi.nlm.nih.gov/34355379/</a>.</li><li>A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA: <a href="https://pubmed.ncbi.nlm.nih.gov/34452028/">https://pubmed.ncbi.nlm.nih.gov/34452028/</a></li><li>Neurosurgical
considerations regarding decompressive craniectomy for intracerebral
hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic
thrombocytopenia-VITT: <a href="https://pubmed.ncbi.nlm.nih.gov/34202817/">https://pubmed.ncbi.nlm.nih.gov/34202817/</a></li><li>Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34237213/">https://pubmed.ncbi.nlm.nih.gov/34237213/</a>.</li><li>Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease associated with the BNT162b2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34105247/">https://pubmed.ncbi.nlm.nih.gov/34105247/</a>.</li><li>Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34405870/">https://pubmed.ncbi.nlm.nih.gov/34405870/</a>.</li><li>Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two cases and review of the literature: <a href="https://pubmed.ncbi.nlm.nih.gov/34416410/">https://pubmed.ncbi.nlm.nih.gov/34416410/</a>.</li><li>Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34462013/">https://pubmed.ncbi.nlm.nih.gov/34462013/</a>.</li><li>Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, after anti-SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34224024/">https://pubmed.ncbi.nlm.nih.gov/34224024/</a>.</li><li>Post-vaccinal encephalitis after ChAdOx1 nCov-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34324214/">https://pubmed.ncbi.nlm.nih.gov/34324214/</a></li><li>Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine: cause or coincidence?: <a href="https://pubmed.ncbi.nlm.nih.gov/34507266/">https://pubmed.ncbi.nlm.nih.gov/34507266/</a></li><li>Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient with multiple myeloma: <a href="https://pubmed.ncbi.nlm.nih.gov/34459725/">https://pubmed.ncbi.nlm.nih.gov/34459725/</a></li><li>Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34463066/">https://pubmed.ncbi.nlm.nih.gov/34463066/</a></li><li>Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination ASIA syndrome: <a href="https://pubmed.ncbi.nlm.nih.gov/34043800/">https://pubmed.ncbi.nlm.nih.gov/34043800/</a>.</li><li>Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the Ad26.COV2.S vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34447646/">https://pubmed.ncbi.nlm.nih.gov/34447646/</a></li><li>Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: <a href="https://pubmed.ncbi.nlm.nih.gov/34479760/">https://pubmed.ncbi.nlm.nih.gov/34479760/</a>.</li><li>fulminant
myocarditis and systemic hyperinflammation temporally associated with
BNT162b2 COVID-19 mRNA vaccination in two patients: <a href="https://pubmed.ncbi.nlm.nih.gov/34416319/">https://pubmed.ncbi.nlm.nih.gov/34416319/</a>.</li><li>Adverse
effects reported after COVID-19 vaccination in a tertiary care
hospital, centered on cerebral venous sinus thrombosis (CVST): <a href="https://pubmed.ncbi.nlm.nih.gov/34092166/">https://pubmed.ncbi.nlm.nih.gov/34092166/</a></li><li>Induction
and exacerbation of subacute cutaneous lupus erythematosus
erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2
vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34291477/">https://pubmed.ncbi.nlm.nih.gov/34291477/</a></li><li>Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA (mRNA)-based COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34513435/">https://pubmed.ncbi.nlm.nih.gov/34513435/</a></li><li>Hepatitis C virus reactivation after COVID-19 vaccination: a case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34512037/">https://pubmed.ncbi.nlm.nih.gov/34512037/</a></li><li>Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2 recombinant viral vector vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34483273/">https://pubmed.ncbi.nlm.nih.gov/34483273/</a>.</li><li>Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19 vaccine in an elderly woman: <a href="https://pubmed.ncbi.nlm.nih.gov/34513446/">https://pubmed.ncbi.nlm.nih.gov/34513446/</a></li><li>Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with the ChAdO × 1 nCov-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34474550/">https://pubmed.ncbi.nlm.nih.gov/34474550/</a></li><li>Reactive arthritis after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34033732/">https://pubmed.ncbi.nlm.nih.gov/34033732/</a>.</li><li>Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune / inflammatory syndrome induced by adjuvants: <a href="https://pubmed.ncbi.nlm.nih.gov/33858208/">https://pubmed.ncbi.nlm.nih.gov/33858208/</a></li><li>Acute relapse and impaired immunization after COVID-19 vaccination in a patient with multiple sclerosis treated with rituximab: <a href="https://pubmed.ncbi.nlm.nih.gov/34015240/">https://pubmed.ncbi.nlm.nih.gov/34015240/</a></li><li>Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34482558/">https://pubmed.ncbi.nlm.nih.gov/34482558/</a></li><li>COVID-19 mRNA vaccine causing CNS inflammation: a case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34480607/">https://pubmed.ncbi.nlm.nih.gov/34480607/</a></li><li>Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34462647/">https://pubmed.ncbi.nlm.nih.gov/34462647/</a></li><li>Acute disseminated encephalomyelitis following vaccination against SARS-CoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/34325334/">https://pubmed.ncbi.nlm.nih.gov/34325334/</a></li><li>Tolosa-Hunt syndrome occurring after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34513398/">https://pubmed.ncbi.nlm.nih.gov/34513398/</a></li><li>Systemic capillary extravasation syndrome following vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): <a href="https://pubmed.ncbi.nlm.nih.gov/34362727/">https://pubmed.ncbi.nlm.nih.gov/34362727/</a></li><li>Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine (Janssen; Johnson & Johnson): <a href="https://pubmed.ncbi.nlm.nih.gov/34469919/">https://pubmed.ncbi.nlm.nih.gov/34469919/</a>.</li><li>Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after vaccination with Ad26.COV2.S: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34516272/">https://pubmed.ncbi.nlm.nih.gov/34516272/</a>.</li><li>Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic response to methylprednisolone: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34512961/">https://pubmed.ncbi.nlm.nih.gov/34512961/</a></li><li>Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34077949/">https://pubmed.ncbi.nlm.nih.gov/34077949/</a></li><li>Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): <a href="https://pubmed.ncbi.nlm.nih.gov/34171435/">https://pubmed.ncbi.nlm.nih.gov/34171435/</a></li><li>Severe relapse of multiple sclerosis after COVID-19 vaccination: a case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34447349/">https://pubmed.ncbi.nlm.nih.gov/34447349/</a></li><li>Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S: <a href="https://pubmed.ncbi.nlm.nih.gov/34514078/">https://pubmed.ncbi.nlm.nih.gov/34514078/</a></li><li>Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34406660/">https://pubmed.ncbi.nlm.nih.gov/34406660/</a>.</li><li>IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34509658/">https://pubmed.ncbi.nlm.nih.gov/34509658/</a></li><li>A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34196469/">https://pubmed.ncbi.nlm.nih.gov/34196469/</a>.</li><li>Onset
/ outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine
(Oxford-AstraZeneca / Covishield): report of two cases: <a href="https://pubmed.ncbi.nlm.nih.gov/34350668/">https://pubmed.ncbi.nlm.nih.gov/34350668/</a></li><li>Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34436620/">https://pubmed.ncbi.nlm.nih.gov/34436620/</a></li><li>Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: <a href="https://pubmed.ncbi.nlm.nih.gov/34116295/">https://pubmed.ncbi.nlm.nih.gov/34116295/</a>.</li><li>COVID-19
vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity:
concern in cases with underlying hepatic problems: <a href="https://pubmed.ncbi.nlm.nih.gov/34509271/">https://pubmed.ncbi.nlm.nih.gov/34509271/</a>.</li><li>Report of the International Cerebral Venous Thrombosis Consortium on cerebral venous thrombosis after SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34462996/">https://pubmed.ncbi.nlm.nih.gov/34462996/</a></li><li>Immune thrombocytopenia after vaccination during the COVID-19 pandemic: <a href="https://pubmed.ncbi.nlm.nih.gov/34435486/">https://pubmed.ncbi.nlm.nih.gov/34435486/</a></li><li>COVID-19:
lessons from the Norwegian tragedy should be taken into account in
planning for vaccine launch in less developed/developing countries: <a href="https://pubmed.ncbi.nlm.nih.gov/34435142/">https://pubmed.ncbi.nlm.nih.gov/34435142/</a></li><li>Rituximab-induced acute lympholysis and pancytopenia following vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34429981/">https://pubmed.ncbi.nlm.nih.gov/34429981/</a></li><li>Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2 vaccines: report of two cases: <a href="https://pubmed.ncbi.nlm.nih.gov/34427024/">https://pubmed.ncbi.nlm.nih.gov/34427024/</a></li><li>Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34510014/">https://pubmed.ncbi.nlm.nih.gov/34510014/</a>.</li><li>Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature: <a href="https://pubmed.ncbi.nlm.nih.gov/34236711/">https://pubmed.ncbi.nlm.nih.gov/34236711/</a></li><li>Vaccine-induced thrombocytopenia with severe headache: <a href="https://pubmed.ncbi.nlm.nih.gov/34525282/">https://pubmed.ncbi.nlm.nih.gov/34525282/</a></li><li>Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34515024/">https://pubmed.ncbi.nlm.nih.gov/34515024/</a></li><li>Rhabdomyolysis and fasciitis induced by COVID-19 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34435250/">https://pubmed.ncbi.nlm.nih.gov/34435250/</a>.</li><li>Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature: <a href="https://pubmed.ncbi.nlm.nih.gov/34363637/">https://pubmed.ncbi.nlm.nih.gov/34363637/</a></li><li>Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA vaccine BNT162b2: <a href="https://www.sciencedirect.com/science/article/pii/S2214250921002018">https://www.sciencedirect.com/science/article/pii/S2214250921002018</a></li><li>Secondary immune thrombocytopenia putatively attributable to COVID-19 vaccination: <a href="https://casereports.bmj.com/content/14/5/e242220.abstract">https://casereports.bmj.com/content/14/5/e242220.abstract</a>.</li><li>Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34155844/">https://pubmed.ncbi.nlm.nih.gov/34155844/</a></li><li>Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine administration: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/</a>.</li><li>Idiopathic thrombocytopenic purpura and the Modern Covid-19 vaccine: <a href="https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext">https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext</a>.</li><li>Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -2: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/</a>.</li><li>Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccination: <a href="https://casereports.bmj.com/content/14/7/e242678">https://casereports.bmj.com/content/14/7/e242678</a>.</li><li>Collection of complement-mediated and autoimmune-mediated hematologic conditions after SARS-CoV-2 vaccination: <a href="https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic">https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic</a></li><li>Petechial rash associated with CoronaVac vaccination: first report of cutaneous side effects before phase 3 results: <a href="https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794">https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794</a></li><li>COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria: <a href="https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in">https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in</a></li><li>Cerebral venous thrombosis associated with COVID-19 vaccine in Germany: <a href="https://pubmed.ncbi.nlm.nih.gov/34288044/">https://pubmed.ncbi.nlm.nih.gov/34288044/</a>.</li><li>Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and radiological management: <a href="https://pubmed.ncbi.nlm.nih.gov/34327553/">https://pubmed.ncbi.nlm.nih.gov/34327553/</a>.</li><li>Cerebral venous thrombosis and thrombocytopenia after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33878469/">https://pubmed.ncbi.nlm.nih.gov/33878469/</a>.</li><li>Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination: report of two cases in the United Kingdom: <a href="https://pubmed.ncbi.nlm.nih.gov/33857630/">https://pubmed.ncbi.nlm.nih.gov/33857630/</a>.</li><li>Cerebral venous thrombosis induced by SARS-CoV-2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34090750/">https://pubmed.ncbi.nlm.nih.gov/34090750/</a>.</li><li>Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19 vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34312301/">https://pubmed.ncbi.nlm.nih.gov/34312301/</a>.</li><li>Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34333995/">https://pubmed.ncbi.nlm.nih.gov/34333995/</a></li><li>The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune-immune thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34455073/">https://pubmed.ncbi.nlm.nih.gov/34455073/</a></li><li>Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34111775/">https://pubmed.ncbi.nlm.nih.gov/34111775/</a>.</li><li>Cerebral venous thrombosis after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34045111/">https://pubmed.ncbi.nlm.nih.gov/34045111/</a></li><li>Lethal cerebral venous sinus thrombosis after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33983464/">https://pubmed.ncbi.nlm.nih.gov/33983464/</a></li><li>Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2 vaccination with adenovirus and after COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34116145/">https://pubmed.ncbi.nlm.nih.gov/34116145/</a></li><li>Cerebral
venous thrombosis after COVID-19 vaccination: is the risk of thrombosis
increased by intravascular administration of the vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34286453/">https://pubmed.ncbi.nlm.nih.gov/34286453/</a>.</li><li>Central
venous sinus thrombosis with subarachnoid hemorrhage after COVID-19
mRNA vaccination: are these reports merely coincidental: <a href="https://pubmed.ncbi.nlm.nih.gov/34478433/">https://pubmed.ncbi.nlm.nih.gov/34478433/</a></li><li>Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a misleading first brain MRI: <a href="https://pubmed.ncbi.nlm.nih.gov/34244448/">https://pubmed.ncbi.nlm.nih.gov/34244448/</a></li><li>Early
results of bivalirudin treatment for thrombotic thrombocytopenia and
cerebral venous sinus thrombosis after vaccination with Ad26.COV2.S: <a href="https://pubmed.ncbi.nlm.nih.gov/34226070/">https://pubmed.ncbi.nlm.nih.gov/34226070/</a></li><li>Cerebral venous sinus thrombosis associated with post-vaccination thrombocytopenia by COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/33845870/">https://pubmed.ncbi.nlm.nih.gov/33845870/</a>.</li><li>Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34101024/">https://pubmed.ncbi.nlm.nih.gov/34101024/</a>.</li><li>Vaccine-induced
immune thrombotic thrombocytopenia causing a severe form of cerebral
venous thrombosis with a high mortality rate: a case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34393988/">https://pubmed.ncbi.nlm.nih.gov/34393988/</a>.</li><li>Adenovirus interactions with platelets and coagulation and vaccine-associated autoimmune thrombocytopenia thrombosis syndrome: <a href="https://pubmed.ncbi.nlm.nih.gov/34407607/">https://pubmed.ncbi.nlm.nih.gov/34407607/</a>.</li><li>Headache
attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the
ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort
study: <a href="https://pubmed.ncbi.nlm.nih.gov/34313952/">https://pubmed.ncbi.nlm.nih.gov/34313952/</a></li><li>Adverse
effects reported after COVID-19 vaccination in a tertiary care
hospital, focus on cerebral venous sinus thrombosis (CVST): <a href="https://pubmed.ncbi.nlm.nih.gov/34092166/">https://pubmed.ncbi.nlm.nih.gov/34092166/</a></li><li>Cerebral
venous sinus thrombosis following vaccination against SARS-CoV-2: an
analysis of cases reported to the European Medicines Agency: <a href="https://pubmed.ncbi.nlm.nih.gov/34293217/">https://pubmed.ncbi.nlm.nih.gov/34293217/</a></li><li>A rare case of a middle-age Asian male with cerebral venous thrombosis after COVID-19 AstraZeneca vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34274191/">https://pubmed.ncbi.nlm.nih.gov/34274191/</a></li><li>Cerebral
venous sinus thrombosis negative for anti-PF4 antibody without
thrombocytopenia after immunization with COVID-19 vaccine in a
non-comorbid elderly Indian male treated with conventional
heparin-warfarin-based anticoagulation: <a href="https://pubmed.ncbi.nlm.nih.gov/34186376/">https://pubmed.ncbi.nlm.nih.gov/34186376/</a></li><li>Arterial
events, venous thromboembolism, thrombocytopenia and bleeding after
vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway:
population-based cohort study: <a href="https://pubmed.ncbi.nlm.nih.gov/33952445/">https://pubmed.ncbi.nlm.nih.gov/33952445/</a></li><li>Procoagulant
microparticles: a possible link between vaccine-induced immune
thrombocytopenia (VITT) and cerebral sinus venous thrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34129181/">https://pubmed.ncbi.nlm.nih.gov/34129181/</a></li><li>S.
case reports of cerebral venous sinus thrombosis with thrombocytopenia
after vaccination with Ad26.COV2.S, March 2-April 21, 2021: <a href="https://pubmed.ncbi.nlm.nih.gov/33929487/">https://pubmed.ncbi.nlm.nih.gov/33929487/</a>.</li><li>Malignant
cerebral infarction after vaccination with ChAdOx1 nCov-19: a
catastrophic variant of vaccine-induced immune-mediated thrombotic
thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34341358/">https://pubmed.ncbi.nlm.nih.gov/34341358/</a></li><li>Acute
ischemic stroke revealing immune thrombotic thrombocytopenia induced by
ChAdOx1 nCov-19 vaccine: impact on recanalization strategy: <a href="https://pubmed.ncbi.nlm.nih.gov/34175640/">https://pubmed.ncbi.nlm.nih.gov/34175640/</a></li><li>Vaccine-induced
immune thrombotic immune thrombocytopenia (VITT): a new
clinicopathologic entity with heterogeneous clinical presentations: <a href="https://pubmed.ncbi.nlm.nih.gov/34159588/">https://pubmed.ncbi.nlm.nih.gov/34159588/</a>.</li><li>Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): <a href="https://pubmed.ncbi.nlm.nih.gov/34402666/">https://pubmed.ncbi.nlm.nih.gov/34402666/</a></li><li>Autoimmunity roots of thrombotic events after vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34508917/">https://pubmed.ncbi.nlm.nih.gov/34508917/</a></li><li>Cerebral venous sinus thrombosis after vaccination: the UK experience: <a href="https://pubmed.ncbi.nlm.nih.gov/34370974/">https://pubmed.ncbi.nlm.nih.gov/34370974/</a></li><li>Massive cerebral venous thrombosis and venous basin infarction as late complications of COVID-19: a case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34373991/">https://pubmed.ncbi.nlm.nih.gov/34373991/</a></li><li>Australian
and New Zealand approach to the diagnosis and treatment of
vaccine-induced immune thrombosis and immune thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34490632/">https://pubmed.ncbi.nlm.nih.gov/34490632/</a></li><li>An
observational study to identify the prevalence of thrombocytopenia and
anti-PF4 / polyanion antibodies in Norwegian health care workers after
COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33909350/">https://pubmed.ncbi.nlm.nih.gov/33909350/</a></li><li>Acute
transverse myelitis (ATM): clinical review of 43 patients with
COVID-19-associated ATM and 3 serious adverse events of post-vaccination
ATM with ChAdOx1 nCoV-19 (AZD1222) vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33981305/">https://pubmed.ncbi.nlm.nih.gov/33981305/</a>.</li><li>A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine:. <a href="https://pubmed.ncbi.nlm.nih.gov/34272622/">https://pubmed.ncbi.nlm.nih.gov/34272622/</a></li><li>Thrombocytopenia
with acute ischemic stroke and hemorrhage in a patient recently
vaccinated with an adenoviral vector-based COVID-19 vaccine:. <a href="https://pubmed.ncbi.nlm.nih.gov/33877737/">https://pubmed.ncbi.nlm.nih.gov/33877737/</a></li><li>Predicted and observed incidence of thromboembolic events among Koreans vaccinated with the ChAdOx1 nCoV-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34254476/">https://pubmed.ncbi.nlm.nih.gov/34254476/</a></li><li>First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic, and hemorrhagic events in Scotland: <a href="https://pubmed.ncbi.nlm.nih.gov/34108714/">https://pubmed.ncbi.nlm.nih.gov/34108714/</a></li><li>ChAdOx1
nCoV-19 vaccine-associated thrombocytopenia: three cases of immune
thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in Thailand:
<a href="https://pubmed.ncbi.nlm.nih.gov/34483267/">https://pubmed.ncbi.nlm.nih.gov/34483267/</a>.</li><li>Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson & Johnson COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34261635/">https://pubmed.ncbi.nlm.nih.gov/34261635/</a></li><li>Neurosurgical
considerations with respect to decompressive craniectomy for
intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced
thrombotic thrombocytopenia-VITT: <a href="https://pubmed.ncbi.nlm.nih.gov/34202817/">https://pubmed.ncbi.nlm.nih.gov/34202817/</a></li><li>Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34273119/">https://pubmed.ncbi.nlm.nih.gov/34273119/</a></li><li>Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34463066/">https://pubmed.ncbi.nlm.nih.gov/34463066/</a></li><li>A
rare case of thrombosis and thrombocytopenia of the superior ophthalmic
vein after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/34276917/">https://pubmed.ncbi.nlm.nih.gov/34276917/</a></li><li>Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34237213/">https://pubmed.ncbi.nlm.nih.gov/34237213/</a>.</li><li>Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced thrombotic immune thrombocytopenia (VITT): <a href="https://pubmed.ncbi.nlm.nih.gov/34268278/">https://pubmed.ncbi.nlm.nih.gov/34268278/</a>.</li><li>Limb
ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine
(Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic
thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/33990339/">https://pubmed.ncbi.nlm.nih.gov/33990339/</a>.</li><li>Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large population-based cohort study: <a href="https://pubmed.ncbi.nlm.nih.gov/34479760/">https://pubmed.ncbi.nlm.nih.gov/34479760/</a>.</li><li>Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of haemorrhage and hematoma after minor oral surgery: <a href="https://pubmed.ncbi.nlm.nih.gov/34314875/">https://pubmed.ncbi.nlm.nih.gov/34314875/</a>.</li><li>Venous thromboembolism and mild thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34384129/">https://pubmed.ncbi.nlm.nih.gov/34384129/</a></li><li>Fatal
exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia
syndrome after successful initial therapy with intravenous
immunoglobulins: a rationale for monitoring immunoglobulin G levels: <a href="https://pubmed.ncbi.nlm.nih.gov/34382387/">https://pubmed.ncbi.nlm.nih.gov/34382387/</a></li><li>A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: <a href="https://pubmed.ncbi.nlm.nih.gov/34416184/">https://pubmed.ncbi.nlm.nih.gov/34416184/</a>.</li><li>Intracerebral
hemorrhage associated with vaccine-induced thrombotic thrombocytopenia
after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: <a href="https://pubmed.ncbi.nlm.nih.gov/34261297/">https://pubmed.ncbi.nlm.nih.gov/34261297/</a></li><li>Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34261296/">https://pubmed.ncbi.nlm.nih.gov/34261296/</a></li><li>Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/34250318/">https://pubmed.ncbi.nlm.nih.gov/34250318/</a>.</li><li>A case of vaccine-induced immune-immune thrombotic thrombocytopenia with massive arteriovenous thrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34059191/">https://pubmed.ncbi.nlm.nih.gov/34059191/</a></li><li>Cutaneous thrombosis associated with cutaneous necrosis following Oxford-AstraZeneca COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34189756/">https://pubmed.ncbi.nlm.nih.gov/34189756/</a></li><li>Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34331506/">https://pubmed.ncbi.nlm.nih.gov/34331506/</a></li><li>Vaccine-induced thrombocytopenia with severe headache: <a href="https://pubmed.ncbi.nlm.nih.gov/34525282/">https://pubmed.ncbi.nlm.nih.gov/34525282/</a></li><li>Myocarditis
associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17
years: stratified analysis of a national database: <a href="https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1">https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1</a></li><li>COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis: <a href="https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09">https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09</a>.</li><li>Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA vaccine: <a href="https://onlinelibrary.wiley.com/doi/10.1111/trf.16672">https://onlinelibrary.wiley.com/doi/10.1111/trf.16672</a></li><li>Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model: <a href="https://t.co/j0IEM8cMXI">https://t.co/j0IEM8cMXI</a></li><li>A
report of myocarditis adverse events in the U.S. Vaccine Adverse Event
Reporting System. (VAERS) in association with COVID-19 injectable
biologics: <a href="https://pubmed.ncbi.nlm.nih.gov/34601006/">https://pubmed.ncbi.nlm.nih.gov/34601006/</a></li><li>This
study concludes that: “The vaccine was associated with an excess risk
of myocarditis (1 to 5 events per 100,000 persons). The risk of this
potentially serious adverse event and of many other serious adverse
events increased substantially after SARS-CoV-2 infection”: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2110475">https://www.nejm.org/doi/full/10.1056/NEJMoa2110475</a></li><li>Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: <a href="https://www.sciencedirect.com/science/article/pii/S1201971221007797">https://www.sciencedirect.com/science/article/pii/S1201971221007797</a></li><li>Myocarditis
associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17
years: stratified analysis of a national database: <a href="https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1">https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1</a>.</li><li>Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but confirmed: <a href="https://www.sciencedirect.com/science/article/pii/S0168827821020936">https://www.sciencedirect.com/science/article/pii/S0168827821020936</a></li><li>Extensive investigations revealed consistent pathophysiologic alterations after vaccination with COVID-19 vaccines: <a href="https://www.nature.com/articles/s41421-021-00329-3">https://www.nature.com/articles/s41421-021-00329-3</a></li><li>Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-based SARS-CoV-2 vaccine: <a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/">https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/</a></li><li>Mrna
COVID vaccines dramatically increase endothelial inflammatory markers
and risk of Acute Coronary Syndrome as measured by PULS cardiac testing:
a caution: <a href="https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712">https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712</a></li><li>ChAdOx1
interacts with CAR and PF4 with implications for thrombosis with
thrombocytopenia
syndrome:https://www.science.org/doi/10.1126/sciadv.abl8213</li><li>Lethal
vaccine-induced immune thrombotic immune thrombocytopenia (VITT)
following announcement 26.COV2.S: first documented case outside the
U.S.: <a href="https://pubmed.ncbi.nlm.nih.gov/34626338/">https://pubmed.ncbi.nlm.nih.gov/34626338/</a></li><li>A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia after coronavirus-19 vaccination: <a href="https://europepmc.org/article/PPR/PPR304469%20435">https://europepmc.org/article/PPR/PPR304469 435</a>.</li><li>VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34731555/">https://pubmed.ncbi.nlm.nih.gov/34731555/</a></li><li>Vaccine-induced
immune thrombotic thrombocytopenia (VITT): a new clinicopathologic
entity with heterogeneous clinical presentations: <a href="https://pubmed.ncbi.nlm.nih.gov/34159588/">https://pubmed.ncbi.nlm.nih.gov/34159588/</a></li><li>Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34461442/">https://pubmed.ncbi.nlm.nih.gov/34461442/</a></li><li>Spectrum of neurological complications after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34719776/">https://pubmed.ncbi.nlm.nih.gov/34719776/</a>.</li><li>Cerebral venous sinus thrombosis after vaccination: the UK experience: <a href="https://pubmed.ncbi.nlm.nih.gov/34370974/">https://pubmed.ncbi.nlm.nih.gov/34370974/</a></li><li>Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34373413/">https://pubmed.ncbi.nlm.nih.gov/34373413/</a></li><li>Portal
vein thrombosis due to vaccine-induced immune thrombotic immune
thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34598301/">https://pubmed.ncbi.nlm.nih.gov/34598301/</a></li><li>Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca ChAdOx1 nCoV-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34620638/">https://pubmed.ncbi.nlm.nih.gov/34620638/</a></li><li>Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1 nCoV-19 in a hemodialysis patient: <a href="https://pubmed.ncbi.nlm.nih.gov/34650896/">https://pubmed.ncbi.nlm.nih.gov/34650896/</a></li><li>Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34625447/">https://pubmed.ncbi.nlm.nih.gov/34625447/</a></li><li>Humoral
response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and
BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with
teriflunomide: <a href="https://pubmed.ncbi.nlm.nih.gov/34696248/">https://pubmed.ncbi.nlm.nih.gov/34696248/</a></li><li>Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34548920/">https://pubmed.ncbi.nlm.nih.gov/34548920/</a></li><li>Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated with delayed therapeutic plasma exchange (TPE): <a href="https://pubmed.ncbi.nlm.nih.gov/34672380/">https://pubmed.ncbi.nlm.nih.gov/34672380/</a>.</li><li>Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous sinus thrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34556531/">https://pubmed.ncbi.nlm.nih.gov/34556531/</a>.</li><li>Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced cerebral venous thrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34535076/">https://pubmed.ncbi.nlm.nih.gov/34535076/</a>.</li><li>Clinical features of vaccine-induced thrombocytopenia and immune thrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34379914/">https://pubmed.ncbi.nlm.nih.gov/34379914/</a>.</li><li>Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score: <a href="https://pubmed.ncbi.nlm.nih.gov/34545400/">https://pubmed.ncbi.nlm.nih.gov/34545400/</a></li><li>Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia induced by ChAdOx1-nCoV-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34035134/">https://pubmed.ncbi.nlm.nih.gov/34035134/</a></li><li>In-hospital observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34688190/">https://pubmed.ncbi.nlm.nih.gov/34688190/</a></li><li>Endovascular
treatment for vaccine-induced cerebral venous sinus thrombosis and
thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three
cases: <a href="https://pubmed.ncbi.nlm.nih.gov/34782400/">https://pubmed.ncbi.nlm.nih.gov/34782400/</a></li><li>Cardiovascular,
neurological, and pulmonary events after vaccination with BNT162b2,
ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European data:
<a href="https://pubmed.ncbi.nlm.nih.gov/34710832/">https://pubmed.ncbi.nlm.nih.gov/34710832/</a></li><li>Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT, TTS and more: <a href="https://pubmed.ncbi.nlm.nih.gov/34695859/">https://pubmed.ncbi.nlm.nih.gov/34695859/</a></li><li>Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study of 74 consecutive cases: <a href="https://pubmed.ncbi.nlm.nih.gov/34453762/">https://pubmed.ncbi.nlm.nih.gov/34453762/</a>.</li><li>Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine, Pfizer-BioNTech: <a href="https://pubmed.ncbi.nlm.nih.gov/34660652/">https://pubmed.ncbi.nlm.nih.gov/34660652/</a>.</li><li>Multiple
sites of arterial thrombosis in a 35-year-old patient after vaccination
with ChAdOx1 (AstraZeneca), which required emergency femoral and
carotid surgical thrombectomy: <a href="https://pubmed.ncbi.nlm.nih.gov/34644642/">https://pubmed.ncbi.nlm.nih.gov/34644642/</a></li><li>Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching hospital: <a href="https://pubmed.ncbi.nlm.nih.gov/34694650/">https://pubmed.ncbi.nlm.nih.gov/34694650/</a></li><li>Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by ChAdOx1 nCoV-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34726934/">https://pubmed.ncbi.nlm.nih.gov/34726934/</a></li><li>Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a population-based study in Italy: <a href="https://pubmed.ncbi.nlm.nih.gov/34835237/">https://pubmed.ncbi.nlm.nih.gov/34835237/</a></li><li>Intracerebral
hemorrhage associated with vaccine-induced thrombotic thrombocytopenia
after ChAdOx1 nCOVID-19 vaccination in a pregnant woman: <a href="https://pubmed.ncbi.nlm.nih.gov/34261297/">https://pubmed.ncbi.nlm.nih.gov/34261297/</a></li><li>Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Ad26.COV2.S COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34724036/">https://pubmed.ncbi.nlm.nih.gov/34724036/</a>.</li><li>Genital necrosis with cutaneous thrombosis following vaccination with COVID-19 mRNA: <a href="https://pubmed.ncbi.nlm.nih.gov/34839563/">https://pubmed.ncbi.nlm.nih.gov/34839563/</a></li><li>Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34783932/">https://pubmed.ncbi.nlm.nih.gov/34783932/</a>.</li><li>COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis (VITT) and shades of gray in thrombus formation: <a href="https://pubmed.ncbi.nlm.nih.gov/34624910/">https://pubmed.ncbi.nlm.nih.gov/34624910/</a></li><li>Inflammatory myositis after vaccination with ChAdOx1: <a href="https://pubmed.ncbi.nlm.nih.gov/34585145/">https://pubmed.ncbi.nlm.nih.gov/34585145/</a></li><li>Acute ST-segment elevation myocardial infarction secondary to vaccine-induced immune thrombosis with thrombocytopenia (VITT): <a href="https://pubmed.ncbi.nlm.nih.gov/34580132/">https://pubmed.ncbi.nlm.nih.gov/34580132/</a>.</li><li>A
rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia
(VITT) affecting the venosplanchnic and pulmonary arterial circulation
from a UK district general hospital: <a href="https://pubmed.ncbi.nlm.nih.gov/34535492/">https://pubmed.ncbi.nlm.nih.gov/34535492/</a></li><li>COVID-19 vaccine-induced thrombotic thrombocytopenia: a case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34527501/">https://pubmed.ncbi.nlm.nih.gov/34527501/</a></li><li>Thrombosis
with thrombocytopenia syndrome (TTS) after vaccination with AstraZeneca
ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for persons
<60% risk-benefit analysis for people <60 years in Australia: <a href="https://pubmed.ncbi.nlm.nih.gov/34272095/">https://pubmed.ncbi.nlm.nih.gov/34272095/</a></li><li>Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine (AstraZeneca), Victoria, Australia: <a href="https://pubmed.ncbi.nlm.nih.gov/34756770/">https://pubmed.ncbi.nlm.nih.gov/34756770/</a></li><li>Characteristics
and outcomes of patients with cerebral venous sinus thrombosis in
thrombotic immune thrombocytopenia induced by SARS-CoV-2 vaccine: <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622">https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622</a></li><li>Case study of thrombosis and thrombocytopenia syndrome after administration of the AstraZeneca COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34781321/">https://pubmed.ncbi.nlm.nih.gov/34781321/</a></li><li>Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34062319/">https://pubmed.ncbi.nlm.nih.gov/34062319/</a></li><li>Cerebral
venous sinus thrombosis following vaccination with ChAdOx1: the first
case of definite thrombosis with thrombocytopenia syndrome in India: <a href="https://pubmed.ncbi.nlm.nih.gov/34706921/">https://pubmed.ncbi.nlm.nih.gov/34706921/</a></li><li>COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): systematic review and post hoc analysis: <a href="https://pubmed.ncbi.nlm.nih.gov/34698582/">https://pubmed.ncbi.nlm.nih.gov/34698582/</a>.</li><li>Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34751013/">https://pubmed.ncbi.nlm.nih.gov/34751013/</a>.</li><li>Acute transverse myelitis after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34684047/">https://pubmed.ncbi.nlm.nih.gov/34684047/</a>.</li><li>Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34541935/">https://pubmed.ncbi.nlm.nih.gov/34541935/</a></li><li>Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34273119/">https://pubmed.ncbi.nlm.nih.gov/34273119/</a></li><li>Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and radiologic management: <a href="https://pubmed.ncbi.nlm.nih.gov/34327553/">https://pubmed.ncbi.nlm.nih.gov/34327553/</a>.</li><li>Thrombocytopenia
with acute ischemic stroke and hemorrhage in a patient recently
vaccinated with an adenoviral vector-based COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33877737/">https://pubmed.ncbi.nlm.nih.gov/33877737/</a></li><li>Intracerebral
hemorrhage and thrombocytopenia after AstraZeneca COVID-19 vaccine:
clinical and diagnostic challenges of vaccine-induced thrombotic
thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34646685/">https://pubmed.ncbi.nlm.nih.gov/34646685/</a></li><li>Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca COVID-19 vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34242687/">https://pubmed.ncbi.nlm.nih.gov/34242687/</a>.</li><li>Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34609603/">https://pubmed.ncbi.nlm.nih.gov/34609603/</a></li><li>Case report: Pityriasis rosea-like rash after vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34557507/">https://pubmed.ncbi.nlm.nih.gov/34557507/</a></li><li>Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34641797/">https://pubmed.ncbi.nlm.nih.gov/34641797/</a>.</li><li>Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222: <a href="https://pubmed.ncbi.nlm.nih.gov/34812326/">https://pubmed.ncbi.nlm.nih.gov/34812326/</a>.</li><li>Thrombocytopenia,
including immune thrombocytopenia after receiving COVID-19 mRNA
vaccines reported to the Vaccine Adverse Event Reporting System (VAERS):
<a href="https://pubmed.ncbi.nlm.nih.gov/34006408/">https://pubmed.ncbi.nlm.nih.gov/34006408/</a></li><li>A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: victim or causality?: <a href="https://pubmed.ncbi.nlm.nih.gov/34416184/">https://pubmed.ncbi.nlm.nih.gov/34416184/</a></li><li>Vaccine-induced
immune thrombosis and thrombocytopenia syndrome after
adenovirus-vectored severe acute respiratory syndrome coronavirus 2
vaccination: a new hypothesis on mechanisms and implications for future
vaccine development: <a href="https://pubmed.ncbi.nlm.nih.gov/34664303/">https://pubmed.ncbi.nlm.nih.gov/34664303/</a>.</li><li>Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following adenoviral COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34649281/">https://pubmed.ncbi.nlm.nih.gov/34649281/</a>.</li><li>Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus disease 2019 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34420249/">https://pubmed.ncbi.nlm.nih.gov/34420249/</a></li><li>Cerebral
venous sinus thrombosis and thrombotic events after vector-based
COVID-19 vaccines: systematic review and meta-analysis: <a href="https://pubmed.ncbi.nlm.nih.gov/34610990/">https://pubmed.ncbi.nlm.nih.gov/34610990/</a>.</li><li>Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an elderly woman: <a href="https://pubmed.ncbi.nlm.nih.gov/34590397/">https://pubmed.ncbi.nlm.nih.gov/34590397/</a></li><li>Sudden sensorineural hearing loss after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34670143/">https://pubmed.ncbi.nlm.nih.gov/34670143/</a>.</li><li>Prevalence
of serious adverse events among health care professionals after
receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine
(Covishield) in Togo, March 2021: <a href="https://pubmed.ncbi.nlm.nih.gov/34819146/">https://pubmed.ncbi.nlm.nih.gov/34819146/</a>.</li><li>Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34581453/">https://pubmed.ncbi.nlm.nih.gov/34581453/</a></li><li>Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in Italy: <a href="https://pubmed.ncbi.nlm.nih.gov/34741583/">https://pubmed.ncbi.nlm.nih.gov/34741583/</a></li><li>Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34631069/">https://pubmed.ncbi.nlm.nih.gov/34631069/</a></li><li>Thrombosis after COVID-19 vaccination: possible link to ACE pathways: <a href="https://pubmed.ncbi.nlm.nih.gov/34479129/">https://pubmed.ncbi.nlm.nih.gov/34479129/</a></li><li>Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34331506/">https://pubmed.ncbi.nlm.nih.gov/34331506/</a></li><li>Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus vaccine nCoV-19 (recombinant): <a href="https://pubmed.ncbi.nlm.nih.gov/34546608/">https://pubmed.ncbi.nlm.nih.gov/34546608/</a></li><li>Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic thrombocytopenia induced by COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34546343/">https://pubmed.ncbi.nlm.nih.gov/34546343/</a></li><li>Longitudinally extensive cervical myelitis after vaccination with inactivated virus based COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34849183/">https://pubmed.ncbi.nlm.nih.gov/34849183/</a></li><li>Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34853744/">https://pubmed.ncbi.nlm.nih.gov/34853744/</a>.</li><li>A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19 (AZD1222): <a href="https://pubmed.ncbi.nlm.nih.gov/34751429/">https://pubmed.ncbi.nlm.nih.gov/34751429/</a>.</li><li>Ocular adverse events following COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34559576/">https://pubmed.ncbi.nlm.nih.gov/34559576/</a></li><li>Depression after ChAdOx1-S / nCoV-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34608345/">https://pubmed.ncbi.nlm.nih.gov/34608345/</a>.</li><li>Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34384129/">https://pubmed.ncbi.nlm.nih.gov/34384129/</a>.</li><li>Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: a case series of two patients: <a href="https://pubmed.ncbi.nlm.nih.gov/34755433/">https://pubmed.ncbi.nlm.nih.gov/34755433/</a></li><li>Major artery thrombosis and vaccination against ChAdOx1 nCov-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34839830/">https://pubmed.ncbi.nlm.nih.gov/34839830/</a></li><li>Rare
case of contralateral supraclavicular lymphadenopathy after vaccination
with COVID-19: computed tomography and ultrasound findings: <a href="https://pubmed.ncbi.nlm.nih.gov/34667486/">https://pubmed.ncbi.nlm.nih.gov/34667486/</a></li><li>Cutaneous
lymphocytic vasculitis after administration of the second dose of
AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome
Coronavirus 2 vaccine: chance or causality: <a href="https://pubmed.ncbi.nlm.nih.gov/34726187/">https://pubmed.ncbi.nlm.nih.gov/34726187/</a>.</li><li>Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34781027/">https://pubmed.ncbi.nlm.nih.gov/34781027/</a></li><li>Understanding the risk of thrombosis with thrombocytopenia syndrome following Ad26.COV2.S vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34595694/">https://pubmed.ncbi.nlm.nih.gov/34595694/</a></li><li>Cutaneous
adverse reactions of 35,229 doses of COVID-19 Sinovac and AstraZeneca
vaccine COVID-19: a prospective cohort study in health care workers: <a href="https://pubmed.ncbi.nlm.nih.gov/34661934/">https://pubmed.ncbi.nlm.nih.gov/34661934/</a></li><li>Comments
on thrombosis after vaccination: spike protein leader sequence could be
responsible for thrombosis and antibody-mediated thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34788138">https://pubmed.ncbi.nlm.nih.gov/34788138</a></li><li>Eosinophilic dermatosis after AstraZeneca COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34753210/">https://pubmed.ncbi.nlm.nih.gov/34753210/</a>.</li><li>Severe immune thrombocytopenia following COVID-19 vaccination: report of four cases and review of the literature: <a href="https://pubmed.ncbi.nlm.nih.gov/34653943/">https://pubmed.ncbi.nlm.nih.gov/34653943/</a>.</li><li>Relapse of immune thrombocytopenia after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34591991/">https://pubmed.ncbi.nlm.nih.gov/34591991/</a></li><li>Thrombosis in pre- and post-vaccination phase of COVID-19; <a href="https://pubmed.ncbi.nlm.nih.gov/34650382/">https://pubmed.ncbi.nlm.nih.gov/34650382/</a></li><li>A
look at the role of postmortem immunohistochemistry in understanding
the inflammatory pathophysiology of COVID-19 disease and vaccine-related
thrombotic adverse events: a narrative review: <a href="https://pubmed.ncbi.nlm.nih.gov/34769454/">https://pubmed.ncbi.nlm.nih.gov/34769454/</a></li><li>COVID-19 vaccine in patients with hypercoagulability disorders: a clinical perspective: <a href="https://pubmed.ncbi.nlm.nih.gov/34786893/">https://pubmed.ncbi.nlm.nih.gov/34786893/</a></li><li>Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy leading to combined venous micro-macrothrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34833382/">https://pubmed.ncbi.nlm.nih.gov/34833382/</a></li><li>Thrombosis
and thrombocytopenia syndrome causing isolated symptomatic carotid
occlusion after COVID-19 Ad26.COV2.S vaccine (Janssen): <a href="https://pubmed.ncbi.nlm.nih.gov/34670287/">https://pubmed.ncbi.nlm.nih.gov/34670287/</a></li><li>An unusual presentation of acute deep vein thrombosis after Modern COVID-19 vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34790811/">https://pubmed.ncbi.nlm.nih.gov/34790811/</a></li><li>Immediate
high-dose intravenous immunoglobulins followed by direct treatment with
thrombin inhibitors is crucial for survival in vaccine-induced immune
thrombotic thrombocytopenia Sars-Covid-19-vector adenoviral VITT with
venous thrombosis of the cerebral sinus and portal vein: <a href="https://pubmed.ncbi.nlm.nih.gov/34023956/">https://pubmed.ncbi.nlm.nih.gov/34023956/</a>.</li><li>Thrombosis formation after COVID-19 vaccination immunologic aspects: review article: <a href="https://pubmed.ncbi.nlm.nih.gov/34629931/">https://pubmed.ncbi.nlm.nih.gov/34629931/</a></li><li>Imaging and hematologic findings in thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-19 (AstraZeneca): <a href="https://pubmed.ncbi.nlm.nih.gov/34402666/">https://pubmed.ncbi.nlm.nih.gov/34402666/</a></li><li>Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and review of the literature: <a href="https://pubmed.ncbi.nlm.nih.gov/34842783/">https://pubmed.ncbi.nlm.nih.gov/34842783/</a></li><li>Cerebral
venous sinus thrombosis, pulmonary embolism, and thrombocytopenia after
COVID-19 vaccination in a Taiwanese man: a case report and review of
the literature: <a href="https://pubmed.ncbi.nlm.nih.gov/34630307/">https://pubmed.ncbi.nlm.nih.gov/34630307/</a></li><li>Fatal cerebral venous sinus thrombosis after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33983464/">https://pubmed.ncbi.nlm.nih.gov/33983464/</a></li><li>Autoimmune roots of thrombotic events after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34508917/">https://pubmed.ncbi.nlm.nih.gov/34508917/</a>.</li><li>New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or COVID-19: <a href="https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext">https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext</a>.</li><li>Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca® COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33962903/">https://pubmed.ncbi.nlm.nih.gov/33962903/</a>.</li><li>Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of BNT162b2: <a href="https://pubmed.ncbi.nlm.nih.gov/34796065/">https://pubmed.ncbi.nlm.nih.gov/34796065/</a>.</li><li>Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination in health care workers taking ACE inhibitors: <a href="https://pubmed.ncbi.nlm.nih.gov/34579248/">https://pubmed.ncbi.nlm.nih.gov/34579248/</a></li><li>A
case of unusual mild clinical presentation of COVID-19 vaccine-induced
immune thrombotic thrombocytopenia with splanchnic vein thrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34843991/">https://pubmed.ncbi.nlm.nih.gov/34843991/</a></li><li>Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech COVID-19 (BNT162b2): <a href="https://pubmed.ncbi.nlm.nih.gov/34595867/">https://pubmed.ncbi.nlm.nih.gov/34595867/</a></li><li>A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19 BNT162b2 vaccine (Pfizer-Biontech): <a href="https://pubmed.ncbi.nlm.nih.gov/34820240/">https://pubmed.ncbi.nlm.nih.gov/34820240/</a></li><li>Vaccine-induced
immune thrombotic immune thrombocytopenia (VITT): targeting pathologic
mechanisms with Bruton’s tyrosine kinase inhibitors: <a href="https://pubmed.ncbi.nlm.nih.gov/33851389/">https://pubmed.ncbi.nlm.nih.gov/33851389/</a></li><li>Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-S: <a href="https://pubmed.ncbi.nlm.nih.gov/33980419/">https://pubmed.ncbi.nlm.nih.gov/33980419/</a></li><li>Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34264151/">https://pubmed.ncbi.nlm.nih.gov/34264151/</a></li><li>Potential risk of thrombotic events after COVID-19 vaccination with Oxford-AstraZeneca in women receiving estrogen: <a href="https://pubmed.ncbi.nlm.nih.gov/34734086/">https://pubmed.ncbi.nlm.nih.gov/34734086/</a></li><li>Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for underlying disease: <a href="https://pubmed.ncbi.nlm.nih.gov/34755555/">https://pubmed.ncbi.nlm.nih.gov/34755555/</a></li><li>Adenovirus interactions with platelets and coagulation and vaccine-induced immune thrombotic thrombocytopenia syndrome: <a href="https://pubmed.ncbi.nlm.nih.gov/34407607/">https://pubmed.ncbi.nlm.nih.gov/34407607/</a></li><li>Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34264514/">https://pubmed.ncbi.nlm.nih.gov/34264514/</a>.</li><li>Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-2019 coronavirus disease (COVID-19): <a href="https://pubmed.ncbi.nlm.nih.gov/34840204/">https://pubmed.ncbi.nlm.nih.gov/34840204/</a></li><li>Neurological side effects of SARS-CoV-2 vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34750810/">https://pubmed.ncbi.nlm.nih.gov/34750810/</a></li><li>Coagulopathies
after SARS-CoV-2 vaccination may derive from a combined effect of
SARS-CoV-2 spike protein and adenovirus vector-activated signaling
pathways: <a href="https://pubmed.ncbi.nlm.nih.gov/34639132/">https://pubmed.ncbi.nlm.nih.gov/34639132/</a></li><li>Isolated
pulmonary embolism after COVID vaccination: 2 case reports and a review
of acute pulmonary embolism complications and follow-up: <a href="https://pubmed.ncbi.nlm.nih.gov/34804412/">https://pubmed.ncbi.nlm.nih.gov/34804412/</a></li><li>Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34571653/">https://pubmed.ncbi.nlm.nih.gov/34571653/</a>.</li><li>Complicated case report of long-term vaccine-induced thrombotic immune thrombocytopenia A: <a href="https://pubmed.ncbi.nlm.nih.gov/34835275/">https://pubmed.ncbi.nlm.nih.gov/34835275/</a>.</li><li>Deep venous thrombosis after vaccination with Ad26.COV2.S in adult males: <a href="https://pubmed.ncbi.nlm.nih.gov/34659839/">https://pubmed.ncbi.nlm.nih.gov/34659839/</a>.</li><li>Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34668274/">https://pubmed.ncbi.nlm.nih.gov/34668274/</a>.</li><li>Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34549821/">https://pubmed.ncbi.nlm.nih.gov/34549821/</a></li><li>Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine (recombinant): <a href="https://pubmed.ncbi.nlm.nih.gov/34528522/">https://pubmed.ncbi.nlm.nih.gov/34528522/</a></li><li>Prevalence
of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated
D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34568726/">https://pubmed.ncbi.nlm.nih.gov/34568726/</a></li><li>Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: <a href="https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/644%205179">https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/644 5179</a>.</li><li>Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate: <a href="https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408">https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408</a></li><li>Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: <a href="https://www.mdpi.com/2075-4426/11/11/1106">https://www.mdpi.com/2075-4426/11/11/1106</a></li><li>Epidemiology
and clinical features of myocarditis/pericarditis before the
introduction of COVID-19 mRNA vaccine in Korean children: a multicenter
study: <a href="https://pubmed.ncbi.nlm.nih.gov/34402230/">https://pubmed.ncbi.nlm.nih.gov/34402230/</a></li><li>Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: <a href="https://pubmed.ncbi.nlm.nih.gov/34696294/">https://pubmed.ncbi.nlm.nih.gov/34696294/</a></li><li>Myocarditis Following mRNA COVID-19 Vaccine: <a href="https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_%20mRNA_COVID_19_Vaccine.9.aspx">https://journals.lww.com/pec-online/Abstract/2021/11000/Myocarditis_Following_ mRNA_COVID_19_Vaccine.9.aspx</a>.</li><li>Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel: <a href="https://pubmed.ncbi.nlm.nih.gov/34614328/">https://pubmed.ncbi.nlm.nih.gov/34614328/</a>.</li><li>Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination: <a href="https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext">https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext</a></li><li>Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34277198/">https://pubmed.ncbi.nlm.nih.gov/34277198/</a></li><li>Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings: <a href="https://pubmed.ncbi.nlm.nih.gov/34246586/">https://pubmed.ncbi.nlm.nih.gov/34246586/</a></li><li>Hypersensitivity Myocarditis and COVID-19 Vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34856634/">https://pubmed.ncbi.nlm.nih.gov/34856634/</a>.</li><li>Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?: <a href="https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext">https://www.internationaljournalofcardiology.com/article/S0167-5273(21)01477-7/fulltext</a>.</li><li>Acute myocardial infarction and myocarditis after COVID-19 vaccination: <a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/">https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/</a></li><li>Myocarditis after Covid-19 vaccination in a large healthcare organization: <a href="https://www.nejm.org/doi/10.1056/NEJMoa2110737">https://www.nejm.org/doi/10.1056/NEJMoa2110737</a></li><li>Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children: <a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052">https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052</a></li><li>Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: <a href="https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed">https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed</a></li><li>STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination:. <a href="https://pubmed.ncbi.nlm.nih.gov/34756746/">https://pubmed.ncbi.nlm.nih.gov/34756746/</a></li><li>Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center: <a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/">https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/</a></li><li>Myocarditis after COVID-19 mRNA vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34546329/">https://pubmed.ncbi.nlm.nih.gov/34546329/</a>.</li><li>Patients with acute myocarditis after COVID-19 mRNA vaccination:. <a href="https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602">https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602</a>.</li><li>Myocarditis after COVID-19 vaccination: a case series: <a href="https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub">https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3Dihub</a>.</li><li>Myocarditis associated with COVID-19 vaccination in adolescents: <a href="https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357">https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357</a></li><li>Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents:. <a href="https://pubmed.ncbi.nlm.nih.gov/34704459/">https://pubmed.ncbi.nlm.nih.gov/34704459/</a></li><li>Myocarditis after COVID-19 vaccination: magnetic resonance imaging study: <a href="https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6%20421640">https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab230/6 421640</a>.</li><li>Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine: <a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/">https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/</a></li><li>Myocarditis after COVID-19 vaccination: <a href="https://www.sciencedirect.com/science/article/pii/S2352906721001603">https://www.sciencedirect.com/science/article/pii/S2352906721001603</a></li><li>Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: <a href="https://pubmed.ncbi.nlm.nih.gov/34712717/">https://pubmed.ncbi.nlm.nih.gov/34712717/</a>.</li><li>Acute myocarditis after administration of BNT162b2 vaccine against COVID-19: <a href="https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration-bnt162b2-S188558572100133X">https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-administration-bnt162b2-S188558572100133X</a>.</li><li>Myocarditis associated with COVID-19 mRNA vaccination: <a href="https://pubs.rsna.org/doi/10.1148/radiol.2021211430">https://pubs.rsna.org/doi/10.1148/radiol.2021211430</a></li><li>Acute myocarditis after COVID-19 vaccination: a case report: <a href="https://www.sciencedirect.com/science/article/pii/S0248866321007098">https://www.sciencedirect.com/science/article/pii/S0248866321007098</a></li><li>Acute myopericarditis after COVID-19 vaccination in adolescents:. <a href="https://pubmed.ncbi.nlm.nih.gov/34589238/">https://pubmed.ncbi.nlm.nih.gov/34589238/</a>.</li><li>Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination: <a href="https://academic.oup.com/jpids/article/10/10/962/6329543">https://academic.oup.com/jpids/article/10/10/962/6329543</a>.</li><li>Acute myocarditis associated with anti-COVID-19 vaccination: <a href="https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196">https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196</a>.</li><li>Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings:. <a href="https://pubmed.ncbi.nlm.nih.gov/34428917/">https://pubmed.ncbi.nlm.nih.gov/34428917/</a>.</li><li>Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination:. <a href="https://pubmed.ncbi.nlm.nih.gov/34088762/">https://pubmed.ncbi.nlm.nih.gov/34088762/</a>.</li><li>Myocarditis
and pericarditis in adolescents after first and second doses of
COVID-19 mRNA vaccines:.
https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcab090/64
42104.</li><li>COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis: <a href="https://www.mdpi.com/2036-7503/13/3/61">https://www.mdpi.com/2036-7503/13/3/61</a>.</li><li>Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA: <a href="https://pubmed.ncbi.nlm.nih.gov/34402228/">https://pubmed.ncbi.nlm.nih.gov/34402228/</a></li><li>Myocarditis temporally associated with COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34133885/">https://pubmed.ncbi.nlm.nih.gov/34133885/</a></li><li>Acute
myocardial injury after COVID-19 vaccination: a case report and review
of current evidence from the vaccine adverse event reporting system
database: <a href="https://pubmed.ncbi.nlm.nih.gov/34219532/">https://pubmed.ncbi.nlm.nih.gov/34219532/</a></li><li>Acute myocarditis associated with COVID-19 vaccination: report of a case: <a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/">https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/</a></li><li>Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34840235/">https://pubmed.ncbi.nlm.nih.gov/34840235/</a>.</li><li>Myocarditis in the setting of a recent COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34712497/">https://pubmed.ncbi.nlm.nih.gov/34712497/</a>.</li><li>Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases: <a href="https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext">https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext</a>.</li><li>Prevalence
of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated
D-dimer in Thais after vaccination with ChAdOx1 nCoV-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34568726/">https://pubmed.ncbi.nlm.nih.gov/34568726/</a></li><li>Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: <a href="https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179">https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab989/6445179</a></li></ol><p> </p><ol start="606"><li>Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination: <a href="https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408">https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab926/6420408</a>.</li><li>Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types: <a href="https://www.mdpi.com/2075-4426/11/11/1106">https://www.mdpi.com/2075-4426/11/11/1106</a></li><li>Epidemiology
and clinical features of myocarditis/pericarditis before the
introduction of COVID-19 mRNA vaccine in Korean children: a multicenter
study: <a href="https://pubmed.ncbi.nlm.nih.gov/34402230/">https://pubmed.ncbi.nlm.nih.gov/34402230/</a></li><li>Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients: <a href="https://pubmed.ncbi.nlm.nih.gov/34696294/">https://pubmed.ncbi.nlm.nih.gov/34696294/</a></li><li>Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34615534/">https://pubmed.ncbi.nlm.nih.gov/34615534/</a></li><li>Three cases of acute venous thromboembolism in women after coronavirus 2019 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34352418/">https://pubmed.ncbi.nlm.nih.gov/34352418/</a></li><li>Clinical and biological features of cerebral venous sinus thrombosis after vaccination with ChAdOx1 nCov-19; <a href="https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340">https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-327340</a>.</li><li>COV2-S
vaccination may reveal hereditary thrombophilia: massive cerebral
venous sinus thrombosis in a young man with normal platelet count: <a href="https://pubmed.ncbi.nlm.nih.gov/34632750/">https://pubmed.ncbi.nlm.nih.gov/34632750/</a></li><li>Post-mortem findings in vaccine-induced thrombotic thrombocytopenia: <a href="https://haematologica.org/article/view/haematol.2021.279075">https://haematologica.org/article/view/haematol.2021.279075</a></li><li>COVID-19 vaccine-induced thrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34802488/">https://pubmed.ncbi.nlm.nih.gov/34802488/</a>.</li><li>Inflammation
and platelet activation after COVID-19 vaccines: possible mechanisms
behind vaccine-induced immune thrombocytopenia and thrombosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34887867/">https://pubmed.ncbi.nlm.nih.gov/34887867/</a>.</li><li>Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34863404/">https://pubmed.ncbi.nlm.nih.gov/34863404/</a>.</li><li>Vaccine-induced
cerebral venous thrombosis and thrombocytopenia. Oxford-AstraZeneca
COVID-19: a missed opportunity for rapid return on experience: <a href="https://www.sciencedirect.com/science/article/pii/S235255682100093X">https://www.sciencedirect.com/science/article/pii/S235255682100093X</a></li><li>Occurrence of splenic infarction due to arterial thrombosis after vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34876440/">https://pubmed.ncbi.nlm.nih.gov/34876440/</a></li><li>Deep venous thrombosis more than two weeks after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33928773/">https://pubmed.ncbi.nlm.nih.gov/33928773/</a></li><li>Case
report: Take a second look: Cerebral venous thrombosis related to
Covid-19 vaccination and thrombotic thrombocytopenia syndrome: <a href="https://pubmed.ncbi.nlm.nih.gov/34880826/">https://pubmed.ncbi.nlm.nih.gov/34880826/</a></li><li>Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic thrombocytopenia: <a href="https://pubmed.ncbi.nlm.nih.gov/34587242/">https://pubmed.ncbi.nlm.nih.gov/34587242/</a></li><li>Change in blood viscosity after COVID-19 vaccination: estimation for persons with underlying metabolic syndrome: <a href="https://pubmed.ncbi.nlm.nih.gov/34868465/">https://pubmed.ncbi.nlm.nih.gov/34868465/</a></li><li>Management
of a patient with a rare congenital limb malformation syndrome after
SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT): <a href="https://pubmed.ncbi.nlm.nih.gov/34097311/">https://pubmed.ncbi.nlm.nih.gov/34097311/</a></li><li>Bilateral
thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune
thrombotic thrombocytopenia or a coincidence due to underlying risk
factors: <a href="https://pubmed.ncbi.nlm.nih.gov/34820232/">https://pubmed.ncbi.nlm.nih.gov/34820232/</a>.</li><li>Thrombocytopenia
and splanchnic thrombosis after vaccination with Ad26.COV2.S
successfully treated with transjugular intrahepatic intrahepatic
portosystemic shunt and thrombectomy: <a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258">https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258</a></li><li>Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34579636/">https://pubmed.ncbi.nlm.nih.gov/34579636/</a></li><li>Successful treatment of vaccine-induced immune immune thrombotic thrombocytopenia in a 26-year-old female patient: <a href="https://pubmed.ncbi.nlm.nih.gov/34614491/">https://pubmed.ncbi.nlm.nih.gov/34614491/</a></li><li>Case
report: vaccine-induced immune immune thrombotic thrombocytopenia in a
patient with pancreatic cancer after vaccination with messenger
RNA-1273: <a href="https://pubmed.ncbi.nlm.nih.gov/34790684/">https://pubmed.ncbi.nlm.nih.gov/34790684/</a></li><li>Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease vaccination (COVID-19): <a href="https://pubmed.ncbi.nlm.nih.gov/33624509/">https://pubmed.ncbi.nlm.nih.gov/33624509/</a>.</li><li>Squamous cell carcinoma of the lung with hemoptysis following vaccination with tozinameran (BNT162b2, Pfizer-BioNTech): <a href="https://pubmed.ncbi.nlm.nih.gov/34612003/">https://pubmed.ncbi.nlm.nih.gov/34612003/</a></li><li>Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a man presenting as acute venous thromboembolism: <a href="https://pubmed.ncbi.nlm.nih.gov/34096082/">https://pubmed.ncbi.nlm.nih.gov/34096082/</a></li><li>Myocarditis associated with COVID-19 vaccination in three adolescent boys: <a href="https://pubmed.ncbi.nlm.nih.gov/34851078/">https://pubmed.ncbi.nlm.nih.gov/34851078/</a>.</li><li>Cardiovascular
magnetic resonance findings in young adult patients with acute
myocarditis after COVID-19 mRNA vaccination: a case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34496880/">https://pubmed.ncbi.nlm.nih.gov/34496880/</a></li><li>Perimyocarditis after vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34866957/">https://pubmed.ncbi.nlm.nih.gov/34866957/</a></li><li>Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34849657/">https://pubmed.ncbi.nlm.nih.gov/34849657/</a>.</li><li>Myocarditis-induced
sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case
report focusing on histopathological findings: <a href="https://pubmed.ncbi.nlm.nih.gov/34664804/">https://pubmed.ncbi.nlm.nih.gov/34664804/</a></li><li>Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older: <a href="https://pubmed.ncbi.nlm.nih.gov/34605853/">https://pubmed.ncbi.nlm.nih.gov/34605853/</a></li><li>Recurrence
of acute myocarditis temporally associated with receipt of the 2019
coronavirus mRNA disease vaccine (COVID-19) in an adolescent male: <a href="https://pubmed.ncbi.nlm.nih.gov/34166671/">https://pubmed.ncbi.nlm.nih.gov/34166671/</a></li><li>Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34744118/">https://pubmed.ncbi.nlm.nih.gov/34744118/</a></li><li>Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male: <a href="https://pubmed.ncbi.nlm.nih.gov/34334935/">https://pubmed.ncbi.nlm.nih.gov/34334935/</a>.</li><li>Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34746968/">https://pubmed.ncbi.nlm.nih.gov/34746968/</a></li><li>Occurrence
of acute infarct-like myocarditis after vaccination with COVID-19: just
an accidental coincidence or rather a vaccination-associated autoimmune
myocarditis?”: <a href="https://pubmed.ncbi.nlm.nih.gov/34333695/">https://pubmed.ncbi.nlm.nih.gov/34333695/</a>.</li><li>Self-limited
myocarditis presenting with chest pain and ST-segment elevation in
adolescents after vaccination with BNT162b2 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34180390/">https://pubmed.ncbi.nlm.nih.gov/34180390/</a></li><li>Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military: <a href="https://pubmed.ncbi.nlm.nih.gov/34185045/">https://pubmed.ncbi.nlm.nih.gov/34185045/</a></li><li>Myocarditis after BNT162b2 vaccination in a healthy male: <a href="https://pubmed.ncbi.nlm.nih.gov/34229940/">https://pubmed.ncbi.nlm.nih.gov/34229940/</a></li><li>Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34133825/">https://pubmed.ncbi.nlm.nih.gov/34133825/</a></li><li>Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34308326/">https://pubmed.ncbi.nlm.nih.gov/34308326/</a>.</li><li>Chest pain with abnormal electrocardiogram redevelopment after injection of COVID-19 vaccine manufactured by Moderna: <a href="https://pubmed.ncbi.nlm.nih.gov/34866106/">https://pubmed.ncbi.nlm.nih.gov/34866106/</a></li><li>Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA in a 40-year-old man: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34487236/">https://pubmed.ncbi.nlm.nih.gov/34487236/</a></li><li>Multimodality
imaging and histopathology in a young man presenting with fulminant
lymphocytic myocarditis and cardiogenic shock after vaccination with
mRNA-1273: <a href="https://pubmed.ncbi.nlm.nih.gov/34848416/">https://pubmed.ncbi.nlm.nih.gov/34848416/</a></li><li>Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male: <a href="https://pubmed.ncbi.nlm.nih.gov/34636504/">https://pubmed.ncbi.nlm.nih.gov/34636504/</a></li><li>Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection: <a href="https://pubmed.ncbi.nlm.nih.gov/34367386/">https://pubmed.ncbi.nlm.nih.gov/34367386/</a></li><li>Acute myocarditis in a young adult two days after vaccination with Pfizer: <a href="https://pubmed.ncbi.nlm.nih.gov/34709227/">https://pubmed.ncbi.nlm.nih.gov/34709227/</a></li><li>Case
report: acute fulminant myocarditis and cardiogenic shock after
messenger RNA coronavirus vaccination in 2019 requiring extracorporeal
cardiopulmonary resuscitation: <a href="https://pubmed.ncbi.nlm.nih.gov/34778411/">https://pubmed.ncbi.nlm.nih.gov/34778411/</a></li><li>Acute myocarditis after 2019 coronavirus disease vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34734821/">https://pubmed.ncbi.nlm.nih.gov/34734821/</a></li><li>A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2: <a href="https://pubmed.ncbi.nlm.nih.gov/34246585/">https://pubmed.ncbi.nlm.nih.gov/34246585/</a></li><li>Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents: <a href="https://pubmed.ncbi.nlm.nih.gov/34228985/">https://pubmed.ncbi.nlm.nih.gov/34228985/</a></li><li>Post-vaccination multisystem inflammatory syndrome in adults without evidence of prior SARS-CoV-2 infection: <a href="https://pubmed.ncbi.nlm.nih.gov/34852213/">https://pubmed.ncbi.nlm.nih.gov/34852213/</a></li><li>Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease: <a href="https://pubmed.ncbi.nlm.nih.gov/34866122/">https://pubmed.ncbi.nlm.nih.gov/34866122/</a></li><li>Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34601566/">https://pubmed.ncbi.nlm.nih.gov/34601566/</a></li><li>Myocarditis following COVID-19 vaccination: MRI study: <a href="https://pubmed.ncbi.nlm.nih.gov/34739045/">https://pubmed.ncbi.nlm.nih.gov/34739045/</a>.</li><li>Acute myocarditis after COVID-19 vaccination: case report: <a href="https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e">https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcCsl/e</a></li><li>Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children: <a href="https://pubmed.ncbi.nlm.nih.gov/34374740/">https://pubmed.ncbi.nlm.nih.gov/34374740/</a></li><li>Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: <a href="https://pubmed.ncbi.nlm.nih.gov/34865500/">https://pubmed.ncbi.nlm.nih.gov/34865500/</a></li><li>Myocarditis following vaccination with Covid-19 in a large healthcare organization: <a href="https://pubmed.ncbi.nlm.nih.gov/34614329/">https://pubmed.ncbi.nlm.nih.gov/34614329/</a></li><li>AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal link: <a href="https://pubmed.ncbi.nlm.nih.gov/34560365/">https://pubmed.ncbi.nlm.nih.gov/34560365/</a></li><li>COVID-19, Guillain-Barré and vaccineA dangerous mix: <a href="https://pubmed.ncbi.nlm.nih.gov/34108736/">https://pubmed.ncbi.nlm.nih.gov/34108736/</a>.</li><li>Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases: <a href="https://pubmed.ncbi.nlm.nih.gov/34796417/">https://pubmed.ncbi.nlm.nih.gov/34796417/</a>.</li><li>Guillain-Barre syndrome after BNT162b2 COVID-19 vaccine: <a href="https://link.springer.com/article/10.1007%2Fs10072-021-05523-5">https://link.springer.com/article/10.1007%2Fs10072-021-05523-5</a>.</li><li>COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial palsy: <a href="https://onlinelibrary.wiley.com/doi/10.1002/ana.26258">https://onlinelibrary.wiley.com/doi/10.1002/ana.26258</a>.</li><li>Association of receipt association of Ad26.COV2.S COVID-19 vaccine with presumed Guillain-Barre syndrome, February-July 2021: <a href="https://jamanetwork.com/journals/jama/fullarticle/2785009">https://jamanetwork.com/journals/jama/fullarticle/2785009</a></li><li>A case of Guillain-Barré syndrome after Pfizer COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34567447/">https://pubmed.ncbi.nlm.nih.gov/34567447/</a></li><li>Guillain-Barré syndrome associated with COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34648420/">https://pubmed.ncbi.nlm.nih.gov/34648420/</a>.</li><li>Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA vaccine: <a href="https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708">https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708</a></li><li>Guillain-Barre syndrome after COVID-19 vaccination in an adolescent: <a href="https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext">https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext</a>.</li><li>Guillain-Barre syndrome after ChAdOx1-S / nCoV-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34114256/">https://pubmed.ncbi.nlm.nih.gov/34114256/</a>.</li><li>Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34767184/">https://pubmed.ncbi.nlm.nih.gov/34767184/</a>.</li><li>Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19 patients: <a href="https://pubmed.ncbi.nlm.nih.gov/34644738/">https://pubmed.ncbi.nlm.nih.gov/34644738/</a>.</li><li>Guillain-Barre syndrome presenting with facial diplegia following vaccination with COVID-19 in two patients: <a href="https://pubmed.ncbi.nlm.nih.gov/34649856/">https://pubmed.ncbi.nlm.nih.gov/34649856/</a></li><li>A rare case of Guillain-Barré syndrome after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34671572/">https://pubmed.ncbi.nlm.nih.gov/34671572/</a></li><li>Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33758714/">https://pubmed.ncbi.nlm.nih.gov/33758714/</a></li><li>COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side effect: <a href="https://pubmed.ncbi.nlm.nih.gov/34484780/">https://pubmed.ncbi.nlm.nih.gov/34484780/</a></li><li>Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case report; <a href="https://pubmed.ncbi.nlm.nih.gov/34779385/">https://pubmed.ncbi.nlm.nih.gov/34779385/</a>.</li><li>Miller Fisher syndrome after Pfizer COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34817727/">https://pubmed.ncbi.nlm.nih.gov/34817727/</a>.</li><li>Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34789193/">https://pubmed.ncbi.nlm.nih.gov/34789193/</a>.</li><li>Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome after Vaxzevria COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34261746/">https://pubmed.ncbi.nlm.nih.gov/34261746/</a></li><li>Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first report: <a href="https://pubmed.ncbi.nlm.nih.gov/34217513/">https://pubmed.ncbi.nlm.nih.gov/34217513/</a>.</li><li>A
case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G
anti-GM1 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine
(Pfizer): <a href="https://pubmed.ncbi.nlm.nih.gov/34871447/">https://pubmed.ncbi.nlm.nih.gov/34871447/</a></li><li>Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: <a href="https://pubmed.ncbi.nlm.nih.gov/34579259/">https://pubmed.ncbi.nlm.nih.gov/34579259/</a></li><li>A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination: AMSAN: <a href="https://pubmed.ncbi.nlm.nih.gov/34370408/">https://pubmed.ncbi.nlm.nih.gov/34370408/</a>.</li><li>A rare variant of Guillain-Barré syndrome after vaccination with Ad26.COV2.S: <a href="https://pubmed.ncbi.nlm.nih.gov/34703690/">https://pubmed.ncbi.nlm.nih.gov/34703690/</a>.</li><li>Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome: <a href="https://pubmed.ncbi.nlm.nih.gov/34810163/">https://pubmed.ncbi.nlm.nih.gov/34810163/</a></li><li>Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector SARS-CoV-2 vaccines: <a href="https://onlinelibrary.wiley.com/doi/10.1002/ana.26218">https://onlinelibrary.wiley.com/doi/10.1002/ana.26218</a>.</li><li>Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of the literature: <a href="https://pubmed.ncbi.nlm.nih.gov/34482455/">https://pubmed.ncbi.nlm.nih.gov/34482455/</a>.</li><li>Variant Guillain-Barré syndrome occurring after SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34114269/">https://pubmed.ncbi.nlm.nih.gov/34114269/</a>.</li><li>Guillian-Barre syndrome with axonal variant temporally associated with Modern SARS-CoV-2 mRNA-based vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34722067/">https://pubmed.ncbi.nlm.nih.gov/34722067/</a></li><li>Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary occurrence, not a causal association: <a href="https://pubmed.ncbi.nlm.nih.gov/33968610/">https://pubmed.ncbi.nlm.nih.gov/33968610/</a></li><li>SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but also by distal small fiber neuropathy: <a href="https://pubmed.ncbi.nlm.nih.gov/34525410/">https://pubmed.ncbi.nlm.nih.gov/34525410/</a></li><li>Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after AstraZeneca 2019 coronavirus disease vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34808658/">https://pubmed.ncbi.nlm.nih.gov/34808658/</a></li><li>Adverse event reporting and risk of Bell’s palsy after COVID-19 vaccination: <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00646-0/fulltext</a>.</li><li>Bilateral facial nerve palsy and COVID-19 vaccination: causality or coincidence: <a href="https://pubmed.ncbi.nlm.nih.gov/34522557/">https://pubmed.ncbi.nlm.nih.gov/34522557/</a></li><li>Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34763263/">https://pubmed.ncbi.nlm.nih.gov/34763263/</a>.</li><li>Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of recurrent Bell’s palsy: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34621891/">https://pubmed.ncbi.nlm.nih.gov/34621891/</a></li><li>Neurological complications after the first dose of COVID-19 vaccines and SARS-CoV-2 infection: <a href="https://pubmed.ncbi.nlm.nih.gov/34697502/">https://pubmed.ncbi.nlm.nih.gov/34697502/</a></li><li>Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with Bell’s palsy: <a href="https://pubmed.ncbi.nlm.nih.gov/33858693/">https://pubmed.ncbi.nlm.nih.gov/33858693/</a></li><li>Acute transverse myelitis following inactivated COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34370410/">https://pubmed.ncbi.nlm.nih.gov/34370410/</a></li><li>Acute transverse myelitis after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34579245/">https://pubmed.ncbi.nlm.nih.gov/34579245/</a>.</li><li>A case of longitudinally extensive transverse myelitis following Covid-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34182207/">https://pubmed.ncbi.nlm.nih.gov/34182207/</a></li><li>Post COVID-19 transverse myelitis; a case report with review of the literature: <a href="https://pubmed.ncbi.nlm.nih.gov/34457267/">https://pubmed.ncbi.nlm.nih.gov/34457267/</a>.</li><li>Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34189662/">https://pubmed.ncbi.nlm.nih.gov/34189662/</a></li><li>Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273: <a href="https://pubmed.ncbi.nlm.nih.gov/34660149/">https://pubmed.ncbi.nlm.nih.gov/34660149/</a></li><li>Acute
bilateral bilateral optic neuritis/chiasm with longitudinal extensive
transverse myelitis in long-standing stable multiple sclerosis after
vector-based vaccination against SARS-CoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/34131771/">https://pubmed.ncbi.nlm.nih.gov/34131771/</a></li><li>A
case series of acute pericarditis after vaccination with COVID-19 in
the context of recent reports from Europe and the United States: <a href="https://pubmed.ncbi.nlm.nih.gov/34635376/">https://pubmed.ncbi.nlm.nih.gov/34635376/</a></li><li>Acute pericarditis and cardiac tamponade after vaccination with Covid-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34749492/">https://pubmed.ncbi.nlm.nih.gov/34749492/</a></li><li>Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34849667/">https://pubmed.ncbi.nlm.nih.gov/34849667/</a></li><li>Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34319393/">https://pubmed.ncbi.nlm.nih.gov/34319393/</a></li><li>Acute myopericarditis after COVID-19 vaccine in adolescents: <a href="https://pubmed.ncbi.nlm.nih.gov/34589238/">https://pubmed.ncbi.nlm.nih.gov/34589238/</a></li><li>Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34149145/">https://pubmed.ncbi.nlm.nih.gov/34149145/</a></li><li>Case report: symptomatic pericarditis post COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34693198/">https://pubmed.ncbi.nlm.nih.gov/34693198/</a>.</li><li>An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old patient: <a href="https://pubmed.ncbi.nlm.nih.gov/34797392/">https://pubmed.ncbi.nlm.nih.gov/34797392/</a></li><li>Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1 nCoV-19): <a href="https://pubmed.ncbi.nlm.nih.gov/34862234/">https://pubmed.ncbi.nlm.nih.gov/34862234/</a></li><li>Myocarditis after SARS-CoV-2 mRNA vaccination, a case series: <a href="https://pubmed.ncbi.nlm.nih.gov/34396358/">https://pubmed.ncbi.nlm.nih.gov/34396358/</a>.</li><li>Miller-Fisher
syndrome and Guillain-Barré syndrome overlap syndrome in a patient
after Oxford-AstraZeneca SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34848426/">https://pubmed.ncbi.nlm.nih.gov/34848426/</a>.</li><li>Immune-mediated disease outbreaks or new-onset disease in 27 subjects after mRNA/DNA vaccination against SARS-CoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/33946748/">https://pubmed.ncbi.nlm.nih.gov/33946748/</a></li><li>Post-mortem investigation of deaths after vaccination with COVID-19 vaccines: <a href="https://pubmed.ncbi.nlm.nih.gov/34591186/">https://pubmed.ncbi.nlm.nih.gov/34591186/</a></li><li>Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34352309/">https://pubmed.ncbi.nlm.nih.gov/34352309/</a></li><li>Relapse of immune thrombocytopenia after covid-19 vaccination in young male patient: <a href="https://pubmed.ncbi.nlm.nih.gov/34804803/">https://pubmed.ncbi.nlm.nih.gov/34804803/</a>.</li><li>Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine Pfizer-BioNTech BNT16B2b2: <a href="https://pubmed.ncbi.nlm.nih.gov/34077572/">https://pubmed.ncbi.nlm.nih.gov/34077572/</a></li><li>Retinal hemorrhage after SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34884407/">https://pubmed.ncbi.nlm.nih.gov/34884407/</a>.</li><li>Case
report: anti-neutrophil cytoplasmic antibody-associated vasculitis with
acute renal failure and pulmonary hemorrhage can occur after COVID-19
vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34859017/">https://pubmed.ncbi.nlm.nih.gov/34859017/</a></li><li>Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34783899/">https://pubmed.ncbi.nlm.nih.gov/34783899/</a></li><li>Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-induced SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34549178/">https://pubmed.ncbi.nlm.nih.gov/34549178/</a>.</li><li>Brain death in a vaccinated patient with COVID-19 infection: <a href="https://pubmed.ncbi.nlm.nih.gov/34656887/">https://pubmed.ncbi.nlm.nih.gov/34656887/</a></li><li>Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34236717/">https://pubmed.ncbi.nlm.nih.gov/34236717/</a>.</li><li>Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-CoV-2 mRNA-based SARS-CoV-2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34729467/">https://pubmed.ncbi.nlm.nih.gov/34729467/</a>.</li><li>A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33932458/">https://pubmed.ncbi.nlm.nih.gov/33932458/</a></li><li>Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine. A post-vaccination reaction: <a href="https://pubmed.ncbi.nlm.nih.gov/34092400/742">https://pubmed.ncbi.nlm.nih.gov/34092400/742</a>.</li><li>Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34754937/">https://pubmed.ncbi.nlm.nih.gov/34754937/</a></li><li>Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination in 2 patients with IgA nephropathy: <a href="https://pubmed.ncbi.nlm.nih.gov/33771584/">https://pubmed.ncbi.nlm.nih.gov/33771584/</a></li><li>Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34846583/">https://pubmed.ncbi.nlm.nih.gov/34846583/</a></li><li>COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis: <a href="https://pubmed.ncbi.nlm.nih.gov/34073536/">https://pubmed.ncbi.nlm.nih.gov/34073536/</a></li><li>Bell’s
palsy after vaccination with mRNA (BNT162b2) and inactivated
(CoronaVac) SARS-CoV-2 vaccines: a case series and a nested case-control
study: <a href="https://pubmed.ncbi.nlm.nih.gov/34411532/">https://pubmed.ncbi.nlm.nih.gov/34411532/</a></li><li>Epidemiology
of myocarditis and pericarditis following mRNA vaccines in Ontario,
Canada: by vaccine product, schedule, and interval: <a href="https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1">https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1</a></li><li>Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria: <a href="https://pubmed.ncbi.nlm.nih.gov/33851711/">https://pubmed.ncbi.nlm.nih.gov/33851711/</a></li><li>Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34675550/">https://pubmed.ncbi.nlm.nih.gov/34675550/</a>.</li><li>Anaphylaxis after Modern COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34734159/">https://pubmed.ncbi.nlm.nih.gov/34734159/</a>.</li><li>Association of self-reported history of high-risk allergy with allergy symptoms after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34698847/">https://pubmed.ncbi.nlm.nih.gov/34698847/</a></li><li>Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34020815/">https://pubmed.ncbi.nlm.nih.gov/34020815/</a></li><li>Allergic
reactions, including anaphylaxis, after receiving the first dose of
Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23,
2020: <a href="https://pubmed.ncbi.nlm.nih.gov/33641264/">https://pubmed.ncbi.nlm.nih.gov/33641264/</a></li><li>Allergic
reactions, including anaphylaxis, after receiving the first dose of
Modern COVID-19 vaccine – United States, December 21, 2020 to January
10, 2021: <a href="https://pubmed.ncbi.nlm.nih.gov/33641268/">https://pubmed.ncbi.nlm.nih.gov/33641268/</a></li><li>Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action: <a href="https://pubmed.ncbi.nlm.nih.gov/33834172/">https://pubmed.ncbi.nlm.nih.gov/33834172/</a></li><li>Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2: <a href="https://pubmed.ncbi.nlm.nih.gov/34579211/">https://pubmed.ncbi.nlm.nih.gov/34579211/</a></li><li>Biphasic
anaphylaxis after first dose of 2019 messenger RNA coronavirus disease
vaccine with positive polysorbate 80 skin test result: <a href="https://pubmed.ncbi.nlm.nih.gov/34343674/">https://pubmed.ncbi.nlm.nih.gov/34343674/</a></li><li>Acute myocardial infarction and myocarditis after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34586408/">https://pubmed.ncbi.nlm.nih.gov/34586408/</a></li><li>Takotsubo syndrome after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34539938/">https://pubmed.ncbi.nlm.nih.gov/34539938/</a>.</li><li>Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on maintenance hemodialysis: <a href="https://pubmed.ncbi.nlm.nih.gov/34731486/">https://pubmed.ncbi.nlm.nih.gov/34731486/</a>.</li><li>Premature myocardial infarction or side effect of COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33824804/">https://pubmed.ncbi.nlm.nih.gov/33824804/</a></li><li>Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older: <a href="https://pubmed.ncbi.nlm.nih.gov/34807248/">https://pubmed.ncbi.nlm.nih.gov/34807248/</a></li><li>Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34148772/">https://pubmed.ncbi.nlm.nih.gov/34148772/</a></li><li>Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis syndrome the culprit: <a href="https://pubmed.ncbi.nlm.nih.gov/34702550/">https://pubmed.ncbi.nlm.nih.gov/34702550/</a></li><li>Deaths associated with the recently launched SARS-CoV-2 vaccination (Comirnaty®): <a href="https://pubmed.ncbi.nlm.nih.gov/33895650/">https://pubmed.ncbi.nlm.nih.gov/33895650/</a></li><li>Deaths associated with recently launched SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34425384/">https://pubmed.ncbi.nlm.nih.gov/34425384/</a></li><li>A
case of acute encephalopathy and non-ST-segment elevation myocardial
infarction after vaccination with mRNA-1273: possible adverse effect: <a href="https://pubmed.ncbi.nlm.nih.gov/34703815/">https://pubmed.ncbi.nlm.nih.gov/34703815/</a></li><li>COVID-19 vaccine-induced urticarial vasculitis: <a href="https://pubmed.ncbi.nlm.nih.gov/34369046/">https://pubmed.ncbi.nlm.nih.gov/34369046/</a>.</li><li>ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34280507/">https://pubmed.ncbi.nlm.nih.gov/34280507/</a>.</li><li>New-onset leukocytoclastic vasculitis after COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34241833/">https://pubmed.ncbi.nlm.nih.gov/34241833/</a></li><li>Cutaneous small vessel vasculitis after COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34529877/">https://pubmed.ncbi.nlm.nih.gov/34529877/</a>.</li><li>Outbreak of leukocytoclastic vasculitis after COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33928638/">https://pubmed.ncbi.nlm.nih.gov/33928638/</a></li><li>Leukocytoclastic vasculitis after exposure to COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34836739/">https://pubmed.ncbi.nlm.nih.gov/34836739/</a></li><li>Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post hoc ergo propter hoc?; <a href="https://pubmed.ncbi.nlm.nih.gov/34495381/">https://pubmed.ncbi.nlm.nih.gov/34495381/</a>.</li><li>Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34327795">https://pubmed.ncbi.nlm.nih.gov/34327795</a></li><li>Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34660867/">https://pubmed.ncbi.nlm.nih.gov/34660867/</a>.</li><li>Case
report: ANCA-associated vasculitis presenting with rhabdomyolysis and
crescentic Pauci-Inmune glomerulonephritis after vaccination with
Pfizer-BioNTech COVID-19 mRNA: <a href="https://pubmed.ncbi.nlm.nih.gov/34659268/">https://pubmed.ncbi.nlm.nih.gov/34659268/</a></li><li>Reactivation of IgA vasculitis after vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34848431/">https://pubmed.ncbi.nlm.nih.gov/34848431/</a></li><li>Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34310759/">https://pubmed.ncbi.nlm.nih.gov/34310759/</a>.</li><li>Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine booster: <a href="https://pubmed.ncbi.nlm.nih.gov/34720009/">https://pubmed.ncbi.nlm.nih.gov/34720009/</a></li><li>A rare case of Henoch-Schönlein purpura after a case report of COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34518812/">https://pubmed.ncbi.nlm.nih.gov/34518812/</a></li><li>Cutaneous vasculitis following COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34611627/">https://pubmed.ncbi.nlm.nih.gov/34611627/</a>.</li><li>Possible case of COVID-19 mRNA vaccine-induced small-vessel vasculitis: <a href="https://pubmed.ncbi.nlm.nih.gov/34705320/">https://pubmed.ncbi.nlm.nih.gov/34705320/</a>.</li><li>IgA vasculitis following COVID-19 vaccination in an adult: <a href="https://pubmed.ncbi.nlm.nih.gov/34779011/">https://pubmed.ncbi.nlm.nih.gov/34779011/</a></li><li>Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis following vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34451967/">https://pubmed.ncbi.nlm.nih.gov/34451967/</a></li><li>Coronavirus
disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and
neutrophil anti-cytoplasmic antibody-associated vasculitis: <a href="https://pubmed.ncbi.nlm.nih.gov/33928459/">https://pubmed.ncbi.nlm.nih.gov/33928459/</a></li><li>Reactivation of IgA vasculitis after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34250509/">https://pubmed.ncbi.nlm.nih.gov/34250509/</a></li><li>Clinical and histopathologic spectrum of delayed adverse skin reactions after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34292611/">https://pubmed.ncbi.nlm.nih.gov/34292611/</a>.</li><li>First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34530771/">https://pubmed.ncbi.nlm.nih.gov/34530771/</a>.</li><li>Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or circumstantial: <a href="https://pubmed.ncbi.nlm.nih.gov/34245294/">https://pubmed.ncbi.nlm.nih.gov/34245294/</a>.</li><li>Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus disease (COVID-19): <a href="https://pubmed.ncbi.nlm.nih.gov/34599716/">https://pubmed.ncbi.nlm.nih.gov/34599716/</a>.</li><li>Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual preponderance of eosinophils: <a href="https://pubmed.ncbi.nlm.nih.gov/34115904/">https://pubmed.ncbi.nlm.nih.gov/34115904/</a>.</li><li>Henoch-Schönlein purpura occurring after vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34247902/">https://pubmed.ncbi.nlm.nih.gov/34247902/</a>.</li><li>Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34696186/">https://pubmed.ncbi.nlm.nih.gov/34696186/</a>.</li><li>Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34237323/">https://pubmed.ncbi.nlm.nih.gov/34237323/</a>.</li><li>Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with BNT162b2 COVID-19 mRNA: <a href="https://pubmed.ncbi.nlm.nih.gov/34851795/">https://pubmed.ncbi.nlm.nih.gov/34851795/</a>.</li><li>A case of generalized Sweet’s syndrome with vasculitis triggered by recent vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34849386/">https://pubmed.ncbi.nlm.nih.gov/34849386/</a></li><li>Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-CoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/34310763/">https://pubmed.ncbi.nlm.nih.gov/34310763/</a></li><li>Relapse of microscopic polyangiitis after COVID-19 vaccination: case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34251683/">https://pubmed.ncbi.nlm.nih.gov/34251683/</a>.</li><li>Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34557622/">https://pubmed.ncbi.nlm.nih.gov/34557622/</a>.</li><li>Recurrent
herpes zoster after COVID-19 vaccination in patients with chronic
urticaria on cyclosporine treatment – A report of 3 cases: <a href="https://pubmed.ncbi.nlm.nih.gov/34510694/">https://pubmed.ncbi.nlm.nih.gov/34510694/</a></li><li>Leukocytoclastic vasculitis after coronavirus disease vaccination 2019: <a href="https://pubmed.ncbi.nlm.nih.gov/34713472/803">https://pubmed.ncbi.nlm.nih.gov/34713472/803</a></li><li>Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2: <a href="https://pubmed.ncbi.nlm.nih.gov/34819272/">https://pubmed.ncbi.nlm.nih.gov/34819272/</a></li><li>Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen Ad26.COV2.S: <a href="https://pubmed.ncbi.nlm.nih.gov/34337124/">https://pubmed.ncbi.nlm.nih.gov/34337124/</a></li><li>Case of immunoglobulin A vasculitis after vaccination against coronavirus disease 2019: <a href="https://pubmed.ncbi.nlm.nih.gov/34535924/">https://pubmed.ncbi.nlm.nih.gov/34535924/</a></li><li>Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA booster vaccination: case report: <a href="https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/">https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/</a></li><li>COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma progression on FDG PET / CT: <a href="https://pubmed.ncbi.nlm.nih.gov/33591026/">https://pubmed.ncbi.nlm.nih.gov/33591026/</a></li><li>Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology patients: <a href="https://pubmed.ncbi.nlm.nih.gov/33625300/">https://pubmed.ncbi.nlm.nih.gov/33625300/</a></li><li>Hypermetabolic
lymphadenopathy after administration of BNT162b2 mRNA vaccine Covid-19:
incidence assessed by [ 18 F] FDG PET-CT and relevance for study
interpretation: <a href="https://pubmed.ncbi.nlm.nih.gov/33774684/">https://pubmed.ncbi.nlm.nih.gov/33774684/</a></li><li>Lymphadenopathy after COVID-19 vaccination: review of imaging findings: <a href="https://pubmed.ncbi.nlm.nih.gov/33985872/">https://pubmed.ncbi.nlm.nih.gov/33985872/</a></li><li>Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on FDG PET/CT after 2-dose COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34735411/">https://pubmed.ncbi.nlm.nih.gov/34735411/</a></li><li>Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT: distinguishing features in adenovirus-vectored vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34115709/">https://pubmed.ncbi.nlm.nih.gov/34115709/</a>.</li><li>COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging clinic in Israel: analysis of 163 cases: <a href="https://pubmed.ncbi.nlm.nih.gov/34257025/">https://pubmed.ncbi.nlm.nih.gov/34257025/</a>.</li><li>COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with literature review: <a href="https://pubmed.ncbi.nlm.nih.gov/34836672/">https://pubmed.ncbi.nlm.nih.gov/34836672/</a>.</li><li>Coronavirus
disease vaccine 2019 mimics lymph node metastases in patients
undergoing skin cancer follow-up: a single-center study: <a href="https://pubmed.ncbi.nlm.nih.gov/34280870/">https://pubmed.ncbi.nlm.nih.gov/34280870/</a></li><li>COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration biopsy cytologic findings: <a href="https://pubmed.ncbi.nlm.nih.gov/34432391/">https://pubmed.ncbi.nlm.nih.gov/34432391/</a></li><li>Regional
lymphadenopathy after COVID-19 vaccination: review of the literature
and considerations for patient management in breast cancer care: <a href="https://pubmed.ncbi.nlm.nih.gov/34731748/">https://pubmed.ncbi.nlm.nih.gov/34731748/</a></li><li>Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on screening mammography: <a href="https://pubmed.ncbi.nlm.nih.gov/34906409/">https://pubmed.ncbi.nlm.nih.gov/34906409/</a></li></ol><p> </p><ol start="816"><li>Adverse
events of COVID injection that may occur in children.Acute-onset
supraclavicular lymphadenopathy coincident with intramuscular mRNA
vaccination against COVID-19 may be related to the injection technique
of the vaccine, Spain, January and February 2021: <a href="https://pubmed.ncbi.nlm.nih.gov/33706861/">https://pubmed.ncbi.nlm.nih.gov/33706861/</a></li><li>Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: <a href="https://pubmed.ncbi.nlm.nih.gov/34116295/">https://pubmed.ncbi.nlm.nih.gov/34116295/</a></li><li>Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: <a href="https://pubmed.ncbi.nlm.nih.gov/33661328/">https://pubmed.ncbi.nlm.nih.gov/33661328/</a></li><li>Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34050949/">https://pubmed.ncbi.nlm.nih.gov/34050949/</a></li><li>Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: <a href="https://pubmed.ncbi.nlm.nih.gov/33624520/">https://pubmed.ncbi.nlm.nih.gov/33624520/</a></li><li>A case of cervical lymphadenopathy following COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34141500/">https://pubmed.ncbi.nlm.nih.gov/34141500/</a></li><li>Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34096896/">https://pubmed.ncbi.nlm.nih.gov/34096896/</a></li><li>Thrombotic
adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca
COVID-19 vaccines: comparison of occurrence and clinical outcomes in the
EudraVigilance database: <a href="https://pubmed.ncbi.nlm.nih.gov/34835256/">https://pubmed.ncbi.nlm.nih.gov/34835256/</a></li><li>Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: <a href="https://pubmed.ncbi.nlm.nih.gov/33713605/">https://pubmed.ncbi.nlm.nih.gov/33713605/</a></li><li>Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: <a href="https://pubmed.ncbi.nlm.nih.gov/34298342/">https://pubmed.ncbi.nlm.nih.gov/34298342/</a></li><li>A systematic review of cases of CNS demyelination following COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34839149/">https://pubmed.ncbi.nlm.nih.gov/34839149/</a></li><li>Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: <a href="https://pubmed.ncbi.nlm.nih.gov/33685772/">https://pubmed.ncbi.nlm.nih.gov/33685772/</a></li><li>COVID-19
vaccine-related axillary and cervical lymphadenopathy in patients with
current or previous breast cancer and other malignancies:
cross-sectional imaging findings on MRI, CT and PET-CT: <a href="https://pubmed.ncbi.nlm.nih.gov/34719892/">https://pubmed.ncbi.nlm.nih.gov/34719892/</a></li><li>Adenopathy after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33625299/">https://pubmed.ncbi.nlm.nih.gov/33625299/</a>.</li><li>Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34292295/">https://pubmed.ncbi.nlm.nih.gov/34292295/</a>.</li><li>COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: <a href="https://pubmed.ncbi.nlm.nih.gov/33947605/">https://pubmed.ncbi.nlm.nih.gov/33947605/</a>.</li><li>Cervical
lymphadenopathy after coronavirus disease vaccination 2019: clinical
features and implications for head and neck cancer services: <a href="https://pubmed.ncbi.nlm.nih.gov/34526175/">https://pubmed.ncbi.nlm.nih.gov/34526175/</a></li><li>Lymphadenopathy associated with the COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33786231/">https://pubmed.ncbi.nlm.nih.gov/33786231/</a></li><li>Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33625301/">https://pubmed.ncbi.nlm.nih.gov/33625301/</a>.</li><li>Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34332438/">https://pubmed.ncbi.nlm.nih.gov/34332438/</a>.</li><li>New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: <a href="https://pubmed.ncbi.nlm.nih.gov/34342187/">https://pubmed.ncbi.nlm.nih.gov/34342187/</a>.</li><li>Massive cervical lymphadenopathy following vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34601889/">https://pubmed.ncbi.nlm.nih.gov/34601889/</a></li><li>ANCA glomerulonephritis following Modern COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34081948/">https://pubmed.ncbi.nlm.nih.gov/34081948/</a></li><li>Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34507942/">https://pubmed.ncbi.nlm.nih.gov/34507942/</a>.</li><li>Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): <a href="https://pubmed.ncbi.nlm.nih.gov/34362727/">https://pubmed.ncbi.nlm.nih.gov/34362727/</a></li><li>Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: <a href="https://pubmed.ncbi.nlm.nih.gov/34325221/">https://pubmed.ncbi.nlm.nih.gov/34325221/</a></li><li>Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: <a href="https://pubmed.ncbi.nlm.nih.gov/34825530/">https://pubmed.ncbi.nlm.nih.gov/34825530/</a>.</li><li>Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34000278/">https://pubmed.ncbi.nlm.nih.gov/34000278/</a></li><li>COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: <a href="https://pubmed.ncbi.nlm.nih.gov/34655312/">https://pubmed.ncbi.nlm.nih.gov/34655312/</a>.</li><li>Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34187985/">https://pubmed.ncbi.nlm.nih.gov/34187985/</a>.</li><li>Acute-onset
supraclavicular lymphadenopathy coincident with intramuscular mRNA
vaccination against COVID-19 may be related to the injection technique
of the vaccine, Spain, January and February 2021: <a href="https://pubmed.ncbi.nlm.nih.gov/33706861/">https://pubmed.ncbi.nlm.nih.gov/33706861/</a></li><li>Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial follow-up by ultrasonography: <a href="https://pubmed.ncbi.nlm.nih.gov/34116295/">https://pubmed.ncbi.nlm.nih.gov/34116295/</a></li><li>Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F] choline PET / CT, not just an FDG finding: <a href="https://pubmed.ncbi.nlm.nih.gov/33661328/">https://pubmed.ncbi.nlm.nih.gov/33661328/</a></li><li>Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34050949/">https://pubmed.ncbi.nlm.nih.gov/34050949/</a></li><li>Axillary adenopathy associated with COVID-19 vaccination: imaging findings and follow-up recommendations in 23 women: <a href="https://pubmed.ncbi.nlm.nih.gov/33624520/">https://pubmed.ncbi.nlm.nih.gov/33624520/</a></li><li>A case of cervical lymphadenopathy following COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34141500/">https://pubmed.ncbi.nlm.nih.gov/34141500/</a></li><li>Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19 vaccination: a case report: <a href="https://pubmed.ncbi.nlm.nih.gov/34096896/">https://pubmed.ncbi.nlm.nih.gov/34096896/</a></li><li>Thrombotic
adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca
COVID-19 vaccines: comparison of occurrence and clinical outcomes in the
EudraVigilance database: <a href="https://pubmed.ncbi.nlm.nih.gov/34835256/">https://pubmed.ncbi.nlm.nih.gov/34835256/</a></li><li>Unilateral lymphadenopathy after COVID-19 vaccination: a practical management plan for radiologists of all specialties: <a href="https://pubmed.ncbi.nlm.nih.gov/33713605/">https://pubmed.ncbi.nlm.nih.gov/33713605/</a></li><li>Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-up: <a href="https://pubmed.ncbi.nlm.nih.gov/34298342/">https://pubmed.ncbi.nlm.nih.gov/34298342/</a></li><li>A systematic review of cases of CNS demyelination following COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34839149/">https://pubmed.ncbi.nlm.nih.gov/34839149/</a></li><li>Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing presentation in the two-week wait neck lump clinic: <a href="https://pubmed.ncbi.nlm.nih.gov/33685772/">https://pubmed.ncbi.nlm.nih.gov/33685772/</a></li><li>COVID-19
vaccine-related axillary and cervical lymphadenopathy in patients with
current or previous breast cancer and other malignancies:
cross-sectional imaging findings on MRI, CT and PET-CT: <a href="https://pubmed.ncbi.nlm.nih.gov/34719892/">https://pubmed.ncbi.nlm.nih.gov/34719892/</a></li><li>Adenopathy after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33625299/">https://pubmed.ncbi.nlm.nih.gov/33625299/</a>.</li><li>Incidence of axillary adenopathy on breast imaging after vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34292295/">https://pubmed.ncbi.nlm.nih.gov/34292295/</a>.</li><li>COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump clinic: a follow-up audit: <a href="https://pubmed.ncbi.nlm.nih.gov/33947605/">https://pubmed.ncbi.nlm.nih.gov/33947605/</a>.</li><li>Cervical
lymphadenopathy after coronavirus disease vaccination 2019: clinical
features and implications for head and neck cancer services: <a href="https://pubmed.ncbi.nlm.nih.gov/34526175/">https://pubmed.ncbi.nlm.nih.gov/34526175/</a></li><li>Lymphadenopathy associated with the COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/33786231/">https://pubmed.ncbi.nlm.nih.gov/33786231/</a></li><li>Evolution of lymphadenopathy on PET/MRI after COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/33625301/">https://pubmed.ncbi.nlm.nih.gov/33625301/</a>.</li><li>Autoimmune hepatitis triggered by SARS-CoV-2 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34332438/">https://pubmed.ncbi.nlm.nih.gov/34332438/</a>.</li><li>New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report and literature review: <a href="https://pubmed.ncbi.nlm.nih.gov/34342187/">https://pubmed.ncbi.nlm.nih.gov/34342187/</a>.</li><li>Massive cervical lymphadenopathy following vaccination with COVID-19: <a href="https://pubmed.ncbi.nlm.nih.gov/34601889/">https://pubmed.ncbi.nlm.nih.gov/34601889/</a></li><li>ANCA glomerulonephritis following Modern COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34081948/">https://pubmed.ncbi.nlm.nih.gov/34081948/</a></li><li>Extensive longitudinal transverse myelitis following AstraZeneca COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34507942/">https://pubmed.ncbi.nlm.nih.gov/34507942/</a>.</li><li>Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-19 (Oxford-AstraZeneca): <a href="https://pubmed.ncbi.nlm.nih.gov/34362727/">https://pubmed.ncbi.nlm.nih.gov/34362727/</a></li><li>Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on screening breast MRI allowing benign evaluation: <a href="https://pubmed.ncbi.nlm.nih.gov/34325221/">https://pubmed.ncbi.nlm.nih.gov/34325221/</a></li><li>Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new diagnostic dilemma: <a href="https://pubmed.ncbi.nlm.nih.gov/34825530/">https://pubmed.ncbi.nlm.nih.gov/34825530/</a>.</li><li>Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19 vaccine: <a href="https://pubmed.ncbi.nlm.nih.gov/34000278/">https://pubmed.ncbi.nlm.nih.gov/34000278/</a></li><li>COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the USA: <a href="https://pubmed.ncbi.nlm.nih.gov/34655312/">https://pubmed.ncbi.nlm.nih.gov/34655312/</a>.</li><li>Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: <a href="https://pubmed.ncbi.nlm.nih.gov/34187985/">https://pubmed.ncbi.nlm.nih.gov/34187985/</a>.</li><li>Abbate,
A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . .
Danielides, S. (2021). Fulminant myocarditis and systemic
hyperinflammation temporally associated with BNT162b2 mRNA COVID-19
vaccination in two patients. Int J Cardiol, 340, 119-121.
doi:10.1016/j.ijcard.2021.08.018. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34416319">https://www.ncbi.nlm.nih.gov/pubmed/34416319</a></li><li>Abu
Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L.,
. . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA
vaccination. Vaccine, 39(29), 3790-3793.
doi:10.1016/j.vaccine.2021.05.087. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34092429">https://www.ncbi.nlm.nih.gov/pubmed/34092429</a></li><li>Albert,
E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis
following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145.
doi:10.1016/j.radcr.2021.05.033. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34025885">https://www.ncbi.nlm.nih.gov/pubmed/34025885</a></li><li>Aye,
Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . .
Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis
following COVID-19 Vaccination. QJM. doi:10.1093/qjmed/hcab252. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34586408">https://www.ncbi.nlm.nih.gov/pubmed/34586408</a></li><li>Azir,
M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic:
Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J
Emerg Med, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34756746">https://www.ncbi.nlm.nih.gov/pubmed/34756746</a></li><li>Barda,
N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . .
Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a
Nationwide Setting. N Engl J Med, 385(12), 1078-1090.
doi:10.1056/NEJMoa2110475. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34432976">https://www.ncbi.nlm.nih.gov/pubmed/34432976</a></li><li>Bhandari,
M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus
and cardiovascular manifestations- getting to the heart of the matter.
World J Cardiol, 13(10), 556-565. doi:10.4330/wjc.v13.i10.556. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34754400">https://www.ncbi.nlm.nih.gov/pubmed/34754400</a></li><li>Bozkurt,
B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19
mRNA Vaccines. Circulation, 144(6), 471-484.
doi:10.1161/CIRCULATIONAHA.121.056135. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34281357">https://www.ncbi.nlm.nih.gov/pubmed/34281357</a></li><li>Buchhorn,
R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H.
(2021). Autoantibody Release in Children after Corona Virus mRNA
Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome?
Vaccines (Basel), 9(11). doi:10.3390/vaccines9111353. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34835284">https://www.ncbi.nlm.nih.gov/pubmed/34835284</a></li><li>Calcaterra,
G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022).
Concerning the unexpected prothrombotic state following some
coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2),
71-74. doi:10.2459/JCM.0000000000001232. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34366403">https://www.ncbi.nlm.nih.gov/pubmed/34366403</a></li><li>Calcaterra,
G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V.,
& Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern
about Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533.
doi:10.3390/pediatric13030061. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34564344">https://www.ncbi.nlm.nih.gov/pubmed/34564344</a></li><li>Chai,
Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., &
Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male
adolescent after his second Pfizer-BioNTech COVID-19 vaccine. Acta
Paediatr, 111(1), 125-127. doi:10.1111/apa.16141. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34617315">https://www.ncbi.nlm.nih.gov/pubmed/34617315</a></li><li>Chamling,
B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . .
Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis
following COVID-19 vaccination: just an accidental co-incidence or
rather vaccination-associated autoimmune myocarditis? Clin Res Cardiol,
110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34333695">https://www.ncbi.nlm.nih.gov/pubmed/34333695</a></li><li>Chang,
J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia
and Thrombosis: Venous Endotheliopathy Leading to Venous Combined
Micro-Macrothrombosis. Medicina (Kaunas), 57(11).
doi:10.3390/medicina57111163. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34833382">https://www.ncbi.nlm.nih.gov/pubmed/34833382</a></li><li>Chelala,
L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C.
(2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA
Vaccination in Adolescents. AJR Am J Roentgenol.
doi:10.2214/AJR.21.26853. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34704459">https://www.ncbi.nlm.nih.gov/pubmed/34704459</a></li><li>Choi,
S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . .
Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA
COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological
Findings. J Korean Med Sci, 36(40), e286.
doi:10.3346/jkms.2021.36.e286. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34664804">https://www.ncbi.nlm.nih.gov/pubmed/34664804</a></li><li>Chouchana,
L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . .
Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following
mRNA COVID-19 Vaccination at a Global Level. Clin Pharmacol Ther.
doi:10.1002/cpt.2499. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34860360">https://www.ncbi.nlm.nih.gov/pubmed/34860360</a></li><li>Chua,
G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C.,
Tian, T., . . . Ip, P. (2021). Epidemiology of Acute
Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty
Vaccination. Clin Infect Dis. doi:10.1093/cid/ciab989. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34849657">https://www.ncbi.nlm.nih.gov/pubmed/34849657</a></li><li>Clarke,
R., & Ioannou, A. (2021). Should T2 mapping be used in cases of
recurrent myocarditis to differentiate between the acute inflammation
and chronic scar? J Pediatr. doi:10.1016/j.jpeds.2021.12.026. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34933012">https://www.ncbi.nlm.nih.gov/pubmed/34933012</a></li><li>Colaneri,
M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi,
A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation:
might there be a link? Int J Infect Dis, 112, 243-246.
doi:10.1016/j.ijid.2021.09.026. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34547487">https://www.ncbi.nlm.nih.gov/pubmed/34547487</a></li><li>Das,
B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain,
T., . . . Khan, D. (2021). Myopericarditis after messenger RNA
Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of
Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34339728">https://www.ncbi.nlm.nih.gov/pubmed/34339728</a></li><li>Das,
B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021).
Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What
Do We Know So Far? Children (Basel), 8(7). doi:10.3390/children8070607. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34356586">https://www.ncbi.nlm.nih.gov/pubmed/34356586</a></li><li>Deb,
A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute
Myocardial Injury Following COVID-19 Vaccination: A Case Report and
Review of Current Evidence from Vaccine Adverse Events Reporting System
Database. J Prim Care Community Health, 12, 21501327211029230.
doi:10.1177/21501327211029230. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34219532">https://www.ncbi.nlm.nih.gov/pubmed/34219532</a></li><li>Dickey,
J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S.,
. . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis
Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. JACC
Cardiovasc Imaging, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34246585">https://www.ncbi.nlm.nih.gov/pubmed/34246585</a></li><li>Dimopoulou,
D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N.
(2021). Safety and tolerability of the COVID-19 mRNA-vaccine in
adolescents with juvenile idiopathic arthritis on treatment with
TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/art.41977. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34492161">https://www.ncbi.nlm.nih.gov/pubmed/34492161</a></li><li>Dimopoulou,
D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021).
Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile
idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis.
doi:10.1136/annrheumdis-2021-221607. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34844930">https://www.ncbi.nlm.nih.gov/pubmed/34844930</a></li><li>Ehrlich,
P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth,
D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis
following first mRNA COVID-19 vaccination in a 40-year-old male: case
report. Clin Res Cardiol, 110(11), 1855-1859.
doi:10.1007/s00392-021-01936-6. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34487236">https://www.ncbi.nlm.nih.gov/pubmed/34487236</a></li></ol><p> </p><ol start="903"><li>El
Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J.
M., Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the
mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J
Med, 385(19), 1774-1785. doi:10.1056/NEJMoa2113017. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34551225">https://www.ncbi.nlm.nih.gov/pubmed/34551225</a></li><li>Facetti,
S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D.
(2021). [Acute myocarditis in a young adult two days after Pfizer
vaccination]. G Ital Cardiol (Rome), 22(11), 891-893.
doi:10.1714/3689.36746. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34709227">https://www.ncbi.nlm.nih.gov/pubmed/34709227</a></li><li>Fazlollahi,
A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M.,
Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications
following mRNA COVID-19 vaccines: A systematic review of case reports
and case series. Rev Med Virol, e2318. doi:10.1002/rmv.2318. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34921468">https://www.ncbi.nlm.nih.gov/pubmed/34921468</a></li><li>Fazolo,
T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto,
R., . . . Bonorino, C. (2021). Pediatric COVID-19 patients in South
Brazil show abundant viral mRNA and strong specific anti-viral
responses. Nat Commun, 12(1), 6844. doi:10.1038/s41467-021-27120-y. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34824230">https://www.ncbi.nlm.nih.gov/pubmed/34824230</a></li><li>Fikenzer,
S., & Laufs, U. (2021). Correction to: Response to Letter to the
editors referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U.,
Falz, R., Busse, M., Hepp, P., & Laufs, U. (2020). Effects of
surgical and FFP2/N95 face masks on cardiopulmonary exercise capacity.
Clinical research in cardiology: official journal of the German Cardiac
Society, 1-9. Advance online publication.
https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8),
1352. doi:10.1007/s00392-021-01896-x. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34170372">https://www.ncbi.nlm.nih.gov/pubmed/34170372</a></li><li>Foltran,
D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . .
Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents
after First and Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual
Care Clin Outcomes. doi:10.1093/ehjqcco/qcab090. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34849667">https://www.ncbi.nlm.nih.gov/pubmed/34849667</a></li><li>Forgacs,
D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson,
A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit
Different Responses in Immunologically Naive and Pre-Immune Humans.
Front Immunol, 12, 728021. doi:10.3389/fimmu.2021.728021. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34646267">https://www.ncbi.nlm.nih.gov/pubmed/34646267</a></li><li>Furer,
V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . .
. Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA
COVID-19 vaccine in adult patients with autoimmune inflammatory
rheumatic diseases and in the general population: a multicentre study.
Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34127481">https://www.ncbi.nlm.nih.gov/pubmed/34127481</a></li><li>Galindo,
R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children:
Clinical Manifestations and Pharmacologic Interventions Including
Vaccine Trials. Pediatr Clin North Am, 68(5), 961-976.
doi:10.1016/j.pcl.2021.05.004. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34538306">https://www.ncbi.nlm.nih.gov/pubmed/34538306</a></li><li>Gargano,
J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M.
E., . . . Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After
Reports of Myocarditis Among Vaccine Recipients: Update from the
Advisory Committee on Immunization Practices – United States, June 2021.
MMWR Morb Mortal Wkly Rep, 70(27), 977-982. doi:10.15585/mmwr.mm7027e2.
<a href="https://www.ncbi.nlm.nih.gov/pubmed/34237049">https://www.ncbi.nlm.nih.gov/pubmed/34237049</a></li><li>Gatti,
M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., &
Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in
Patients Receiving Immune Checkpoint Inhibitors: Investigating the
Likelihood of Interaction through the Vaccine Adverse Event Reporting
System and VigiBase. Vaccines (Basel), 9(1).
doi:10.3390/vaccines9010019. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33406694">https://www.ncbi.nlm.nih.gov/pubmed/33406694</a></li><li>Gautam,
N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S.
(2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis.
Cureus, 13(9), e17890. doi:10.7759/cureus.17890. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34660088">https://www.ncbi.nlm.nih.gov/pubmed/34660088</a></li><li>Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375, n3090. doi:10.1136/bmj.n3090. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34916217">https://www.ncbi.nlm.nih.gov/pubmed/34916217</a></li><li>Greenhawt,
M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . .
Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2
Vaccines and Recommended Evaluation and Management: A Systematic Review,
Meta-Analysis, GRADE Assessment, and International Consensus Approach. J
Allergy Clin Immunol Pract, 9(10), 3546-3567.
doi:10.1016/j.jaip.2021.06.006. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34153517">https://www.ncbi.nlm.nih.gov/pubmed/34153517</a></li><li>Haaf,
P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., .
. . Tanner, F. C. (2021). The very low risk of myocarditis and
pericarditis after mRNA COVID-19 vaccination should not discourage
vaccination. Swiss Med Wkly, 151, w30087. doi:10.4414/smw.2021.w30087. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34668687">https://www.ncbi.nlm.nih.gov/pubmed/34668687</a></li><li>Hasnie,
A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G.,
& Prabhu, S. D. (2021). Perimyocarditis following first dose of the
mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case
report. BMC Cardiovasc Disord, 21(1), 375.
doi:10.1186/s12872-021-02183-3. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34348657">https://www.ncbi.nlm.nih.gov/pubmed/34348657</a></li><li>Hause,
A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . .
. Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17
Years – United States, December 14, 2020-July 16, 2021. MMWR Morb
Mortal Wkly Rep, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34351881">https://www.ncbi.nlm.nih.gov/pubmed/34351881</a></li><li>Helms,
J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S.,
Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune
Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12,
221-224. doi:10.2147/JBM.S307047. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33854395">https://www.ncbi.nlm.nih.gov/pubmed/33854395</a></li><li>Hippisley-Cox,
J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . .
Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism
after covid-19 vaccination and SARS-CoV-2 positive testing:
self-controlled case series study. BMJ, 374, n1931.
doi:10.1136/bmj.n1931. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34446426">https://www.ncbi.nlm.nih.gov/pubmed/34446426</a></li><li>Ho,
J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K.,
& Poh, K. K. (2021). A review of COVID-19 vaccination and the
reported cardiac manifestations. Singapore Med J.
doi:10.11622/smedj.2021210. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34808708">https://www.ncbi.nlm.nih.gov/pubmed/34808708</a></li><li>Iguchi,
T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., &
Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After
mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The
First-Month Report. Drug Saf, 44(11), 1209-1214.
doi:10.1007/s40264-021-01104-9. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34347278">https://www.ncbi.nlm.nih.gov/pubmed/34347278</a></li><li>In
brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19
vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from <a href="https://www.ncbi.nlm.nih.gov/pubmed/34544112https:/www.ncbi.nlm.nih.gov/pubmed/3454412">https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pubmed/3454412</a></li><li>Ioannou,
A. (2021a). Myocarditis should be considered in those with a troponin
rise and unobstructed coronary arteries following Pfizer-BioNTech
COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34463755">https://www.ncbi.nlm.nih.gov/pubmed/34463755</a></li><li>Ioannou,
A. (2021b). T2 mapping should be utilised in cases of suspected
myocarditis to confirm an acute inflammatory process. QJM.
doi:10.1093/qjmed/hcab326. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34931681">https://www.ncbi.nlm.nih.gov/pubmed/34931681</a></li><li>Isaak,
A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following
COVID-19 Vaccination. Radiology, 301(1), E378-E379.
doi:10.1148/radiol.2021211766. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34342500">https://www.ncbi.nlm.nih.gov/pubmed/34342500</a></li><li>Istampoulouoglou,
I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin,
S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis
in association with COVID-19 mRNA-vaccination: cases from a regional
pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118.
doi:10.21542/gcsp.2021.18. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34805376">https://www.ncbi.nlm.nih.gov/pubmed/34805376</a></li><li>Jaafar,
R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . .
. La Scola, B. (2021). High Individual Heterogeneity of Neutralizing
Activities against the Original Strain and Nine Different Variants of
SARS-CoV-2. Viruses, 13(11). doi:10.3390/v13112177. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34834983">https://www.ncbi.nlm.nih.gov/pubmed/34834983</a></li><li>Jain,
S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S.
A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated
Myocarditis in Adolescents. Pediatrics, 148(5).
doi:10.1542/peds.2021-053427. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34389692">https://www.ncbi.nlm.nih.gov/pubmed/34389692</a></li><li>Jhaveri,
R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S.,
Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of
Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in
Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939.
doi:10.1093/jpids/piab061. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34270752">https://www.ncbi.nlm.nih.gov/pubmed/34270752</a></li><li>Kaneta,
K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young
Male With Myocarditis Following mRNA-1273 Vaccination Against
Coronavirus Disease-2019 (COVID-19). Circ J.
doi:10.1253/circj.CJ-21-0818. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34744118">https://www.ncbi.nlm.nih.gov/pubmed/34744118</a></li><li>Kaul,
R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., .
. . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination.
Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34568540">https://www.ncbi.nlm.nih.gov/pubmed/34568540</a></li><li>Khogali,
F., & Abdelrahman, R. (2021). Unusual Presentation of Acute
Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination.
Cureus, 13(7), e16590. doi:10.7759/cureus.16590. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34447639">https://www.ncbi.nlm.nih.gov/pubmed/34447639</a></li><li>Kim,
H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J.,
Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis
Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201.
doi:10.1001/jamacardio.2021.2828. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34185046">https://www.ncbi.nlm.nih.gov/pubmed/34185046</a></li><li>Kim,
I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021).
Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA
Vaccination. J Korean Med Sci, 36(32), e229.
doi:10.3346/jkms.2021.36.e229. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34402228">https://www.ncbi.nlm.nih.gov/pubmed/34402228</a></li><li>King,
W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L.,
& Petersen, J. W. (2021). Myocarditis following mRNA vaccination
against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042.
doi:10.1016/j.ahjo.2021.100042. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34396358">https://www.ncbi.nlm.nih.gov/pubmed/34396358</a></li><li>Klein,
N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., .
. . Weintraub, E. S. (2021). Surveillance for Adverse Events After
COVID-19 mRNA Vaccination. JAMA, 326(14), 1390-1399.
doi:10.1001/jama.2021.15072. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34477808">https://www.ncbi.nlm.nih.gov/pubmed/34477808</a></li><li>Klimek,
L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T.,
Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic
reactions to COVID-19 vaccines: A position paper from German and
Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. Allergo J Int,
1-17. doi:10.1007/s40629-021-00165-7. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33898162">https://www.ncbi.nlm.nih.gov/pubmed/33898162</a></li><li>Klimek,
L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . .
. Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination
with the Pfizer/BioNTech vaccine in Great Britain and USA: Position
statement of the German Allergy Societies: Medical Association of German
Allergologists (AeDA), German Society for Allergology and Clinical
Immunology (DGAKI) and Society for Pediatric Allergology and
Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55.
doi:10.1007/s40629-020-00160-4. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33643776">https://www.ncbi.nlm.nih.gov/pubmed/33643776</a></li><li>Kohli,
U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong,
A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated
Myopericarditis in Adolescents: A Survey Study. J Pediatr.
doi:10.1016/j.jpeds.2021.12.025. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34952008">https://www.ncbi.nlm.nih.gov/pubmed/34952008</a></li><li>Kostoff,
R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P.,
Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we
vaccinating children against COVID-19?” [Toxicol. Rep. 8C (2021)
1665-1684 / 1193]. Toxicol Rep, 8, 1981.
doi:10.1016/j.toxrep.2021.10.003. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34642628">https://www.ncbi.nlm.nih.gov/pubmed/34642628</a></li><li>Kostoff,
R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P.,
Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating
children against COVID-19? Toxicol Rep, 8, 1665-1684.
doi:10.1016/j.toxrep.2021.08.010. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34540594">https://www.ncbi.nlm.nih.gov/pubmed/34540594</a></li><li>Kremsner,
P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J.
J., . . . Group, C.-N.-S. (2021). Safety and immunogenicity of an
mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1
randomized clinical trial. Wien Klin Wochenschr, 133(17-18), 931-941.
doi:10.1007/s00508-021-01922-y. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34378087">https://www.ncbi.nlm.nih.gov/pubmed/34378087</a></li><li>Kustin,
T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . .
Stern, A. (2021). Evidence for increased breakthrough rates of
SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.
Nat Med, 27(8), 1379-1384. doi:10.1038/s41591-021-01413-7. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34127854">https://www.ncbi.nlm.nih.gov/pubmed/34127854</a></li><li>Kwan,
M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen,
K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in
adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34393110">https://www.ncbi.nlm.nih.gov/pubmed/34393110</a></li></ol><p> </p><ol start="947"><li>Lee,
E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter
to the editor: Myocarditis should be considered in those with a troponin
rise and unobstructed coronary arteries following PfizerBioNTech
COVID-19 vaccination”. QJM. doi:10.1093/qjmed/hcab232. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34463770">https://www.ncbi.nlm.nih.gov/pubmed/34463770</a></li><li>Lee,
E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M.,
Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following
Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol, 96(5),
534-537. doi:10.1002/ajh.26132. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33606296">https://www.ncbi.nlm.nih.gov/pubmed/33606296</a></li><li>Levin,
D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag,
A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination –
A case series. Vaccine, 39(42), 6195-6200.
doi:10.1016/j.vaccine.2021.09.004. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34535317">https://www.ncbi.nlm.nih.gov/pubmed/34535317</a></li><li>Li,
J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F.
(2021). Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA
vaccine in younger and older Chinese adults: a randomized,
placebo-controlled, double-blind phase 1 study. Nat Med, 27(6),
1062-1070. doi:10.1038/s41591-021-01330-9. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33888900">https://www.ncbi.nlm.nih.gov/pubmed/33888900</a></li><li>Li,
M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021).
Myocarditis and Pericarditis following COVID-19 Vaccination:
Inequalities in Age and Vaccine Types. J Pers Med, 11(11).
doi:10.3390/jpm11111106. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34834458">https://www.ncbi.nlm.nih.gov/pubmed/34834458</a></li><li>Lim,
Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D.,
& Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and
Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019
Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation.
Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34778411">https://www.ncbi.nlm.nih.gov/pubmed/34778411</a></li><li>Long,
S. S. (2021). Important Insights into Myopericarditis after the Pfizer
mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5.
doi:10.1016/j.jpeds.2021.07.057. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34332972">https://www.ncbi.nlm.nih.gov/pubmed/34332972</a></li><li>Luk,
A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . .
. McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA
Vaccination: Practical Considerations for Care Providers. Can J
Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34375696">https://www.ncbi.nlm.nih.gov/pubmed/34375696</a></li><li>Madelon,
N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey,
D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in
anti-CD20 treated patients following COVID-19 vaccination: a prospective
cohort study. Clin Infect Dis. doi:10.1093/cid/ciab954. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34791081">https://www.ncbi.nlm.nih.gov/pubmed/34791081</a></li><li>Mangat,
C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during
Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S
Antibodies Persistently Positive in an Infant at 6 Months of Age. Case
Rep Pediatr, 2021, 6901131. doi:10.1155/2021/6901131. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34676123">https://www.ncbi.nlm.nih.gov/pubmed/34676123</a></li><li>Mark,
C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . .
Alexander, S. (2021). Safety of administration of BNT162b2 mRNA
(Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a
history of acute lymphoblastic leukemia and allergy to PEG-asparaginase.
Pediatr Blood Cancer, 68(11), e29295. doi:10.1002/pbc.29295. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34398511">https://www.ncbi.nlm.nih.gov/pubmed/34398511</a></li></ol><p> </p><ol start="958"><li>Martins-Filho,
P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B.,
Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021).
Socio-economic inequalities and COVID-19 incidence and mortality in
Brazilian children: a nationwide register-based study. Public Health,
190, 4-6. doi:10.1016/j.puhe.2020.11.005. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33316478">https://www.ncbi.nlm.nih.gov/pubmed/33316478</a></li><li>McLean,
K., & Johnson, T. J. (2021). Myopericarditis in a previously
healthy adolescent male following COVID-19 vaccination: A case report.
Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34133825">https://www.ncbi.nlm.nih.gov/pubmed/34133825</a></li><li>Mevorach,
D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . .
Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against
Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149.
doi:10.1056/NEJMoa2109730. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34614328">https://www.ncbi.nlm.nih.gov/pubmed/34614328</a></li><li>Minocha,
P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of
Acute Myocarditis Temporally Associated with Receipt of the mRNA
Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J
Pediatr, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34166671">https://www.ncbi.nlm.nih.gov/pubmed/34166671</a></li><li>Mizrahi,
B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . .
Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections
to time-from-vaccine. Nat Commun, 12(1), 6379.
doi:10.1038/s41467-021-26672-3. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34737312">https://www.ncbi.nlm.nih.gov/pubmed/34737312</a></li><li>Moffitt,
K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021).
Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue
Abscesses and Comparison to Murine Infections. Infect Immun, 89(4).
doi:10.1128/IAI.00715-20. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33526560">https://www.ncbi.nlm.nih.gov/pubmed/33526560</a></li><li>Mohamed,
L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M.
G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG
vaccination scars after vaccination with mRNA-Covid-vaccines: two case
reports. BMC Infect Dis, 21(1), 1264. doi:10.1186/s12879-021-06949-0. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34930152">https://www.ncbi.nlm.nih.gov/pubmed/34930152</a></li><li>Montgomery,
J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . .
. Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With
mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol,
6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34185045">https://www.ncbi.nlm.nih.gov/pubmed/34185045</a></li><li>Murakami,
Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . .
Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA
Vaccination: A Japanese Case Series. Intern Med.
doi:10.2169/internalmedicine.8731-21. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34840235">https://www.ncbi.nlm.nih.gov/pubmed/34840235</a></li><li>Nagasaka,
T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., .
. . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19
Vaccination: A Case Report. J Cardiol Cases.
doi:10.1016/j.jccase.2021.11.006. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34876937">https://www.ncbi.nlm.nih.gov/pubmed/34876937</a></li></ol><p> </p><ol start="968"><li>Ntouros,
P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P.,
Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage
response after acute but not chronic immune challenge: SARS-CoV-2
vaccine versus Systemic Lupus Erythematosus. Clin Immunol, 229, 108765.
doi:10.1016/j.clim.2021.108765. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34089859">https://www.ncbi.nlm.nih.gov/pubmed/34089859</a></li><li>Nygaard,
U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B.,
. . . Stensballe, L. G. (2022). Population-based Incidence of
Myopericarditis After COVID-19 Vaccination in Danish Adolescents.
Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34889875">https://www.ncbi.nlm.nih.gov/pubmed/34889875</a></li><li>Oberhardt,
V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese,
S., . . . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T
cells by SARS-CoV-2 mRNA vaccine. Nature, 597(7875), 268-273.
doi:10.1038/s41586-021-03841-4. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34320609">https://www.ncbi.nlm.nih.gov/pubmed/34320609</a></li><li>Park,
H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . .
Kim, Y. J. (2021). Epidemiology and Clinical Features of
Myocarditis/Pericarditis before the Introduction of mRNA COVID-19
Vaccine in Korean Children: a Multicenter Study. J Korean Med Sci,
36(32), e232. doi:10.3346/jkms.2021.36.e232. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34402230">https://www.ncbi.nlm.nih.gov/pubmed/34402230</a></li><li>Park,
J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited
myocarditis presenting with chest pain and ST segment elevation in
adolescents after vaccination with the BNT162b2 mRNA vaccine. Cardiol
Young, 1-4. doi:10.1017/S1047951121002547. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34180390">https://www.ncbi.nlm.nih.gov/pubmed/34180390</a></li><li>Patel,
Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021).
Cardiovascular magnetic resonance findings in young adult patients with
acute myocarditis following mRNA COVID-19 vaccination: a case series. J
Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-4. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34496880">https://www.ncbi.nlm.nih.gov/pubmed/34496880</a></li><li>Patone,
M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F.,
Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis,
pericarditis, and cardiac arrhythmias associated with COVID-19
vaccination or SARS-CoV-2 infection. Nat Med.
doi:10.1038/s41591-021-01630-0. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34907393">https://www.ncbi.nlm.nih.gov/pubmed/34907393</a></li><li>Patrignani,
A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia,
G., & Mariani, A. (2021). Acute myocarditis following Comirnaty
vaccination in a healthy man with previous SARS-CoV-2 infection. Radiol
Case Rep, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34367386">https://www.ncbi.nlm.nih.gov/pubmed/34367386</a></li><li>Perez,
Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson,
M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA
Vaccine: A Case Series and Incidence Rate Determination. Clin Infect
Dis. doi:10.1093/cid/ciab926. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34734240">https://www.ncbi.nlm.nih.gov/pubmed/34734240</a></li><li>Perrotta,
A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A.
G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects
of COVID-19 vaccines among healthcare professionals and armed forces
with a focus on headache. Panminerva Med, 63(3), 324-331.
doi:10.23736/S0031-0808.21.04435-9. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34738774">https://www.ncbi.nlm.nih.gov/pubmed/34738774</a></li></ol><p> </p><p> </p><ol start="978" style="text-align: left;"><li>Pinana,
J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez,
A., . . . Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody
detection after SARS-CoV-2 vaccination in hematopoietic stem cell
transplant recipients: Prospective survey from the Spanish Hematopoietic
Stem Cell Transplantation and Cell Therapy Group. Am J Hematol, 97(1),
30-42. doi:10.1002/ajh.26385. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34695229">https://www.ncbi.nlm.nih.gov/pubmed/34695229</a></li><li>Revon-Riviere,
G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . .
Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and
young adults with cancer: A monocentric experience. Eur J Cancer, 154,
30-34. doi:10.1016/j.ejca.2021.06.002. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34233234">https://www.ncbi.nlm.nih.gov/pubmed/34233234</a></li><li>Sanchez
Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., &
Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial
Inflammation: State of the Art Review and Update on Myocarditis
Associated with COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6),
e210252. doi:10.1148/ryct.210252. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34934954">https://www.ncbi.nlm.nih.gov/pubmed/34934954</a></li><li>Schauer,
J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli
Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After
the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in
Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34228985">https://www.ncbi.nlm.nih.gov/pubmed/34228985</a></li><li>Schneider,
J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C.,
. . . Schmeling, A. (2021). Postmortem investigation of fatalities
following vaccination with COVID-19 vaccines. Int J Legal Med, 135(6),
2335-2345. doi:10.1007/s00414-021-02706-9. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34591186">https://www.ncbi.nlm.nih.gov/pubmed/34591186</a></li><li>Schramm,
R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken,
U., . . . Gummert, J. (2021). Poor humoral and T-cell response to
two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic
transplant recipients. Clin Res Cardiol, 110(8), 1142-1149.
doi:10.1007/s00392-021-01880-5. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34241676">https://www.ncbi.nlm.nih.gov/pubmed/34241676</a></li><li>Sessa,
F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara,
C. (2021). Autopsy Findings and Causality Relationship between Death
and COVID-19 Vaccination: A Systematic Review. J Clin Med, 10(24).
doi:10.3390/jcm10245876. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34945172">https://www.ncbi.nlm.nih.gov/pubmed/34945172</a></li><li>Sharif,
N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy,
Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and
Meta-Analysis. Front Immunol, 12, 714170. doi:10.3389/fimmu.2021.714170.
<a href="https://www.ncbi.nlm.nih.gov/pubmed/34707602">https://www.ncbi.nlm.nih.gov/pubmed/34707602</a></li><li>Shay,
D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . .
Shimabukuro, T. T. (2021). Safety Monitoring of the Janssen (Johnson
& Johnson) COVID-19 Vaccine – United States, March-April 2021. MMWR
Morb Mortal Wkly Rep, 70(18), 680-684. doi:10.15585/mmwr.mm7018e2. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33956784">https://www.ncbi.nlm.nih.gov/pubmed/33956784</a></li><li>Shazley,
O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man
Presented With Venous Thromboembolism and Disseminated Intravascular
Coagulation Following Johnson & Johnson Vaccination: A Case-Study.
Cureus, 13(7), e16383. doi:10.7759/cureus.16383. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34408937">https://www.ncbi.nlm.nih.gov/pubmed/34408937</a></li><li>Shiyovich,
A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . .
Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic
resonance imaging study. Eur Heart J Cardiovasc Imaging.
doi:10.1093/ehjci/jeab230. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34739045">https://www.ncbi.nlm.nih.gov/pubmed/34739045</a></li><li>Simone,
A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., &
Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination
in Adults Aged 18 Years or Older. JAMA Intern Med, 181(12), 1668-1670.
doi:10.1001/jamainternmed.2021.5511. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34605853">https://www.ncbi.nlm.nih.gov/pubmed/34605853</a></li><li>Singer,
M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis
from COVID-19 Infection in People Under Age 20: A Population-Based
Analysis. medRxiv. doi:10.1101/2021.07.23.21260998. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34341797">https://www.ncbi.nlm.nih.gov/pubmed/34341797</a></li><li>Smith,
C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . .
Fraser, L. K. (2021). Deaths in children and young people in England
after SARS-CoV-2 infection during the first pandemic year. Nat Med.
doi:10.1038/s41591-021-01578-1. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34764489">https://www.ncbi.nlm.nih.gov/pubmed/34764489</a></li><li>Snapiri,
O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A.,
Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in
Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect
Dis J, 40(10), e360-e363. doi:10.1097/INF.0000000000003235. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34077949">https://www.ncbi.nlm.nih.gov/pubmed/34077949</a></li><li>Spinner,
J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E.,
Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies
after vaccination in pediatric heart transplantation: A first report. J
Heart Lung Transplant. doi:10.1016/j.healun.2021.11.001. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34911654">https://www.ncbi.nlm.nih.gov/pubmed/34911654</a></li><li>Starekova,
J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L.,
& Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19
Vaccination. Radiology, 301(2), E409-E411.
doi:10.1148/radiol.2021211430. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34282971">https://www.ncbi.nlm.nih.gov/pubmed/34282971</a></li><li>Sulemankhil,
I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association
between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case
report and literature review. Cardiovasc Revasc Med.
doi:10.1016/j.carrev.2021.08.012. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34420869">https://www.ncbi.nlm.nih.gov/pubmed/34420869</a></li><li>Tailor,
P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case
report: acute myocarditis following the second dose of mRNA-1273
SARS-CoV-2 vaccine. Eur Heart J Case Rep, 5(8), ytab319.
doi:10.1093/ehjcr/ytab319. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34514306">https://www.ncbi.nlm.nih.gov/pubmed/34514306</a></li><li>Takeda,
M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N.
(2021). Eosinophilic Myocarditis Following Coronavirus Disease 2019
(COVID-19) Vaccination. Circ J. doi:10.1253/circj.CJ-21-0935. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34955479">https://www.ncbi.nlm.nih.gov/pubmed/34955479</a></li><li>Team,
C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including
Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19
Vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly
Rep, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33444297">https://www.ncbi.nlm.nih.gov/pubmed/33444297</a></li><li>Thompson,
M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece,
J., . . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19
with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329.
doi:10.1056/NEJMoa2107058. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34192428">https://www.ncbi.nlm.nih.gov/pubmed/34192428</a></li><li>Tinoco,
M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . .
Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination.
Clin Med Insights Cardiol, 15, 11795468211056634.
doi:10.1177/11795468211056634. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34866957">https://www.ncbi.nlm.nih.gov/pubmed/34866957</a></li><li>Truong,
D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A.,
Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected
Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents
and Young Adults. Circulation. doi:10.1161/CIRCULATIONAHA.121.056583. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34865500">https://www.ncbi.nlm.nih.gov/pubmed/34865500</a></li><li>Tutor,
A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021).
Spectrum of Suspected Cardiomyopathy Due to COVID-19: A Case Series.
Curr Probl Cardiol, 46(10), 100926. doi:10.1016/j.cpcardiol.2021.100926.
<a href="https://www.ncbi.nlm.nih.gov/pubmed/34311983">https://www.ncbi.nlm.nih.gov/pubmed/34311983</a></li><li>Umei,
T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., &
Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19
vaccination in a male adolescent. CJC Open.
doi:10.1016/j.cjco.2021.12.002. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34904134">https://www.ncbi.nlm.nih.gov/pubmed/34904134</a></li><li>Vidula,
M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V.
A., & Han, Y. (2021). Myocarditis and Other Cardiovascular
Complications of the mRNA-Based COVID-19 Vaccines. Cureus, 13(6),
e15576. doi:10.7759/cureus.15576. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34277198">https://www.ncbi.nlm.nih.gov/pubmed/34277198</a></li><li>Visclosky,
T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis
Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584.
doi:10.1097/PEC.0000000000002557. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34731877">https://www.ncbi.nlm.nih.gov/pubmed/34731877</a></li><li>Warren,
C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A.,
. . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic
Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US
Regional Health System. JAMA Netw Open, 4(9), e2125524.
doi:10.1001/jamanetworkopen.2021.25524. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34533570">https://www.ncbi.nlm.nih.gov/pubmed/34533570</a></li><li>Watkins,
K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis
after BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815
e811-815 e812. doi:10.1016/j.ajem.2021.06.051. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34229940">https://www.ncbi.nlm.nih.gov/pubmed/34229940</a></li><li>Weitzman,
E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA Vaccine
Attitudes as Expressed in U.S. FDA Public Commentary: Need for a
Public-Private Partnership in a Learning Immunization System. Front
Public Health, 9, 695807. doi:10.3389/fpubh.2021.695807. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34336774">https://www.ncbi.nlm.nih.gov/pubmed/34336774</a></li><li>Welsh,
K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021).
Thrombocytopenia including immune thrombocytopenia after receipt of mRNA
COVID-19 vaccines reported to the Vaccine Adverse Event Reporting
System (VAERS). Vaccine, 39(25), 3329-3332.
doi:10.1016/j.vaccine.2021.04.054. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34006408">https://www.ncbi.nlm.nih.gov/pubmed/34006408</a></li><li>Witberg,
G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . .
Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large
Health Care Organization. N Engl J Med, 385(23), 2132-2139.
doi:10.1056/NEJMoa2110737. <a href="https://www.ncbi.nlm.nih.gov/pubmed/34614329">https://www.ncbi.nlm.nih.gov/pubmed/34614329</a></li><li>Zimmermann,
P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A
review of the proposed mechanisms underlying the age-related difference
in severity of SARS-CoV-2 infections. Arch Dis Child.
doi:10.1136/archdischild-2020-320338. <a href="https://www.ncbi.nlm.nih.gov/pubmed/33262177">https://www.ncbi.nlm.nih.gov/pubmed/33262177</a> </li><li> <div class="separator" style="clear: both; text-align: center;"><h2>THE END<br /></h2></div></li></ol></div></span></span></span></div></div></span></div></div></div></div></span></h1><p style="text-align: center;"><iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="266" src="https://www.youtube.com/embed/zK53iiZ2WhI" title="YouTube video player" width="320"></iframe></p><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-91062380219517003202021-09-26T02:27:00.010-03:002021-12-30T17:08:18.976-03:00Como todos podem ajudar, apoiando nossa produção literária, traduções, ilustrações etc...<div dir="auto"><div class="ecm0bbzt hv4rvrfc ihqw7lf3 dati1w0a" data-ad-comet-preview="message" data-ad-preview="message" id="jsc_c_23"><div class="j83agx80 cbu4d94t ew0dbk1b irj2b8pg"><div class="qzhwtbm6 knvmm38d"><span class="d2edcug0 hpfvmrgz qv66sw1b c1et5uql lr9zc1uh a8c37x1j keod5gw0 nxhoafnm aigsh9s9 d3f4x2em fe6kdd0r mau55g9w c8b282yb iv3no6db jq4qci2q a3bd9o3v b1v8xokw oo9gr5id hzawbc8m" dir="auto"><div class="kvgmc6g5 cxmmr5t8 oygrvhab hcukyx3x c1et5uql ii04i59q"><div dir="auto" style="text-align: start;"><b>Os bloqueios(17) tornaram nossa produção literária mais penosa!</b></div><div dir="auto" style="text-align: start;"><b>Doações podem ser enviadas via Bancaria para:</b></div><div dir="auto" style="text-align: start;"> </div><dl class="tw-definition-list d-flex flex-column"><div class="tw-definition-list__item"><dd><div class="media-body" style="text-align: center;"><div class="h5"><h2>Dólar americano</h2></div></div><div class="media-right"><b><span aria-hidden="true" class="tw-icon tw-icon-chevron-up tw-chevron chevron-color top" role="presentation"><svg fill="currentColor" height="16" width="16"></svg></span></b></div><div class="media"><div class="media-body"><hr class="m-t-0 hidden-xs hidden-sm" /><div><div class="m-y-2"><div class="tabs receive-options-tabs tabs--auto-width"><ul class="tabs__tab-list" role="tablist"><li aria-controls="receive-options-panel-0" aria-disabled="false" aria-selected="true" class="tabs__tab tabs__tab--selected" id="receive-options-tab-0" role="tab" tabindex="0"><b>Dentro dos EUA</b></li></ul></div></div></div></div></div><div class="w-100"><hr class="m-y-2" /></div><div class="account-details__receive-details m-t-2 p-a-3 bg-default"><dl class="tw-definition-list d-flex flex-column"><div class="tw-definition-list__item"><dt><b>Titular da conta</b></dt><dd><b>Fernando Magalhaes Correa de Mello</b></dd></div><div class="tw-definition-list__item"><dt><b>Routing number</b></dt><dd><b>084009519</b></dd></div><div class="tw-definition-list__item"><dt><b>Número da conta</b></dt><dd><b>9600 0000 0055 8480</b></dd></div><div class="tw-definition-list__item"><dt><b>Tipo de conta</b></dt><dd><b>Checking/Corrente</b></dd></div><div class="tw-definition-list__item"><dt><b>Endereço<span aria-label="Saiba mais" class="account-details__receive-details__description-icon m-l-1" role="button" tabindex="0"><span aria-hidden="true" class="tw-icon tw-icon-help-circle" role="presentation"><svg fill="currentColor" height="16" width="16"></svg></span></span></b></dt></div></dl></div><b>TransferWise
19 W 24th Street
New York NY 10010
United States</b></dd></div></dl><div style="text-align: center;"><h2>----- OU ----</h2></div><dl class="tw-definition-list d-flex flex-column"><div class="tw-definition-list__item"><dd><div class="media-body"><hr class="m-t-0 hidden-xs hidden-sm" /><div><div class="m-y-2"><div class="tabs receive-options-tabs tabs--auto-width"><ul class="tabs__tab-list" role="tablist"><li aria-controls="receive-options-panel-0" aria-disabled="false" aria-selected="true" class="tabs__tab tabs__tab--selected" id="receive-options-tab-0" role="tab" tabindex="0"><b>Dentro da UE e SEPA</b></li></ul></div></div></div></div><div class="np-summary__body m-l-2"><div class="np-summary__title d-flex"><b>A SEPA inclui países da UE e EEE</b></div></div><div class="w-100"><ul class="p-a-0 m-a-0"><li class="np-summary d-flex align-items-start"><b><br /></b></li></ul><hr class="m-y-2" /></div><div class="account-details__receive-details m-t-2 p-a-3 bg-default"><dl class="tw-definition-list d-flex flex-column"><div class="tw-definition-list__item"><dt style="text-align: center;"><b><br /></b></dt><h2 style="text-align: center;"> EURO</h2><dt style="text-align: center;"><b><br /></b></dt><dt><b>Titular da conta</b></dt><dd><b>Fernando Magalhaes Correa de Mello</b></dd></div><div class="tw-definition-list__item"><dt><b>BIC</b></dt><dd><b>TRWIBEB1XXX</b></dd></div><div class="tw-definition-list__item"><dt><b>IBAN<span aria-label="Saiba mais" class="account-details__receive-details__description-icon m-l-1" role="button" tabindex="0"><span aria-hidden="true" class="tw-icon tw-icon-help-circle" role="presentation"><svg fill="currentColor" height="16" width="16"></svg></span></span></b></dt></div></dl></div></dd><dd><b>BE73 9672 2651 4160</b></dd></div><div class="tw-definition-list__item"><dt><b>Endereço<span aria-label="Saiba mais" class="account-details__receive-details__description-icon m-l-1" role="button" tabindex="0"><span aria-hidden="true" class="tw-icon tw-icon-help-circle" role="presentation"><svg fill="currentColor" height="16" width="16"></svg></span></span></b></dt></div><b>Avenue Louise 54, Room S52
Brussels
1050
Belgium</b></dl></div><div dir="auto" style="text-align: start;"><b>__________________________________________</b></div><div dir="auto" style="text-align: start;"><b>FORA DA UE E SEPA </b></div><div dir="auto" style="text-align: start;"><div class="tw-definition-list__item"><dt><b>Titular da conta</b></dt><dd><b>Fernando Magalhaes Correa de Mello</b></dd></div><div class="tw-definition-list__item"><dt><b>SWIFT/BIC</b></dt><dd><b>TRWIBEB1XXX</b></dd></div><div class="tw-definition-list__item"><dt><b>IBAN<span aria-label="Saiba mais" class="account-details__receive-details__description-icon m-l-1" role="button" tabindex="0"><span aria-hidden="true" class="tw-icon tw-icon-help-circle" role="presentation"><svg fill="currentColor" height="16" width="16"></svg></span></span></b></dt></div><div class="tw-definition-list__item"><dd><b>BE73 9672 2651 4160</b></dd></div><div class="tw-definition-list__item"><dt><b>Endereço<span aria-label="Saiba mais" class="account-details__receive-details__description-icon m-l-1" role="button" tabindex="0"><span aria-hidden="true" class="tw-icon tw-icon-help-circle" role="presentation"><svg fill="currentColor" height="16" width="16"></svg></span></span></b></dt></div><b>Avenue Louise 54, Room S52
Brussels
1050
Belgium </b></div><div dir="auto" style="text-align: start;"><b>___________________________________________</b></div><div dir="auto" style="text-align: start;"><br /><div style="text-align: center;"><b>BRASIL EM REAIS</b></div><div style="text-align: center;"><b>PIX</b></div><div style="text-align: center;"><b> </b></div></div></span><span class="d2edcug0 hpfvmrgz qv66sw1b c1et5uql lr9zc1uh a8c37x1j keod5gw0 nxhoafnm aigsh9s9 d3f4x2em fe6kdd0r mau55g9w c8b282yb iv3no6db jq4qci2q a3bd9o3v b1v8xokw oo9gr5id hzawbc8m" dir="auto"><div dir="auto" style="text-align: start;"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgXMSNkjSbsTwMD_l7IVAoRFyD2oNjUnFYc4C2WoYzOBjsqxPYH8do_0CYIhiaIPmVjJfumuOXbpsLICkL3IQ50inMV946yMVWw9G-sd3jURtO_WlivH1s6cbF_Jx-3F_HQnCZiNrU5-WY/s1998/IMG_1632472260000.jpg" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1998" data-original-width="1080" height="400" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgXMSNkjSbsTwMD_l7IVAoRFyD2oNjUnFYc4C2WoYzOBjsqxPYH8do_0CYIhiaIPmVjJfumuOXbpsLICkL3IQ50inMV946yMVWw9G-sd3jURtO_WlivH1s6cbF_Jx-3F_HQnCZiNrU5-WY/w216-h400/IMG_1632472260000.jpg" width="216" /></a></div><br /><b><br /></b></div><div dir="auto" style="text-align: start;"><b><br /></b></div></span><div style="text-align: center;"><b>***</b><br /></div><span class="d2edcug0 hpfvmrgz qv66sw1b c1et5uql lr9zc1uh a8c37x1j keod5gw0 nxhoafnm aigsh9s9 d3f4x2em fe6kdd0r mau55g9w c8b282yb iv3no6db jq4qci2q a3bd9o3v b1v8xokw oo9gr5id hzawbc8m" dir="auto"><div dir="auto" style="text-align: start;"><b><br /></b></div></span><h2 style="text-align: center;"><span class="d2edcug0 hpfvmrgz qv66sw1b c1et5uql lr9zc1uh a8c37x1j keod5gw0 nxhoafnm aigsh9s9 d3f4x2em fe6kdd0r mau55g9w c8b282yb iv3no6db jq4qci2q a3bd9o3v b1v8xokw oo9gr5id hzawbc8m" dir="auto"><div style="text-align: left;"><b>Agradecemos pelo Apoio !</b></div></span></h2><span class="d2edcug0 hpfvmrgz qv66sw1b c1et5uql lr9zc1uh a8c37x1j keod5gw0 nxhoafnm aigsh9s9 d3f4x2em fe6kdd0r mau55g9w c8b282yb iv3no6db jq4qci2q a3bd9o3v b1v8xokw oo9gr5id hzawbc8m" dir="auto"><div style="text-align: center;"><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh41qyhbucz5LrQfR2wQy7JzvVKECNsybjKTGT9hBsbZ5gRXsv3ykFWUQEMcFf9obm4UgUq68K4q9NB_PNJpMNpy4nFlfLslKOm2AGN7ifowj8WGLJR2Yhbv0ZGCP8gqw-1Ro9KTDUrHAoS/s543/cAPAaIRAMteKTONIKEfINAL.jpg" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="543" data-original-width="419" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh41qyhbucz5LrQfR2wQy7JzvVKECNsybjKTGT9hBsbZ5gRXsv3ykFWUQEMcFf9obm4UgUq68K4q9NB_PNJpMNpy4nFlfLslKOm2AGN7ifowj8WGLJR2Yhbv0ZGCP8gqw-1Ro9KTDUrHAoS/s320/cAPAaIRAMteKTONIKEfINAL.jpg" width="247" /></a></div><br /><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhqwB69H1a0KsfpR_KMq9RhUT_4r9C4sD-Iic9OQzdtLDZpOGb3hfxJmNZwIHI-19bxeIXOqMDl0593ZvCewuLFb6jmoIxSMhGdFD0Ts9hGyDgWsjHXnB4Lt1JTmkmCzwR8kzb6DB23REkM/s600/Contra_Capa_taca+-+Copia.jpg" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="600" data-original-width="470" height="660" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhqwB69H1a0KsfpR_KMq9RhUT_4r9C4sD-Iic9OQzdtLDZpOGb3hfxJmNZwIHI-19bxeIXOqMDl0593ZvCewuLFb6jmoIxSMhGdFD0Ts9hGyDgWsjHXnB4Lt1JTmkmCzwR8kzb6DB23REkM/w518-h660/Contra_Capa_taca+-+Copia.jpg" width="518" /></a></div><b> </b></div><div style="text-align: center;"><b>... <br /></b></div><div style="text-align: center;"><b>https://twitcasting.tv/g:103400015531128642418/windowcomment?embedded=1&style=2&auth_user_id=g:103400015531128642418&auth_key=sdpp3ea2tk</b></div></span></div></div></div></div><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-49688066472851984752021-06-25T14:48:00.003-03:002021-07-06T21:54:44.932-03:00Edificando o Despertar das Consciências para enfrentamento correto com estima adequada da realidade <p><b>Edificando o Despertar das Consciências para enfrentamento correto com estima adequada da realidade </b></p><p><b>Num contexto onde a fantasia tenta manipular as Nações e atomizar o Ser humano, Tektonike reage, Edificando o Despertar das Consciências para enfrentamento correto com estima adequada da realidade.
Sigamos Juntos!</b></p><div style="text-align: center;"><iframe allow="autoplay; clipboard-write; encrypted-media; picture-in-picture; web-share" allowfullscreen="true" frameborder="0" height="1000" scrolling="no" src="https://twitcasting.tv/fernand37083872/?fbclid=IwAR1AeKI83Desb8ZvjR7SofQYNTStkzhFo1PP7TjE7e39njwYclZTxNQOWbg" style="border: none; overflow: hidden;" width="500"></iframe></div><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-53875933463526694712021-06-21T13:48:00.001-03:002021-06-21T13:48:21.005-03:00NUNCA NA HISTORIA A VERDADE TEVE TANTOS INIMIGOS !<div style="text-align: center;"><h1><b>NUNCA</b></h1></div><p style="text-align: center;"><iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/GSKKi9lh1bA" title="YouTube video player" width="560"></iframe></p><p style="text-align: left;">
<br />
Século XXI !
21-06-2021 do Século 21
"Nunca" (Fernando M C de Mello) </p><p style="text-align: left;">Registro para historiadores ! </p><p style="text-align: left;">"<b>NUNCA A VERDADE TEVE TANTA DIFICULDADE EM BRILHAR COMO O SOL PARA A HISTÓRIA DA HUMANIDADE
NUNCA A VERDADE TEVE TANTOS INIMIGOS !
MAS CONFIAMOS QUE A ONISCIÊNCIA, ONIPRESENÇA E ONIPOTÊNCIA DO NOSSO CRIADOR E DEFENSOR, DESPERTARÁ EM CADA CORAÇÃO A VERDADE IMPEDIDA PELO CRIME E PELA GANÂNCIA DE PODER!
SOMENTE OS DE BAIXO PRECISAM DE COMUNICAÇÃO, REDES, TELEFONES, JORNAIS E REVISTAS PARA COMBINAREM SUAS PERVERSAS ESTRATÉGIAS.
OS QUE SE MANTÉM EM UNIDADE COM NOSSO CRIADOR E YAOHUSHUA, SEU FILHO ENCARNADO, POSSUEM OUTROS DIVERSOS E MAIS EXCELENTES CAMINHOS DE LUZ ! </b>"</p><p style="text-align: left;"> (<i>Fernando M C de Mello<b></b></i>) </p><p style="text-align: left;">#SecXXI #Verdade #HeyJudge @IntlCrimCourt <br /></p>
<div style="text-align: center;"><h2><b>APOSTASIA</b></h2><h2><b> </b><iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/g90eKxENFO0" title="YouTube video player" width="560"></iframe>
</h2></div><p style="text-align: center;"><i>NUNCA NA HISTORIA A VERDADE TEVE TANTOS INIMIGOS !</i></p><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-23115272797467910332021-01-13T10:33:00.000-03:002021-01-13T10:33:04.569-03:00Mensagem para a "Próxima Era".<p></p><center> .</center><p></p>
<p>
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/TBuIGBCF9jc" width="560"></iframe></p><p><br /></p><p> ..</p>
<p> Afraid of having to swear on the Bible, fraud management should cancel
the Act and in particular take an oath on the Book of Saint Cyprian!
A tsunami of curses will strike America and the world!
We must pray a lot for the protection of Yaohushua!</p><p> Com medo de ter que jurar sobre a Bíblia, a gestão da fraude deve cancelar a lei e, em particular, fazer um juramento sobre o Livro de São Cipriano!<br />Um tsunami de maldições atingirá a América e o mundo!<br />Devemos orar muito pela proteção de Yaohushua!</p><p style="text-align: center;"></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEijH55fGsf_0wLQXpDEVki1c6Q4G0TbtIykmA2wIrYZLfSeNDxd8QKJ9Pzo3klF-LIEvhNTWqXlWHhf4veLh8CWkPQP7fcjwOYEurqkBdYi1rggUpGez3_smztw_qCopLx4NIAspkyYdTk/s438/escudo%25281%2529.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="438" data-original-width="286" height="640" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEijH55fGsf_0wLQXpDEVki1c6Q4G0TbtIykmA2wIrYZLfSeNDxd8QKJ9Pzo3klF-LIEvhNTWqXlWHhf4veLh8CWkPQP7fcjwOYEurqkBdYi1rggUpGez3_smztw_qCopLx4NIAspkyYdTk/w418-h640/escudo%25281%2529.jpg" width="418" /></a></div><br /> <p></p><center>
</center><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-52397862651393390532020-06-27T18:02:00.003-03:002020-06-27T18:03:18.135-03:00BEM VINDO AO SITE ALTERNATIVO !<div style="text-align: center;">
.</div>
<div style="text-align: center;">
.</div>
<div style="text-align: center;">
https://youhitek.blogspot.com/2020/06/transposicao-das-aguas-do-s-francisco.html<br />
<a href="https://youhitek.blogspot.com/2020/06/transposicao-das-aguas-do-s-francisco.html" target="_blank">REDEFININDO O SITE PARA PUBLICAÇÕES DE TEKTONIKE EVITANDO BLOQUEIOS </a><br />
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen='allowfullscreen' webkitallowfullscreen='webkitallowfullscreen' mozallowfullscreen='mozallowfullscreen' width='320' height='266' src='https://www.blogger.com/video.g?token=AD6v5dzjW3UubiphCzBI-vvk0GEvIUAvki6Zfy1LYK90ok7q5Z4nOvFbGvNeiB-2KJZv8PqKiiBWiGv5QvDa55CROg' class='b-hbp-video b-uploaded' frameborder='0'></iframe></div>
<br />
<br />
<a href="https://youhitek.blogspot.com/2020/06/transposicao-das-aguas-do-s-francisco.html" target="_blank">BEM VINDO AO NOSSO BLOG ALTERNATIVO ! </a></div>
<div style="text-align: center;">
<br />
<div class="separator" style="clear: both; text-align: center;">
<img border="0" data-original-height="600" data-original-width="800" height="240" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg-WuALDhBCIOZebFyz5vJvly_vK2mQ8byhk3LCuCn7mlFFXmLvDeJmwxQSOBdRXWTQHihw8XmtNgSx0g87-MlsuaNQitLhv2I1hqljzdEeJ5B4qnm74WU8KnqFAVnaW1IInT7NEnmNcs4/s320/gaiatekani%255B1%255D.gif" width="320" /></div>
<br /></div>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-52779287289617163752020-05-01T12:54:00.003-03:002020-09-27T14:55:17.273-03:00ONL - ORGANIZAÇÃO DAS NAÇÕES LIVRES = FN ! #BRUSA #USABR<div style="text-align: center;">
.
.Preste atenção a estes antecedentes Históricos e consciente assuma sua posição de Cristã - Filhos de YAUH -
Salvos por YAOHUSHUA
.
.</div>
<div style="text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjQsqgf8sX_7FeHChdqiQ2BPJjj1AEQ10DLFI5LB_TDoO8dr-L6ZXMVBQ6KF4c9QJDREM39Z4XmTdVJKpYZ89ZFNERvqpJV1CvM1MJ4FzVzkJvRz6hmctVW-dTcG_M0EH4gLLT14xbJ2s_-/s1600/YHSWH.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="162" data-original-width="336" height="307" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjQsqgf8sX_7FeHChdqiQ2BPJjj1AEQ10DLFI5LB_TDoO8dr-L6ZXMVBQ6KF4c9QJDREM39Z4XmTdVJKpYZ89ZFNERvqpJV1CvM1MJ4FzVzkJvRz6hmctVW-dTcG_M0EH4gLLT14xbJ2s_-/s640/YHSWH.jpg" width="640" /></a></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
Atenção à exposição dos Antecedentes Históricos !</div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
</div>
<div style="text-align: center;">
<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/M-YLwLU_3ww" width="560"></iframe></div>
<div style="text-align: center;">
<br />
<br />
<span style="color: lime;"><b>QUE O ARCANJO DE YAOHUSHUA NOS DEFENDA </b></span><br />
<span style="color: lime;"><b>.......</b></span><br />
<span style="color: lime;"><b>.</b></span><br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgaDvcSmcPUaEhYcZXeu4gZxIOTbSje6dd8a0Wcl1y7F4iBipfFEmYAqc454RrpjeghDOzy-kchPGRhcpTYC6W-x01_DL0L-A1pVZfAvSJwqHSM5hFIdjLV5394TnZ_uelaWzbUazVVmBBv/s1600/GuardandoTesourosFUNDOPRETO+%25282%2529.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="363" data-original-width="332" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgaDvcSmcPUaEhYcZXeu4gZxIOTbSje6dd8a0Wcl1y7F4iBipfFEmYAqc454RrpjeghDOzy-kchPGRhcpTYC6W-x01_DL0L-A1pVZfAvSJwqHSM5hFIdjLV5394TnZ_uelaWzbUazVVmBBv/s320/GuardandoTesourosFUNDOPRETO+%25282%2529.png" width="292" /></a></div>
<span style="color: lime;"><b> </b></span></div>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Master Tektonikehttp://www.blogger.com/profile/16445303901402580247noreply@blogger.com1tag:blogger.com,1999:blog-3644878695846633294.post-80929066776748103222020-03-08T08:18:00.004-03:002020-03-08T08:18:41.890-03:00Satisfação em rever este colega de Ginasio nesta entrevista: Eustáquio, o Grego, hoje um Ufologo!.
.Satisfação em rever este colega de Ginasio nesta entrevista:
Eustáquio, o Grego, hoje um Ufologo!
.
<iframe width="560" height="315" src="https://www.youtube.com/embed/jMBKVAQWsYQ" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Master Tektonikehttp://www.blogger.com/profile/16445303901402580247noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-10863739932920453402019-12-19T19:32:00.003-03:002019-12-23T14:08:44.159-03:00Thanks<h2 style="text-align: center;">
THANK YOU FOR YOUR SUPPORT</h2>
<h2 style="text-align: center;">
OBRIGADO PELO APOIO</h2>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjs5qrPRZTbhkI378XC7m2kxQjUSdNO3hBPYqtwuN-b2RkuoM-RwGvc4ft6kfXLMMGKHvYqhmdGKQBL0U6FtTkpgfpkeLsz7zf31-7VVMb9dgugNw67DDMT_79Z51abE7N8OsTCZkuSGWo/s1600/SolCoracaoAzul.bmp" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="404" data-original-width="385" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjs5qrPRZTbhkI378XC7m2kxQjUSdNO3hBPYqtwuN-b2RkuoM-RwGvc4ft6kfXLMMGKHvYqhmdGKQBL0U6FtTkpgfpkeLsz7zf31-7VVMb9dgugNw67DDMT_79Z51abE7N8OsTCZkuSGWo/s320/SolCoracaoAzul.bmp" width="304" /></a></div>
<h2 style="text-align: center;">
Que a chama Azul </h2>
<h2 style="text-align: center;">
Inunde sua Vida !</h2>
<h2 style="text-align: center;">
***</h2>
<h2 style="text-align: center;">
</h2>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-65376018463713177012019-08-22T14:57:00.003-03:002019-12-14T01:05:07.122-03:00Brazil Under Attack - O Brazil está sob ataque do Terrorismo Internacional !<div style="text-align: center;">
<h3 style="text-align: center;">
APÓS BREVE TRATAMENTO, ESTÁ DE VOLTA ESTE BRASILEIRO PATRIOTA E CERTAMENTE PARA NOS AJUDAR A EXIGIR DECÊNCIA E HONRADEZ NAS DECISÕES DO STF, POIS COMUNGAMOS COM O POVO BRASILEIRO O ODIO PELA IMPUNIDADE !</h3>
<h3 style="text-align: center;">
<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/T-P05e7-Hss" width="560"></iframe></h3>
<h3 style="text-align: center;">
</h3>
<h3 style="text-align: center;">
*****</h3>
<h3 style="text-align: left;">
General Vilas Boas conclama a Nação Brasileira à Unidade em defesa da nossa Soberania !<br />
Mais uma vez a Democracia Brasileira agradecerá a este Heroi Brasileiro
que em todos os momentos fundamentais age adequadamente dissuadindo
inimigos, garantindo o Direito da Nação Brasileira e a nossa Unidade !<br /> Mais uma vez "Obrigado General Vilas Boas" !<span class="_5mfr"><span class="_6qdm" style="background-image: url("https://www.facebook.com/images/emoji.php/v9/ta2/1.5/16/1f1e7_1f1f7.png"); font-size: 16px; height: 16px; width: 16px;"> </span></span></h3>
<h3 style="text-align: left;">
<span class="_5mfr"><span class="_6qdm" style="background-image: url("https://www.facebook.com/images/emoji.php/v9/ta2/1.5/16/1f1e7_1f1f7.png"); font-size: 16px; height: 16px; width: 16px;">🇧🇷 </span></span><span class="_5mfr"><span class="_6qdm" style="background-image: url("https://www.facebook.com/images/emoji.php/v9/t2c/1.5/16/1f1fa_1f1f8.png"); font-size: 16px; height: 16px; width: 16px;">🇺🇸 </span></span><span class="_5mfr"><span class="_6qdm" style="background-image: url("https://www.facebook.com/images/emoji.php/v9/t8c/1.5/16/1f1f3_1f1ee.png"); font-size: 16px; height: 16px; width: 16px;">🇳🇮 </span></span><span class="_5mfr"><span class="_6qdm" style="background-image: url("https://www.facebook.com/images/emoji.php/v9/tf/1.5/16/1f1ef_1f1f5.png"); font-size: 16px; height: 16px; width: 16px;">🇯🇵</span></span></h3>
<br />
<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/vMjdDfqyWF0" width="560"></iframe>
<br />
Pronunciamento do General Vilas Boas <br />
<br />
<br />
<br />
OBSERVAÇÃO DA NASA POR SATELITE SOBRE A AMAZONIA<br />
rELATORIO ATUALIZADO EM 22/08/2019<br />
<a href="https://earthobservatory.nasa.gov/images/145464/fires-in-brazil" target="_blank">Esta é a mais recente observação publicada sobre a Amazonia</a>:</div>
<div style="text-align: center;">
<br /></div>
<i>Editor’s Note: This story was updated on 22 August 2019 to clarify our data source.</i>
<br />
In the Amazon rainforest, fire season has arrived. The <a href="https://modis.gsfc.nasa.gov/about/">Moderate Resolution Imaging Spectroradiometer</a> (MODIS) on NASA’s <a href="http://aqua.nasa.gov/">Aqua</a>
satellite captured these images of several fires burning in the states
of Rondônia, Amazonas, Pará, and Mato Grosso on August 11 and August 13,
2019.<br />
In the Amazon region, fires are rare for much of the year because wet
weather prevents them from starting and spreading. However, in July and
August, activity typically increases due to the arrival of the dry
season. Many people use fire to maintain farmland and pastures or to
clear land for other purposes. Typically, activity peaks in early
September and mostly stops by November.<br />
As of August 16, 2019, an analysis of NASA satellite data indicated
that total fire activity across the Amazon basin this year has been
close to the average in comparison to the past 15 years. (The Amazon
spreads across Brazil, Peru, Colombia, and parts of other countries.)
Though activity appears to be above average in the states of Amazonas
and Rondônia, it has so far appeared below average in Mato Grosso and
Pará, according to estimates from the <a href="https://www.globalfiredata.org/updates.html#2016_totals">Global Fire Emissions Database,</a>
a research project that compiles and analyzes NASA data. (Note that
while the chart label says 2016, the 2019 data is listed on all of the
plots as a green line. Roll your cursor over the green 2019 block below
the plot to isolate the 2019 numbers.)<br />
<i>NASA Earth Observatory images by Lauren Dauphin, using MODIS data from <a href="https://earthdata.nasa.gov/">NASA EOSDIS/LANCE and GIBS/Worldview</a> and VIIRS data from <a href="https://earthdata.nasa.gov/">NASA EOSDIS/LANCE and GIBS/Worldview</a>, and the <a href="http://npp.gsfc.nasa.gov/">Suomi National Polar-orbiting Partnership</a>. Caption by Adam Voiland.</i><br />
<br />
<i>OBSERVE O SEGUINTE PARAGRAFO</i><br />
<i>" As of August 16, 2019, an analysis of NASA satellite data indicated
that total fire activity across the Amazon basin this year has been
close to the average in comparison to the past 15 years. "</i><br />
<i><br /></i>
<i>"... uma analise do Satelite da NASA indicou que a atividade total que queimadas atraves da Amazonia ... </i><br />
Embora a atividade pareça estar acima da média nos estados do Amazonas e Rondônia, ela tem se mostrado muito abaixo da média em Mato Grosso e Pará,<br />
"<br />
<a href="https://www.blogger.com/u/1/goog_608135852"><br /></a>
<br />
<div style="text-align: center;">
<a href="https://eoimages.gsfc.nasa.gov/images/imagerecords/145000/145421/activefireani_tmo_2000_2019.mp4" target="_blank">VISÃO GERAL DO MUNDO </a></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<a href="https://eoimages.gsfc.nasa.gov/images/imagerecords/145000/145421/activefireani_tmo_2000_2019.mp4">VISÃO GERAL DAS OCORRENCIAS NO MUNDO !</a></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<a href="http://www.folhapolitica.org/2017/03/auditoria-do-tcu-procura-r-12-trilhao.html?fbclid=IwAR0fGxaeFJ_5zkbV-HN7Wy_SwpdnJC-9RshqKnACDTmH81dlsgA9X0mUsA8" target="_blank">MEDIDAS DO TRIBUNAL DE CONTAS DA UNIÃO ATÉ HOJE SEM SOLUÇÃO !</a><br />
<a href="http://www.folhapolitica.org/2017/03/auditoria-do-tcu-procura-r-12-trilhao.html?fbclid=IwAR0fGxaeFJ_5zkbV-HN7Wy_SwpdnJC-9RshqKnACDTmH81dlsgA9X0mUsA8" target="_blank">VEJA NESTE LINK PARECER DE MINISTRO DO TRIBUNAL DE CONTAS ENCARREGADO DE AUDITORIA DA BANDESPAR</a></div>
<br />
<div class="css-1dbjc4n r-156q2ks">
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
<span class="r-18u37iz"><span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0" dir="ltr">#ONGs</span></span><span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0"> "ONGs"
O Brasil esta sob ataque do TERRORISMO internacional associados a nacionais Traidores da Pátria sincronizados.
A Policia tem que abater bandidos portando Fuzil nas ruas. Peão com caixa de fosforo no mato e Jornalista alarmista Mentiroso ! </span><span class="r-18u37iz"><span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0" dir="ltr">#G1</span></span><span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0"> !
Veja NASA do dia 16/08/2019.</span></div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
</div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
<span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0"> A AÇÃO TERRORISTA INTERNACIONAL, ASSOCIADA A NACIONAIS TRAIDORES DA PATRIA, JÁ SAQUEARAM DO TESOURO NACIONAL ROUBO E EVASÃO DE DIVISA DA ORDEM DE TRILHÃO DE DOLARES.</span></div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
</div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
<span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0">OS TERRORISTAS NACIONAIS PROVIDENCIARAM TUDO QUE FOI NECESSÁRIO, EMPRESAS, REGISTROS, CNPJ, ´PROJETOS E TUDO MAIS, PARA DAR ACESSO À QUADRILHA AOS RECURSOS SUBSIDIADOS DO TESOURO NACIONAL NO BANCO ESTATAL DE FOMENTO DO DESENVOLVIMENTO NACIONAL E ASSIM EVADIRAM MAIS DE TRILHÃO DE DOLARES, PARA PASISES SOB DITADURAS NA AMERICA DO SUL (VENEZUELA, CUBA, BOLIVIA, NICARAGUA) E AFRICANAS !</span></div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
</div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
<span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0">A GUERRA ESTÁ ARMADA, INICIALMENTE NO ÂMBITO DA GUERRA DE INFORMAÇÃO, EMPREENDIDAS POR EMPRESAS ESTRANGEIRAS MULTADAS POR ATIVIDADES ILEGAIS E PREDATÁRIAS NA AMAZONIA BRASILEIRA, QUE ESTÃO BUSCANDO APOUO NA ONU PARA REVETER A OPINIÃO PUBLICA SOBRE TAIS CRIMES DE POLUIÇÃO E ENVENENAMENTO DE NASCENTES NA REGIÃO !</span></div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
</div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
<span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0">Já haviamos alertado há muito tempo para estas ameaças em função dos diagnosticos sobre os Negocios Ocultos do BNDES feitos pela quadrilha criminosa com a corrupção e desvio dos recursos do Tesouro Nacional !</span></div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
</div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
<a href="https://tektonike.blogspot.com/2017/05/rt-por-que-vira-guerra-porque-o-assalto.html" target="_blank"><span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0">Leia AQUI </span></a></div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
<a href="https://tektonike.blogspot.com/2017/05/rt-por-que-vira-guerra-porque-o-assalto.html" target="_blank"><span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0">https://tektonike.blogspot.com/2017/05/rt-por-que-vira-guerra-porque-o-assalto.html </span></a></div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
</div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt">
</div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt" style="text-align: center;">
<span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0"><b>DEUS PROTEJA O BRASIL </b></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiI8ykZu5SmD7Kw7Yq-zY3_jQevP1vzJSAA9IpauNkSM9WtE7Nn4kLofkYJcJSEyIZWYczawqM9nLlmfF6XC6GZTc8cLsPTN08Mjn3bobWPMTQ6aFsNoejKVeYFNtgh0vNcAwSvujz_MaI/s1600/Selo_Sacerdocio.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="332" data-original-width="175" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiI8ykZu5SmD7Kw7Yq-zY3_jQevP1vzJSAA9IpauNkSM9WtE7Nn4kLofkYJcJSEyIZWYczawqM9nLlmfF6XC6GZTc8cLsPTN08Mjn3bobWPMTQ6aFsNoejKVeYFNtgh0vNcAwSvujz_MaI/s320/Selo_Sacerdocio.png" width="168" /></a></div>
<div class="css-901oao r-9ilb82 r-1qd0xha r-a023e6 r-16dba41 r-ad9z0x r-bcqeeo r-bnwqim r-qvutc0" dir="auto" id="notification-tweet-text" lang="pt" style="text-align: center;">
</div>
</div>
<div class="panel-body">
<div class="panel-map">
<a class="no-underline panel-map-pinpoint" href="https://www.blogger.com/u/1/null" id="pointer" style="left: 110.46770032043288px; top: 85.93566427361131px;"><svg id="Layer_1" style="enable-background: new 0 0 98.2 98.2;" viewbox="0 0 98.2 98.2" x="0px" xml:space="preserve" xmlns="http://www.w3.org/2000/svg" y="0px">
</svg>
</a>
<img alt="Location" id="map" src="https://earthobservatory.nasa.gov/img/detailMap.jpg" />
</div>
<div class="panel-map-description">
<b>Satellites begin to detect heightened fire activity in July and August in the Amazon.</b><br />
<dl class="instruments">
<dt>Instruments:</dt>
<dd>Aqua — MODIS</dd><dd>Suomi NPP — VIIRS</dd></dl>
</div>
</div>
<div class="btn-tag-group">
</div>
<div class="col-lg-4 col-md-4 col-sm-4 col-xs-12">
<div class="panel panel-default hidden-xs">
</div>
</div>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com1tag:blogger.com,1999:blog-3644878695846633294.post-27263999999966008182019-08-14T03:15:00.001-03:002019-08-14T03:15:45.097-03:00Tektonike: RT - #Povo, #Poder, #Democracia: #Força e #Direito... EM FUNÇÃO DA VASTA REFLEXÃO PUBLICADA NO LINK ACIMA. ESPERAMOS DAS FORÇAS ARMADAS A AÇÃO EM CONTRAGOLPE !<br /> <a class="_58cn" data-ft="{"type":104,"tn":"*N"}" href="https://www.facebook.com/hashtag/direitaseguedireita?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARA6i_DBP8iVb3yv2LJZSlPY0dLqGq_8P-HAyNQgabZoQbPJb59N0wQPZaLn_Mf7gzdOvBSH_i2Sisb8XV6rH2kxt950nEp06QIK2I6LVRpDsKIR2hPqs1a0tIt3XSF7fWDFQtjdslAlf57IiKr80_QcssrW6YTpYjpvVbvJdcrS_8_Bz-pNrAQaW6zLpOYVX2WPzcy8OQfSb0ckYkcJWZZ6ctXczyD230mySUUuCdlj_v4DhuHGSh5I2wcCVXI0Q5diL7VaBQ77oEcByzwUqTrLtJlS0iGUt3sZ&__tn__=%2ANK-R"><span class="_5afx"><span aria-label="hashtag" class="_58cl _5afz">#</span><span class="_58cm">DireitaSegueDireita</span></span></a> <a class="_58cn" data-ft="{"type":104,"tn":"*N"}" href="https://www.facebook.com/hashtag/direitaunida?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARA6i_DBP8iVb3yv2LJZSlPY0dLqGq_8P-HAyNQgabZoQbPJb59N0wQPZaLn_Mf7gzdOvBSH_i2Sisb8XV6rH2kxt950nEp06QIK2I6LVRpDsKIR2hPqs1a0tIt3XSF7fWDFQtjdslAlf57IiKr80_QcssrW6YTpYjpvVbvJdcrS_8_Bz-pNrAQaW6zLpOYVX2WPzcy8OQfSb0ckYkcJWZZ6ctXczyD230mySUUuCdlj_v4DhuHGSh5I2wcCVXI0Q5diL7VaBQ77oEcByzwUqTrLtJlS0iGUt3sZ&__tn__=%2ANK-R"><span class="_5afx"><span aria-label="hashtag" class="_58cl _5afz">#</span><span class="_58cm">DireitaUnida</span></span></a> <a class="_58cn" data-ft="{"type":104,"tn":"*N"}" href="https://www.facebook.com/hashtag/stfvergonhanacional?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARA6i_DBP8iVb3yv2LJZSlPY0dLqGq_8P-HAyNQgabZoQbPJb59N0wQPZaLn_Mf7gzdOvBSH_i2Sisb8XV6rH2kxt950nEp06QIK2I6LVRpDsKIR2hPqs1a0tIt3XSF7fWDFQtjdslAlf57IiKr80_QcssrW6YTpYjpvVbvJdcrS_8_Bz-pNrAQaW6zLpOYVX2WPzcy8OQfSb0ckYkcJWZZ6ctXczyD230mySUUuCdlj_v4DhuHGSh5I2wcCVXI0Q5diL7VaBQ77oEcByzwUqTrLtJlS0iGUt3sZ&__tn__=%2ANK-R"><span class="_5afx"><span aria-label="hashtag" class="_58cl _5afz">#</span><span class="_58cm">STFVergonhaNAcional</span></span></a> <a class="_58cn" data-ft="{"type":104,"tn":"*N"}" href="https://www.facebook.com/hashtag/stftraidor?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARA6i_DBP8iVb3yv2LJZSlPY0dLqGq_8P-HAyNQgabZoQbPJb59N0wQPZaLn_Mf7gzdOvBSH_i2Sisb8XV6rH2kxt950nEp06QIK2I6LVRpDsKIR2hPqs1a0tIt3XSF7fWDFQtjdslAlf57IiKr80_QcssrW6YTpYjpvVbvJdcrS_8_Bz-pNrAQaW6zLpOYVX2WPzcy8OQfSb0ckYkcJWZZ6ctXczyD230mySUUuCdlj_v4DhuHGSh5I2wcCVXI0Q5diL7VaBQ77oEcByzwUqTrLtJlS0iGUt3sZ&__tn__=%2ANK-R"><span class="_5afx"><span aria-label="hashtag" class="_58cl _5afz">#</span><span class="_58cm">STFTraidor</span></span></a> <a class="_58cn" data-ft="{"type":104,"tn":"*N"}" href="https://www.facebook.com/hashtag/cortebolivariana?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARA6i_DBP8iVb3yv2LJZSlPY0dLqGq_8P-HAyNQgabZoQbPJb59N0wQPZaLn_Mf7gzdOvBSH_i2Sisb8XV6rH2kxt950nEp06QIK2I6LVRpDsKIR2hPqs1a0tIt3XSF7fWDFQtjdslAlf57IiKr80_QcssrW6YTpYjpvVbvJdcrS_8_Bz-pNrAQaW6zLpOYVX2WPzcy8OQfSb0ckYkcJWZZ6ctXczyD230mySUUuCdlj_v4DhuHGSh5I2wcCVXI0Q5diL7VaBQ77oEcByzwUqTrLtJlS0iGUt3sZ&__tn__=%2ANK-R"><span class="_5afx"><span aria-label="hashtag" class="_58cl _5afz">#</span><span class="_58cm">CorteBolivariana</span></span></a> <a class="_58cn" data-ft="{"type":104,"tn":"*N"}" href="https://www.facebook.com/hashtag/cortegolpista?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARA6i_DBP8iVb3yv2LJZSlPY0dLqGq_8P-HAyNQgabZoQbPJb59N0wQPZaLn_Mf7gzdOvBSH_i2Sisb8XV6rH2kxt950nEp06QIK2I6LVRpDsKIR2hPqs1a0tIt3XSF7fWDFQtjdslAlf57IiKr80_QcssrW6YTpYjpvVbvJdcrS_8_Bz-pNrAQaW6zLpOYVX2WPzcy8OQfSb0ckYkcJWZZ6ctXczyD230mySUUuCdlj_v4DhuHGSh5I2wcCVXI0Q5diL7VaBQ77oEcByzwUqTrLtJlS0iGUt3sZ&__tn__=%2ANK-R"><span class="_5afx"><span aria-label="hashtag" class="_58cl _5afz">#</span><span class="_58cm">CORTEGOLPISTA</span></span></a><br /><br />
<br /><br />
<a href="https://tektonike.blogspot.com/2014/12/rt-povo-poder-democracia-forca-e.html?spref=bl">Tektonike: RT - #Povo, #Poder, #Democracia: #Força e #Direito...</a>: TEMOS UMA FORÇA ARMADA COMPROMETIDA COM A LIBERDADE E O DIREITO DO POVO BRASILEIRO ! GENERAL VILAS BOAS ! Ter poder é importa...<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-1335596424472121772019-07-17T10:50:00.006-03:002019-07-19T16:43:08.115-03:00BNDES - CAIXA PRETA - POSSE PRESIDENTE NOVONa Posse do Novo Presidente Gustavo Montezano, o mesmo promete explicar a Caixa Preta !
Espero que considere as observações que fizemos na Postagem "Porquê vira a Guerra ? Porque o Assalto foi ao Tesouro Nacional!"<br />
<a href="https://tektonike.blogspot.com/2017/05/rt-por-que-vira-guerra-porque-o-assalto.html">https://tektonike.blogspot.com/2017/05/rt-por-que-vira-guerra-porque-o-assalto.html </a><br />
<br />
<div style="text-align: center;">
<a href="https://tektonike.blogspot.com/2017/05/rt-por-que-vira-guerra-porque-o-assalto.html" target="_blank">O IMPACTO DA AÇÃO TERRORISTA INTERNACIONAL SAQUEANDO O TESOURO NACIONAL</a></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhdfqmRybkAxFVYa0sVkwxRlUJuYZ0kIskeUPmdmKTm0SNxSpOs0E_Zj9lcjKfFPkeb3Wazews8VoXrqroQrPTlcCQGNqjRyIoqoR2Kyd5QGir0AZKpDU2CjmaOYnFnBkg-Nqj6Jyik53s/s1600/roubodireto.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="504" data-original-width="640" height="504" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhdfqmRybkAxFVYa0sVkwxRlUJuYZ0kIskeUPmdmKTm0SNxSpOs0E_Zj9lcjKfFPkeb3Wazews8VoXrqroQrPTlcCQGNqjRyIoqoR2Kyd5QGir0AZKpDU2CjmaOYnFnBkg-Nqj6Jyik53s/s640/roubodireto.jpg" width="640" /></a></div>
<div style="text-align: center;">
<a href="https://www.oantagonista.com/brasil/caixa-preta-do-bndes-sigilo-escondeu-emprestimos-a-custo-quase-zero-para-angola/" target="_blank"><br /></a></div>
<a href="https://www.oantagonista.com/brasil/caixa-preta-do-bndes-sigilo-escondeu-emprestimos-a-custo-quase-zero-para-angola/" target="_blank">TRANSCREVEMOS MATERIA PUBLICAFA NO ANTAGONISTA SOBRE UM DOS MUITOS CASOS:</a><br />
"<br />
<div class="col-md-4">
<div class="visible-desktop" id="sidebar">
<div class="sticky-wrapper is-sticky" id="fixed-sidebar-sticky-wrapper" style="height: 50px;">
<aside id="fixed-sidebar" style="position: fixed; top: 0px; width: 350px; z-index: inherit;">
<div class="visible-desktop dfp_ad_pos" id="div-gpt-halfpage">
</div>
</aside></div>
</div>
</div>
<div class="col-md-8">
<section id="single">
<article class="post-224746 post type-post status-publish format-standard hentry category-brasil tag-bndes tag-caixa-preta tag-angola tag-banco-do-brasil tag-cayman tag-fernando-pimentel" id="post_224746">
<header class="entry-header">
<h1 class="entry-title" id="single-title">
CAIXA-PRETA DO BNDES: Sigilo escondeu empréstimos a custo quase zero para Angola</h1>
<span class="postmeta">
<a class="fav" data-id="224746" href="https://www.oantagonista.com/brasil/caixa-preta-do-bndes-sigilo-escondeu-emprestimos-a-custo-quase-zero-para-angola/#" rel="fav" title="Guardar em seus favoritos"><small>salvar</small></a>
<span class="categoria">
<a href="https://www.oantagonista.com/brasil" title="Ver assunto sobre Brasil">Brasil</a>
</span>
<time class="entry-date published" datetime="2019-07-19 16:19:26">19.07.19 16:19</time><div>
Por Claudio Dantas</div>
</span>
<div class="box-home-captacao-email" id="form-catchment-box" style="margin: 0px auto; max-width: 400px;">
<h2 style="color: #04a3c8; font-family: inherit; font-size: 2rem; font-weight: 200; line-height: 2.9rem; margin: 0 30px 0 0;">
Leia mais sobre este assunto</h2>
<form action="post" class="catchment-box" data-xpromo-desktop="XA-MEL-OA-BOX-DESK-TOPO-CC-X-D" data-xpromo-mobile="XA-MEL-OA-BOX-MOB-TOPO-CC-X-D" id="form-catchment-box-email">
<div class="container-form">
<input class="input" id="catch-email" placeholder="Digite seu e-mail e receba gratuitamente" type="text" />
</div>
</form>
</div>
</header></article></section></div>
<header class="entry-header"><div class="box-home-captacao-email" id="form-catchment-box" style="margin: 0px auto; max-width: 400px;">
<form action="post" class="catchment-box" data-xpromo-desktop="XA-MEL-OA-BOX-DESK-TOPO-CC-X-D" data-xpromo-mobile="XA-MEL-OA-BOX-MOB-TOPO-CC-X-D" id="form-catchment-box-email">
<a class="privacidade" href="https://www.oantagonista.com/politica-de-privacidade/" style="color: #888888; display: block; font-size: 1.3rem; text-align: center; text-decoration: none;" target="_blank">Newsletter - Política de privacidade</a>
</form>
</div>
<span class="share visible-desktop visible-tablet">
<a class="fb" href="https://www.oantagonista.com/brasil/caixa-preta-do-bndes-sigilo-escondeu-emprestimos-a-custo-quase-zero-para-angola/#" rel="fb"></a>
<a class="tw" data-id="224746" href="https://www.oantagonista.com/brasil/caixa-preta-do-bndes-sigilo-escondeu-emprestimos-a-custo-quase-zero-para-angola/#" rel="tw"></a>
<a class="gm" href="https://www.oantagonista.com/brasil/caixa-preta-do-bndes-sigilo-escondeu-emprestimos-a-custo-quase-zero-para-angola/#" rel="gm"></a>
<hr />
</span>
</header>
<div class="entry-content" id="entry-text-post">
Quando era ministro
de Desenvolvimento, Indústria e Comércio (MDIC), o petista Fernando
Pimentel decretou sigilo sobre as condições especiais dos empréstimos do
BNDES a países amigos do PT.<br />
No termo de classificação referente a Angola, por exemplo, Pimentel
alegou que a divulgação das condições de financiamento e da estrutura de
garantia poderia “prejudicar a negociação de outros financiamentos
brasileiros com terceiros países”.<br />
<div class="container-banner-single" id="move-banner-box1">
<div class="banner-box-single">
<div class="advise-banner-single">
</div>
</div>
</div>
Na verdade, o então ministro queria evitar um escândalo.<br />
Como mostram documentos secretos do MDIC, obtidos por <strong>O Antagonista</strong> com a agência de dados <a href="http://www.fiquemsabendo.com.br/"><em>“Fiquem Sabendo”</em></a>, o governo petista emprestou bilhões à ditadura de José Eduardo dos Santos a custo quase zero.<br />
No empréstimo de US$ 1 bilhão feito em 2012, o BNDES concedeu prazo
de 10 anos (além de período de carência), com taxa de juros Libor + 2%
a.a., além de prêmio de seguro com custo de 9,86%.<br />
Em outra linha de crédito adicional de US$ 2 bilhões, contratada no
ano seguinte, as condições especiais praticamente se repetiram, com
Libor + 2,5% a.a. e 15 anos de prazo.<br />
Fontes de mercado consultadas afirmam que as condições desses
empréstimos para Angola são impraticáveis e não cobririam sequer o custo
de captação do recurso pelo BNDES.<br />
<img alt="" class="alignnone size-medium wp-image-224758" height="182" src="https://cdn.oantagonista.net/uploads/2019/07/detalhe-Angola-628x182.png" width="628" /><br />
<img alt="" class="alignnone size-medium wp-image-224776" height="353" src="https://cdn.oantagonista.net/uploads/2019/07/detalhe-Angola1-449x353.png" width="449" /><br />
<img alt="" class="alignnone size-medium wp-image-224749" height="353" src="https://cdn.oantagonista.net/uploads/2019/07/Pimental-Angola-250x353.png" width="250" /><br />
</div>
.
.<br />
<div style="text-align: center;">
POSSE DO NOVO PRESIDENTE
.
<br />
<iframe allowfullscreen="" frameborder="0" height="360px" src="https://twitcasting.tv/fmcmello1/embeddedplayer/live?auto_play=true&default_mute=false" width="640px"></iframe></div>
<br />
<a href="http://www.folhapolitica.org/2017/03/auditoria-do-tcu-procura-r-12-trilhao.html?fbclid=IwAR0fGxaeFJ_5zkbV-HN7Wy_SwpdnJC-9RshqKnACDTmH81dlsgA9X0mUsA8">.</a><br />
<div style="text-align: center;">
<a href="https://www.blogger.com/u/1/goog_229418672">.</a><a href="http://www.folhapolitica.org/2017/03/auditoria-do-tcu-procura-r-12-trilhao.html?fbclid=IwAR0fGxaeFJ_5zkbV-HN7Wy_SwpdnJC-9RshqKnACDTmH81dlsgA9X0mUsA8" target="_blank">MEDIDAS DO TRIBUNAL DE CONTAS DA UNIÃO ATÉ HOJE SEM SOLUÇÃO !</a><br />
<a href="http://www.folhapolitica.org/2017/03/auditoria-do-tcu-procura-r-12-trilhao.html?fbclid=IwAR0fGxaeFJ_5zkbV-HN7Wy_SwpdnJC-9RshqKnACDTmH81dlsgA9X0mUsA8" target="_blank">VEJA NESTE LINK PARECER DE MINISTRO DO TRIBUNAL DE CONTAS ENCARREGADO DE AUDITORIA DA BANDESPAR</a></div>
<div style="text-align: center;">
<a href="https://www.blogger.com/u/1/goog_229418672"> MEDIDAS DOS TCU CGU E ORGAOS DE CONTROLE</a></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.blogger.com/u/1/goog_229418672"><img border="0" data-original-height="360" data-original-width="640" height="360" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhhYICGbWzZN7-wavqWobJgCYyHiS4CZ-R9Ad8Ds8rUgYEw_AwwjC5KcXbQHp2qDPIboJ4lVvIaXfAR-C6-I5IAbXuiIt6kQi4xC92BBtrH8HjKPM58hfcxhnxfFKIH4pjFGnrrQj4ho5E/s640/TCU_BNDES.jpg" width="640" /></a></div>
.<br />
<div style="text-align: center;">
.O POVO EXIGE A FAXINA GERAL E A DEVOLUÇÃO DE TUDO QUE FOI ROUBADO !</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgxI9wlChL_Xsa6u8aWQmlcZai7kSAzyVr5bpNchEPUGhAAOGa002a4X6rLvxPq_Vi-P0wSeGfoxi4bUnjjYyQmk5Cu8sEokCAbPOPxGSvDOW93GHn9ziFE3jUhJhicaiRZPdNhvC7SkM/s1600/Zello_FRONT+BRASIL+CAMINHONEIROS_20180705_190240.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="640" data-original-width="640" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhgxI9wlChL_Xsa6u8aWQmlcZai7kSAzyVr5bpNchEPUGhAAOGa002a4X6rLvxPq_Vi-P0wSeGfoxi4bUnjjYyQmk5Cu8sEokCAbPOPxGSvDOW93GHn9ziFE3jUhJhicaiRZPdNhvC7SkM/s1600/Zello_FRONT+BRASIL+CAMINHONEIROS_20180705_190240.jpg" /></a></div>
<div style="text-align: center;">
<a href="http://./">.</a></div>
<div style="text-align: center;">
<br /></div>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-82814465320796421652019-07-12T11:15:00.004-03:002019-08-13T21:00:51.677-03:00Nosso Respeito e Gratidão Ao General Vilas Boas e a todos os Veteranos que deram a Vida por Nossa Liberdade !<div style="text-align: center;">
<br />
<br />
Homenagem no Congresso ao General Vilas Boas !<br />
O General que garantiu a Democracia Brasileira e nossas Liberdades !<br />
<iframe width="560" height="315" src="https://www.youtube.com/embed/UDKAZHq8JoI" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe><br />
<br />
<br />
<br />
Nossa Gratidão a todos os Veteranos
<br />
<br />
<br />
<iframe allow="encrypted-media" allowfullscreen="true" allowtransparency="true" frameborder="0" height="851" scrolling="no" src="https://www.facebook.com/plugins/video.php?href=https%3A%2F%2Fwww.facebook.com%2Fpslbrasilnovo%2Fvideos%2F455855874955260%2F&show_text=1&width=261" style="border: none; overflow: hidden;" width="261"></iframe></div>
<br /><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Master Tektonikehttp://www.blogger.com/profile/16445303901402580247noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-55530427505384703152019-07-11T03:35:00.001-03:002019-07-11T03:43:10.542-03:00#rt MORO E DELTAN DALLAGNOL TOTALMENTE AMPARADOS NA LEI<div style="text-align: center;">
.</div>
<div style="text-align: center;">
.</div>
<div style="text-align: center;">
<a href="http://www.planalto.gov.br/ccivil_03/_Ato2011-2014/2013/Lei/L12850.htm">http://www.planalto.gov.br/ccivil_03/_Ato2011-2014/2013/Lei/L12850.htm</a></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhT_q8wu1kI0QsPd_c-ZtRa_iWreXHCGgAKunsm20Z9rT7rQimmZPix8Gc9UJYDJU4wTrOO6SYZjGMgZRMxPT1sPA5arqjyjQ9dBum5-Zk2nov2qTauTL52djNZ51mbvovYG56u_NAW0HU/s1600/BAsilicaImaculadaConcei%25C3%25A7%25C3%25A3o.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="777" data-original-width="1493" height="331" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhT_q8wu1kI0QsPd_c-ZtRa_iWreXHCGgAKunsm20Z9rT7rQimmZPix8Gc9UJYDJU4wTrOO6SYZjGMgZRMxPT1sPA5arqjyjQ9dBum5-Zk2nov2qTauTL52djNZ51mbvovYG56u_NAW0HU/s640/BAsilicaImaculadaConcei%25C3%25A7%25C3%25A3o.jpg" width="640" /></a></div>
<div style="text-align: center;">
.</div>
<h2>
</h2>
<h2>
</h2>
<h2>
</h2>
<br />
<br />
<header>
<h2>
<span style="color: #eeeeee;"><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">Presidência da República
</span></span></span></h2>
<h2>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></h2>
<h2>
<span style="color: #eeeeee;"><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Casa Civil
</span></span></span></h2>
<h2>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></h2>
<h2>
<span style="color: #eeeeee;"><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Subchefia para Assuntos Jurídicos
</span></span></span></h2>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></header><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><br />
<div align="CENTER" style="margin-bottom: 20px; margin-top: 20px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: navy; font-family: "arial";">
<a href="http://legislacao.planalto.gov.br/legisla/legislacao.nsf/Viw_Identificacao/lei%2012.850-2013?OpenDocument" style="color: navy;">
LEI Nº 12.850, DE 2 DE AGOSTO DE 2013.
</a>
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="font-family: "arial"; font-size: xx-small;">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%px;">
<tbody>
<tr>
<td width="49%"><span style="font-size: xx-small;">
<a href="http://www.planalto.gov.br/ccivil_03/_Ato2011-2014/2013/Lei/L12850.htm#art27">
Vigência
</a>
</span>
</td>
<td width="51%"><div align="justify" style="margin-bottom: 0; margin-top: 0;">
<span style="font-family: "arial"; font-size: xx-small;">
<span style="color: maroon;">
Define organização criminosa e dispõe sobre a investigação
criminal, os meios de obtenção da prova, infrações penais correlatas e o
procedimento criminal; altera o Decreto-Lei nº 2.848, de 7 de dezembro
de 1940 (Código Penal); revoga a Lei nº 9.034, de 3 de maio de 1995; e
dá outras providências.
</span>
</span>
</div>
</td>
</tr>
</tbody>
</table>
</span></span></span></b></span><br />
<div class="MsoNormal" style="margin-left: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="font-family: "arial"; font-size: xx-small;"><span style="color: black;">
A
PRESIDENTA DA REPÚBLICA
Faço saber que o Congresso Nacional decreta e eu sanciono a seguinte Lei:
</span>
</span></span></span></b></span></div>
<span style="font-family: "arial"; font-size: x-small;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span>
<br />
<div align="center" class="MsoNormal" style="margin-left: 0cm; text-align: center;">
<span style="font-family: "arial"; font-size: x-small;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
CAPÍTULO I
</span></span></span></b></span>
</span></div>
<span style="font-family: "arial"; font-size: x-small;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span><br />
<div align="center" class="MsoNormal" style="margin-left: 0cm; text-align: center;">
<span style="font-family: "arial"; font-size: x-small;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
DA ORGANIZAÇÃO CRIMINOSA
</span></span></span></b></span>
</span></div>
<span style="font-family: "arial"; font-size: x-small;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span><br />
<div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="font-family: "arial"; font-size: x-small;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art1">
</a>
Art. 1º
Esta Lei define organização criminosa e dispõe sobre a investigação
criminal, os meios de obtenção da prova, infrações penais correlatas e o
procedimento criminal a ser aplicado.
</span></span></b></span>
</span></div>
<span style="font-family: "arial"; font-size: x-small;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span><br />
<div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="font-family: "arial"; font-size: x-small;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art1§1">
</a>
§ 1º Considera-se organização criminosa a associação de 4 (quatro)
ou mais pessoas estruturalmente ordenada e caracterizada pela divisão de
tarefas, ainda que informalmente, com objetivo de obter, direta ou
indiretamente, vantagem de qualquer natureza, mediante a prática de
infrações penais cujas penas máximas sejam superiores a 4 (quatro) anos,
ou que sejam de caráter transnacional.
</span></span></b></span>
</span></div>
<span style="font-family: "arial"; font-size: x-small;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span><br />
<div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="font-family: "arial"; font-size: x-small;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art1§2">
</a>
§ 2º Esta Lei se aplica também:
</span></span></b></span>
</span></div>
<span style="font-family: "arial"; font-size: x-small;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art1§2i">
</a>
I - às infrações penais previstas em tratado ou convenção
internacional quando, iniciada a execução no País, o resultado tenha ou
devesse ter ocorrido no estrangeiro, ou reciprocamente;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="text-decoration: line-through;">
<a href="https://www.blogger.com/null" name="art1§2ii">
</a>
II - às organizações terroristas internacionais, reconhecidas
segundo as normas de direito internacional, por foro do qual o Brasil
faça parte, cujos atos de suporte ao terrorismo, bem como os atos
preparatórios ou de execução de atos terroristas, ocorram ou possam
ocorrer em território nacional.
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span lang="PT" style="color: black;">
<a href="https://www.blogger.com/null" name="art1§2ii.">
</a>
II - às organizações terroristas, entendidas como aquelas voltadas
para a prática dos atos de terrorismo legalmente definidos.
<a href="http://www.planalto.gov.br/ccivil_03/_Ato2015-2018/2016/Lei/L13260.htm#art19">
(Redação dada pela lei nº 13.260, de 2016)
</a>
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art2">
</a>
Art. 2º Promover, constituir, financiar ou integrar, pessoalmente ou por interposta pessoa, organização criminosa:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Pena - reclusão, de 3 (três) a 8 (oito) anos, e multa, sem prejuízo
das penas correspondentes às demais infrações penais praticadas.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 1º Nas mesmas penas incorre quem impede ou, de qualquer forma,
embaraça a investigação de infração penal que envolva organização
criminosa.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 2º As penas aumentam-se até a metade se na atuação da organização criminosa houver emprego de arma de fogo.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 3º A pena é agravada para quem exerce o comando, individual ou
coletivo, da organização criminosa, ainda que não pratique pessoalmente
atos de execução.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 4º A pena é aumentada de 1/6 (um sexto) a 2/3 (dois terços):
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
I - se há participação de criança ou adolescente;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
II - se há concurso de funcionário público, valendo-se a
organização criminosa dessa condição para a prática de infração penal;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
III - se o produto ou proveito da infração penal destinar-se, no todo ou em parte, ao exterior;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
IV - se a organização criminosa mantém conexão com outras organizações criminosas independentes;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
V - se as circunstâncias do fato evidenciarem a transnacionalidade da organização.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 5º Se houver indícios suficientes de que o funcionário público
integra organização criminosa, poderá o juiz determinar seu afastamento
cautelar do cargo, emprego ou função, sem prejuízo da remuneração,
quando a medida se fizer necessária à investigação ou instrução
processual.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 6º A condenação com trânsito em julgado acarretará ao funcionário
público a perda do cargo, função, emprego ou mandato eletivo e a
interdição para o exercício de função ou cargo público pelo prazo de 8
(oito) anos subsequentes ao cumprimento da pena.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 7º Se houver indícios de participação de policial nos crimes de
que trata esta Lei, a Corregedoria de Polícia instaurará inquérito
policial e comunicará ao Ministério Público, que designará membro para
acompanhar o feito até a sua conclusão.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<span style="background-color: black;"><span style="color: red;">CAPÍTULO II
</span></span></span></span></b></span><span style="background-color: black;">
</span></div>
<span style="background-color: black;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="background-color: black;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<span style="color: red;">DA INVESTIGAÇÃO E DOS MEIOS DE OBTENÇÃO DA PROVA
</span></span></span></b></span><span style="color: red;">
</span></span></div>
<span style="background-color: black;">
<span style="color: red;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="background-color: black;"><span style="color: red;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art3">
</a>
<span style="color: red;">Art. 3º Em qualquer fase da persecução penal, serão permitidos, sem
prejuízo de outros já previstos em lei, os seguintes meios de obtenção
da prova:
</span></span></span></b></span></span><span style="color: red;">
</span></span></div>
<span style="background-color: black;">
<span style="color: red;">
<span style="color: red;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span></span></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="background-color: black;"><span style="color: red;"><span style="color: red;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
I<span style="color: red;"> - colaboração premiada;
</span></span></span></b></span></span></span><span style="color: red;">
</span></span></div>
<span style="background-color: black;">
<span style="color: red;">
<span style="color: red;">
<span style="color: red;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span></span></span></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="background-color: black;"><span style="color: red;"><span style="color: red;"><span style="color: red;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
II - captação ambiental de sinais eletromagnéticos, ópticos ou acústicos;
</span></span></b></span></span></span></span></span>
</div>
<span style="background-color: black;">
<span style="color: red;">
<span style="color: red;">
<span style="color: red;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span></span></span></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="background-color: black;"><span style="color: red;"><span style="color: red;"><span style="color: red;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
III - ação controlada;
</span></span></b></span></span></span></span></span>
</div>
<span style="background-color: black;">
<span style="color: red;">
<span style="color: red;">
<span style="color: red;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span></span></span></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="background-color: black;"><span style="color: red;"><span style="color: red;"><span style="color: red;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
IV - acesso a registros de ligações telefônicas e telemáticas, a
dados cadastrais constantes de bancos de dados públicos ou privados e a
informações eleitorais ou comerciais;
</span></span></b></span></span></span></span></span>
</div>
<span style="background-color: black;">
<span style="color: red;">
<span style="color: red;">
<span style="color: red;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span></span></span></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="background-color: black;"><span style="color: red;"><span style="color: red;"><span style="color: red;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
V - interceptação de comunicações telefônicas e telemáticas, nos termos da legislação específica;
</span></span></b></span></span></span></span></span>
</div>
<span style="background-color: black;">
<span style="color: red;">
<span style="color: red;">
<span style="color: red;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span></span></span></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="background-color: black;"><span style="color: red;"><span style="color: red;"><span style="color: red;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
VI - afastamento dos sigilos financeiro, bancário e fiscal, nos termos da legislação específica;
</span></span></b></span></span></span></span></span>
</div>
<span style="background-color: black;">
<span style="color: red;">
<span style="color: red;">
<span style="color: red;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span></span></span></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="background-color: black;"><span style="color: red;"><span style="color: red;"><span style="color: red;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
VII - infiltração, por policiais, em atividade de investigação, na forma do art. 11;
</span></span></b></span></span></span></span></span>
</div>
<span style="background-color: black;">
<span style="color: red;">
<span style="color: red;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span></span></span></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="background-color: yellow;"><span style="color: red;"><span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="background-color: black;"><span style="color: red;">
VIII - cooperação entre instituições e órgãos federais, distritais,
estaduais e municipais na busca de provas e informações de interesse da
investigação ou da instrução criminal.</span></span>
</span></span></b></span></span></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="justify" class="Artart" style="line-height: 12.0pt; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><a href="https://www.blogger.com/null" name="art3§1">
</a>
§ 1º Havendo necessidade justificada de manter sigilo sobre a
capacidade investigatória, poderá ser dispensada licitação para
contratação de serviços técnicos especializados, aquisição ou locação de
equipamentos destinados à polícia judiciária para o rastreamento e
obtenção de provas previstas nos incisos II e V.
<a href="http://www.planalto.gov.br/ccivil_03/_Ato2015-2018/2015/Lei/L13097.htm#art158">
(Incluído pela Lei nº 13.097, de 2015)
</a></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="justify" class="Artart" style="line-height: 12.0pt; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">§ 2º No caso do § 1º , fica dispensada a publicação de que trata o parágrafo único do
<a href="http://www.planalto.gov.br/ccivil_03/LEIS/L8666cons.htm#art61">
art. 61 da Lei nº 8.666, de 21 de junho de 1993,
</a>
devendo ser comunicado o órgão de controle interno da realização da contratação.
<a href="http://www.planalto.gov.br/ccivil_03/_Ato2015-2018/2015/Lei/L13097.htm#art158">
(Incluído pela Lei nº 13.097, de 2015)
</a></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Seção I
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Da Colaboração Premiada
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art4">
</a>
Art. 4º O juiz poderá, a requerimento das partes, conceder o perdão
judicial, reduzir em até 2/3 (dois terços) a pena privativa de
liberdade ou substituí-la por restritiva de direitos daquele que tenha
colaborado efetiva e voluntariamente com a investigação e com o processo
criminal, desde que dessa colaboração advenha um ou mais dos seguintes
resultados:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
I - a identificação dos demais coautores e partícipes da organização criminosa e das infrações penais por eles praticadas;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
II - a revelação da estrutura hierárquica e da divisão de tarefas da organização criminosa;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
III - a prevenção de infrações penais decorrentes das atividades da organização criminosa;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
IV - a recuperação total ou parcial do produto ou do proveito das infrações penais praticadas pela organização criminosa;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
V - a localização de eventual vítima com a sua integridade física preservada.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 1º Em qualquer caso, a concessão do benefício levará em conta a
personalidade do colaborador, a natureza, as circunstâncias, a gravidade
e a repercussão social do fato criminoso e a eficácia da colaboração.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 2º Considerando a relevância da colaboração prestada, o
Ministério Público, a qualquer tempo, e o delegado de polícia, nos autos
do inquérito policial, com a manifestação do Ministério Público,
poderão requerer ou representar ao juiz pela concessão de perdão
judicial ao colaborador, ainda que esse benefício não tenha sido
previsto na proposta inicial, aplicando-se, no que couber, o
<a href="http://www.planalto.gov.br/ccivil_03/Decreto-Lei/Del3689.htm#art28">
art. 28 do Decreto-Lei nº 3.689, de 3 de outubro de 1941 (Código de Processo Penal).
</a>
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 3º O prazo para oferecimento de denúncia ou o processo, relativos
ao colaborador, poderá ser suspenso por até 6 (seis) meses,
prorrogáveis por igual período, até que sejam cumpridas as medidas de
colaboração, suspendendo-se o respectivo prazo prescricional.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 4º Nas mesmas hipóteses do
<span style="color: black;">
caput
</span>
, o Ministério Público poderá deixar de oferecer denúncia se o colaborador:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
I - não for o líder da organização criminosa;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
II - for o primeiro a prestar efetiva colaboração nos termos deste artigo.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 5º Se a colaboração for posterior à sentença, a pena poderá ser
reduzida até a metade ou será admitida a progressão de regime ainda que
ausentes os requisitos objetivos.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 6º O juiz não participará das negociações realizadas entre as
partes para a formalização do acordo de colaboração, que ocorrerá entre o
delegado de polícia, o investigado e o defensor, com a manifestação do
Ministério Público, ou, conforme o caso, entre o Ministério Público e o
investigado ou acusado e seu defensor.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 7º Realizado o acordo na forma do § 6º , o respectivo termo,
acompanhado das declarações do colaborador e de cópia da investigação,
será remetido ao juiz para homologação, o qual deverá verificar sua
regularidade, legalidade e voluntariedade, podendo para este fim,
sigilosamente, ouvir o colaborador, na presença de seu defensor.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 8º O juiz poderá recusar homologação à proposta que não atender aos requisitos legais, ou adequá-la ao caso concreto.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 9º Depois de homologado o acordo, o colaborador poderá, sempre
acompanhado pelo seu defensor, ser ouvido pelo membro do Ministério
Público ou pelo delegado de polícia responsável pelas investigações.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 10. As partes podem retratar-se da proposta, caso em que as
provas autoincriminatórias produzidas pelo colaborador não poderão ser
utilizadas exclusivamente em seu desfavor.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 11. A sentença apreciará os termos do acordo homologado e sua eficácia.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 12. Ainda que beneficiado por perdão judicial ou não denunciado, o
colaborador poderá ser ouvido em juízo a requerimento das partes ou por
iniciativa da autoridade judicial.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 13. Sempre que possível, o registro dos atos de colaboração será
feito pelos meios ou recursos de gravação magnética, estenotipia,
digital ou técnica similar, inclusive audiovisual, destinados a obter
maior fidelidade das informações.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 14. Nos depoimentos que prestar, o colaborador renunciará, na
presença de seu defensor, ao direito ao silêncio e estará sujeito ao
compromisso legal de dizer a verdade.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 15. Em todos os atos de negociação, confirmação e execução da
colaboração, o colaborador deverá estar assistido por defensor.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 16. Nenhuma sentença condenatória será proferida com fundamento apenas nas declarações de agente colaborador.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art5">
</a>
Art. 5º São direitos do colaborador:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
I - usufruir das medidas de proteção previstas na legislação específica;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
II - ter nome, qualificação, imagem e demais informações pessoais preservados;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
III - ser conduzido, em juízo, separadamente dos demais coautores e partícipes;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
IV - participar das audiências sem contato visual com os outros acusados;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
V - não ter sua identidade revelada pelos meios de comunicação, nem
ser fotografado ou filmado, sem sua prévia autorização por escrito;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
VI - cumprir pena em estabelecimento penal diverso dos demais corréus ou condenados.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art6">
</a>
Art. 6º O termo de acordo da colaboração premiada deverá ser feito por escrito e conter:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
I - o relato da colaboração e seus possíveis resultados;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
II - as condições da proposta do Ministério Público ou do delegado de polícia;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
III - a declaração de aceitação do colaborador e de seu defensor;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
IV - as assinaturas do representante do Ministério Público ou do delegado de polícia, do colaborador e de seu defensor;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
V - a especificação das medidas de proteção ao colaborador e à sua família, quando necessário.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art7">
</a>
Art. 7º O pedido de homologação do acordo será sigilosamente
distribuído, contendo apenas informações que não possam identificar o
colaborador e o seu objeto.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 1º As informações pormenorizadas da colaboração serão dirigidas
diretamente ao juiz a que recair a distribuição, que decidirá no prazo
de 48 (quarenta e oito) horas.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 2º O acesso aos autos será restrito ao juiz, ao Ministério
Público e ao delegado de polícia, como forma de garantir o êxito das
investigações, assegurando-se ao defensor, no interesse do representado,
amplo acesso aos elementos de prova que digam respeito ao exercício do
direito de defesa, devidamente precedido de autorização judicial,
ressalvados os referentes às diligências em andamento.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 3º O acordo de colaboração premiada deixa de ser sigiloso assim
que recebida a denúncia, observado o disposto no art. 5º .
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center; text-indent: 0cm;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Seção II
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center; text-indent: 0cm;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Da Ação Controlada
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art8">
</a>
Art. 8º Consiste a ação controlada em retardar a intervenção
policial ou administrativa relativa à ação praticada por organização
criminosa ou a ela vinculada, desde que mantida sob observação e
acompanhamento para que a medida legal se concretize no momento mais
eficaz à formação de provas e obtenção de informações.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 1º O retardamento da intervenção policial ou administrativa será
previamente comunicado ao juiz competente que, se for o caso,
estabelecerá os seus limites e comunicará ao Ministério Público.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 2º A comunicação será sigilosamente distribuída de forma a não
conter informações que possam indicar a operação a ser efetuada.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 3º Até o encerramento da diligência, o acesso aos autos será
restrito ao juiz, ao Ministério Público e ao delegado de polícia, como
forma de garantir o êxito das investigações.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 4º Ao término da diligência, elaborar-se-á auto circunstanciado acerca da ação controlada.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art9">
</a>
Art. 9º Se a ação controlada envolver transposição de fronteiras, o
retardamento da intervenção policial ou administrativa somente poderá
ocorrer com a cooperação das autoridades dos países que figurem como
provável itinerário ou destino do investigado, de modo a reduzir os
riscos de fuga e extravio do produto, objeto, instrumento ou proveito do
crime.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Seção III
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Da Infiltração de Agentes
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art10">
</a>
Art. 10. A infiltração de agentes de polícia em tarefas de
investigação, representada pelo delegado de polícia ou requerida pelo
Ministério Público, após manifestação técnica do delegado de polícia
quando solicitada no curso de inquérito policial, será precedida de
circunstanciada, motivada e sigilosa autorização judicial, que
estabelecerá seus limites.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 1º Na hipótese de representação do delegado de polícia, o juiz competente, antes de decidir, ouvirá o Ministério Público.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 2º Será admitida a infiltração se houver indícios de infração
penal de que trata o art. 1º e se a prova não puder ser produzida por
outros meios disponíveis.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 3º A infiltração será autorizada pelo prazo de até 6 (seis)
meses, sem prejuízo de eventuais renovações, desde que comprovada sua
necessidade.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 4º Findo o prazo previsto no § 3º , o relatório circunstanciado
será apresentado ao juiz competente, que imediatamente cientificará o
Ministério Público.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 5º No curso do inquérito policial, o delegado de polícia poderá
determinar aos seus agentes, e o Ministério Público poderá requisitar, a
qualquer tempo, relatório da atividade de infiltração.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art11">
</a>
Art. 11. O requerimento do Ministério Público ou a representação do
delegado de polícia para a infiltração de agentes conterão a
demonstração da necessidade da medida, o alcance das tarefas dos agentes
e, quando possível, os nomes ou apelidos das pessoas investigadas e o
local da infiltração.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art12">
</a>
Art. 12. O pedido de infiltração será sigilosamente distribuído, de
forma a não conter informações que possam indicar a operação a ser
efetivada ou identificar o agente que será infiltrado.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 1º As informações quanto à necessidade da operação de infiltração
serão dirigidas diretamente ao juiz competente, que decidirá no prazo
de 24 (vinte e quatro) horas, após manifestação do Ministério Público na
hipótese de representação do delegado de polícia, devendo-se adotar as
medidas necessárias para o êxito das investigações e a segurança do
agente infiltrado.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 2º Os autos contendo as informações da operação de infiltração
acompanharão a denúncia do Ministério Público, quando serão
disponibilizados à defesa, assegurando-se a preservação da identidade do
agente.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
§ 3º Havendo indícios seguros de que o agente infiltrado sofre
risco iminente, a operação será sustada mediante requisição do
Ministério Público ou pelo delegado de polícia, dando-se imediata
ciência ao Ministério Público e à autoridade judicial.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art13">
</a>
Art. 13. O agente que não guardar, em sua atuação, a devida
proporcionalidade com a finalidade da investigação, responderá pelos
excessos praticados.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Parágrafo único. Não é punível, no âmbito da infiltração, a prática
de crime pelo agente infiltrado no curso da investigação, quando
inexigível conduta diversa.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art14">
</a>
Art. 14. São direitos do agente:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
I - recusar ou fazer cessar a atuação infiltrada;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
II - ter sua identidade alterada, aplicando-se, no que couber, o disposto no
<a href="http://www.planalto.gov.br/ccivil_03/LEIS/L9807.htm#art9">
art. 9º da Lei nº 9.807, de 13 de julho de 1999,
</a>
bem como usufruir das medidas de proteção a testemunhas;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
III - ter seu nome, sua qualificação, sua imagem, sua voz e demais
informações pessoais preservadas durante a investigação e o processo
criminal, salvo se houver decisão judicial em contrário;
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
IV - não ter sua identidade revelada, nem ser fotografado ou
filmado pelos meios de comunicação, sem sua prévia autorização por
escrito.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Seção IV
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Do Acesso a Registros, Dados Cadastrais, Documentos e Informações
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art15">
</a>
Art. 15. O delegado de polícia e o Ministério Público terão acesso,
independentemente de autorização judicial, apenas aos dados cadastrais
do investigado que informem exclusivamente a qualificação pessoal, a
filiação e o endereço mantidos pela Justiça Eleitoral, empresas
telefônicas, instituições financeiras, provedores de internet e
administradoras de cartão de crédito.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art16">
</a>
Art. 16. As empresas de transporte possibilitarão, pelo prazo de 5
(cinco) anos, acesso direto e permanente do juiz, do Ministério Público
ou do delegado de polícia aos bancos de dados de reservas e registro de
viagens.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art17">
</a>
Art. 17. As concessionárias de telefonia fixa ou móvel manterão,
pelo prazo de 5 (cinco) anos, à disposição das autoridades mencionadas
no art. 15, registros de identificação dos números dos terminais de
origem e de destino das ligações telefônicas internacionais,
interurbanas e locais.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Seção V
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Dos Crimes Ocorridos na Investigação e na Obtenção da Prova
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art18">
</a>
Art. 18. Revelar a identidade, fotografar ou filmar o colaborador, sem sua prévia autorização por escrito:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Pena - reclusão, de 1 (um) a 3 (três) anos, e multa.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art19">
</a>
Art. 19. Imputar falsamente, sob pretexto de colaboração com a
Justiça, a prática de infração penal a pessoa que sabe ser inocente, ou
revelar informações sobre a estrutura de organização criminosa que sabe
inverídicas:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Pena - reclusão, de 1 (um) a 4 (quatro) anos, e multa.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art20">
</a>
Art. 20. Descumprir determinação de sigilo das investigações que envolvam a ação controlada e a infiltração de agentes:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Pena - reclusão, de 1 (um) a 4 (quatro) anos, e multa.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art21">
</a>
Art. 21. Recusar ou omitir dados cadastrais, registros, documentos e
informações requisitadas pelo juiz, Ministério Público ou delegado de
polícia, no curso de investigação ou do processo:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Pena - reclusão, de 6 (seis) meses a 2 (dois) anos, e multa.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Parágrafo único. Na mesma pena incorre quem, de forma indevida, se
apossa, propala, divulga ou faz uso dos dados cadastrais de que trata
esta Lei.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center; text-indent: 0cm;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
CAPÍTULO III
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div align="center" class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-align: center; text-indent: 0cm;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
DISPOSIÇÕES FINAIS
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art22">
</a>
Art. 22. Os crimes previstos nesta Lei e as infrações penais
conexas serão apurados mediante procedimento ordinário previsto no
<a href="http://www.planalto.gov.br/ccivil_03/Decreto-Lei/Del3689.htm">
Decreto-Lei nº 3.689, de 3 de outubro de 1941 (Código de Processo Penal),
</a>
observado o disposto no parágrafo único deste artigo.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Parágrafo único. A instrução criminal deverá ser encerrada em prazo
razoável, o qual não poderá exceder a 120 (cento e vinte) dias quando o
réu estiver preso, prorrogáveis em até igual período, por decisão
fundamentada, devidamente motivada pela complexidade da causa ou por
fato procrastinatório atribuível ao réu.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art23">
</a>
Art. 23. O sigilo da investigação poderá ser decretado pela
autoridade judicial competente, para garantia da celeridade e da
eficácia das diligências investigatórias, assegurando-se ao defensor, no
interesse do representado, amplo acesso aos elementos de prova que
digam respeito ao exercício do direito de defesa, devidamente precedido
de autorização judicial, ressalvados os referentes às diligências em
andamento.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Parágrafo único. Determinado o depoimento do investigado, seu
defensor terá assegurada a prévia vista dos autos, ainda que
classificados como sigilosos, no prazo mínimo de 3 (três) dias que
antecedem ao ato, podendo ser ampliado, a critério da autoridade
responsável pela investigação.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art24">
</a>
Art. 24. O art. 288 do
<a href="http://www.planalto.gov.br/ccivil_03/Decreto-Lei/Del2848.htm">
Decreto-Lei nº 2.848, de 7 de dezembro de 1940 (Código Penal),
</a>
passa a vigorar com a seguinte redação:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><blockquote>
<blockquote>
<div class="Artigo">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
“
<span style="color: black;">
Associação Criminosa
</span></span></span></b></span>
</div>
<div class="Artigo">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="http://www.planalto.gov.br/ccivil_03/Decreto-Lei/Del2848.htm#art288.">
Art. 288.
</a>
Associarem-se 3 (três) ou mais pessoas, para o fim específico de cometer crimes:
</span></span></b></span>
</div>
<div class="Artigo">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Pena - reclusão, de 1 (um) a 3 (três) anos.
</span></span></b></span>
</div>
<div class="Artigo">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
Parágrafo único. A pena aumenta-se até a metade se a associação é
armada ou se houver a participação de criança ou adolescente.” (NR)
</span></span></b></span>
</div>
</blockquote>
</blockquote>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art25">
</a>
Art. 25. O art. 342 do
<a href="http://www.planalto.gov.br/ccivil_03/Decreto-Lei/Del2848.htm">
Decreto-Lei nº 2.848, de 7 de dezembro de 1940 (Código Penal),
</a>
passa a vigorar com a seguinte redação:
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><blockquote>
<blockquote>
<div class="Artigo" style="margin-right: 0cm;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
“Art. 342. ...................................................................................
</span></span></b></span>
</div>
<div class="Artigo" style="margin-right: 0cm;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="http://www.planalto.gov.br/ccivil_03/Decreto-Lei/Del2848.htm#art342pena">
Pena -
</a>
reclusão, de 2 (dois) a 4 (quatro) anos, e multa.
</span></span></b></span>
</div>
<div class="Artigo" style="margin-left: 0cm; margin-right: 0cm;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
..................................................................................................” (NR)
</span></span></b></span>
</div>
</blockquote>
</blockquote>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art26">
</a>
Art. 26. Revoga-se a
<a href="http://www.planalto.gov.br/ccivil_03/LEIS/L9034.htm">
Lei nº 9.034, de 3 de maio de 1995.
</a>
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="Artigo" style="margin-left: 0cm; margin-right: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
<a href="https://www.blogger.com/null" name="art27">
</a>
Art. 27. Esta Lei entra em vigor após decorridos 45 (quarenta e cinco) dias de sua publicação oficial.
</span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="MsoNormal" style="margin-left: 0cm; text-indent: 35px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
Brasília, 2 de agosto de 2013; 192º da Independência e 125º da República.
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="MsoNormal" style="margin-bottom: 0; margin-left: 0cm; margin-top: 0;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: black;">
DILMA ROUSSEFF
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="MsoNormal" style="margin-bottom: 0; margin-left: 0cm; margin-top: 0;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="font-style: italic;">
José Eduardo Cardozo
</span></span></span></b></span>
</div>
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">
</span></span></b></span><div class="MsoNormal" style="margin-bottom: 20px; margin-left: 0cm; margin-top: 20px;">
<span style="color: #eeeeee;"><b><span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="color: red;">
Este texto não substitui o publicado no DOU de 5.8.2013 - Edição extra
</span></span></span></b></span>
</div>
</span><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-42654803508435178292019-07-06T17:24:00.003-03:002019-07-06T17:24:56.041-03:00O BRASIL ESTÁ SOB ATAQUE DO TERRORISMO INTERNACIONAL ! <div class="separator" style="clear: both; text-align: center;">
<a href="https://mc115news.blogspot.com/2019/07/rt-brazil-under-attack.html" target="_blank"><img alt="rt-brazil-under-attack.html" border="0" data-original-height="670" data-original-width="828" height="515" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEib4mr7eO0etbh0a86sHNVAQdKpL5eERe8mSbEgd7xzWJVAqibiBAKj8Dvy9ub9TQk9Leg55-jeuyZCKi9Np4tKVmLNoQh4l0LUiXFfwFgaZoBp77sFWBXDO6OBuck_GY_cXgvXkmllRW8/s640/Teruz.jpg" width="640" /></a></div>
<div style="text-align: center;">
https://mc115news.blogspot.com/2019/07/rt-brazil-under-attack.html</div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: justify;">
O BRASIL ESTÁ SOB ATAQUE DO TERRORISMO INTERNACIONAL ! <br />
As autoridades, a Imprensa e a Sociedade de um modo Geral não podem passar batidas por esse tema !<br />
Não é tão simplório assim: "Ah ! Mandaram nosso dinheiro pra fora !"<br />
-NÃO !<br />
A coisa é MUITO MAIS GRAVE ! O caso BNDES tem potencial para gerar Guerra !<span class="text_exposed_show"><br />
Estrangeiros invadiram o Brasil e saquearam Banco Estatal acessando com
Terroristas Nacionais que pavimentaram o acesso ao Dinheiro Subsidiado
pelo Povo e evadiram as divisas, em escalas de CENTENAS DE BILHÕES DE
DÓLARES !<br /> AGENTES USANDO CAMUFLAGENS, ARTIFÍCIOS, DISSIMULAÇÕES,
EMPRESAS TERRORISTAS (ATÉ MESMO COM ORIGENS NAZISTAS ALEMÃS) TRAINDO A
ECONOMIA, FRAUDANDO COM RESERVA MENTAL, COM FALSO IDEOLÓGICO FRANQUEARAM
ACESSO AOS RECURSOS DO TESOURO NACIONAL EMPRESTANDO SEUS REGISTROS E
CNPJ PARA OS INVASORES E AGRESSORES DA NOSSA NAÇÃO !<br /> ARROMBARAM OS COFRES DO TESOURO NACIONAL, ROUBARAM BILHÕES E EVADIRAM O BOTIM !<br /> ***<br />
O BRASIL ESTÁ SOB ATAQUE DO TERRORISMO INTERNACIONAL COM MEMBROS
NACIONAIS TRAIDORES DA PÁTRIA, COLABORACIONISTAS COM OS AGRESSORES!" O
FORO DE SÃO PAULO REUNIU ESTA QUADRILHA !<br /> PRESTEM ATENÇÃO A AÇÃO DA ODEBRECHT NESTES ESCÂNDALOS DO BNDES E DO PT NA AMÉRICA LATINA,<br />
(HÁ POUCOS DIAS O DITADOR MADURO E SEU REGIME COM O CARTEL NARCO DE LOS
SOLES FOI DENUNCIADO ESTAR TRANSPORTANDO PARA A RÚSSIA LINGOTES DE OURO
FUNDIDOS NA ALEMANHA NAZISTA, OURO EXPROPRIADO DE JUDEUS PERSEGUIDOS
PELOS NAZISTAS QUE NA DÉCADA DE 1940 FORAM DERROTADOS E MUITOS
EMPRESÁRIOS FUGIRAM PARA A AMÉRICA DO SUL !)<br /> ISSO É GRAVE POIS SE
REUNIRAM (TERRORISTAS, GUERRILHEIROS, RADICAIS ISLÂMICOS,
NARCOTRAFICANTES, SOCIALISTAS E REMANESCENTES NAZIFASCISTAS EUROPEUS )
EM UM BLOCO E AGEM EM ATAQUE CONTRA NOSSAS NAÇÕES LATINO AMERICANAS!<br /> ***<br />
A INTELIGÊNCIA BRASILEIRA, AS FFAA E INSTITUIÇÕES DA SEGURANÇA TEM QUE
ANALISAR MUITO BEM AS DELAÇÕES DO PALOCCI SOBRE O BNDES - É ATAQUE
DIRETO TERRORISTA AO TESOURO NACIONAL CONDUZINDO O ESFORÇO PARA O
DOMÍNIO DA PROTEÍNA ANIMAL ! <br /> *** <br /> COM ESTES BILHÕES ROUBADOS
ESTÃO FINANCIANDO AS AÇÕES TERRORISTAS CONTRA O ESTADO BRASILEIRO, nossa
NAÇÃO E NOSSAS INSTITUIÇÕES.<br /> <a class="_58cn" data-ft="{"type":104,"tn":"*N"}" href="https://www.facebook.com/hashtag/crime?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARCOiKNdZ4x4Vys-ykOpNmuaIpTnifHbNxIB43c-_9imDfaVAYdCHr4Fo_Q1gIDZ5evzWMv_a5z0L_SLOhOnSZMyJpzhRzvGQjYBXzQzgaXa9PN1kDWbl-dd3Qt3WeYb9blC4RkpzKJcrNRRyzl3mvA_zS2qefFaXgIR0vrniDaJqZrMJTLhwnE47zqO99GPhLWX1bbwl67gejEODeZ0qTXe03lF0xqzDvTMpyxj0lnrsnnuKvM0NVuhVnaxYdPu5rjjlfSQ-CFPMoSpDpO0HWE-itJlW5DxKAp7&__tn__=%2ANK-R"><span class="_5afx"><span aria-label="hashtag" class="_58cl _5afz">#</span><span class="_58cm">Crime</span></span></a>
é GRAVÍSSIMO, UMA VERDADEIRA GUERRA E COM AÇÕES DE TERRORISTAS
NACIONAIS QUE TRAEM A PÁTRIA ! SÃO COLABORACIONISTAS COM O INIMIGO
ESTRANGEIRO QUE ROUBOU NOSSO TESOURO NACIONAL E EVADIRAM NOSSAS DIVISAS !<br /> ÀS FFAA ATIVAS E NOSSAS INSTITUIÇÕES TÊM O DEVER DE DEFENDEREM A NAÇÃO, NOSSO TERRITÓRIO E NOSSAS INSTITUIÇÕES INVADIDAS !<br /> ISSO É MUITO GRAVE !<br /> Em RESUMO:<br />
Estrangeiros invadiram o Brasil e saquearam Banco Estatal acessando com
Terroristas Nacionais que DERAM acesso ao Dinheiro Subsidiado pelo Povo
e evadiram as divisas de CENTENAS DE BILHÕES DE DÓLARES !<br /> <a class="_58cn" data-ft="{"type":104,"tn":"*N"}" href="https://www.facebook.com/hashtag/bolsonaro?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARCOiKNdZ4x4Vys-ykOpNmuaIpTnifHbNxIB43c-_9imDfaVAYdCHr4Fo_Q1gIDZ5evzWMv_a5z0L_SLOhOnSZMyJpzhRzvGQjYBXzQzgaXa9PN1kDWbl-dd3Qt3WeYb9blC4RkpzKJcrNRRyzl3mvA_zS2qefFaXgIR0vrniDaJqZrMJTLhwnE47zqO99GPhLWX1bbwl67gejEODeZ0qTXe03lF0xqzDvTMpyxj0lnrsnnuKvM0NVuhVnaxYdPu5rjjlfSQ-CFPMoSpDpO0HWE-itJlW5DxKAp7&__tn__=%2ANK-R"><span class="_5afx"><span aria-label="hashtag" class="_58cl _5afz">#</span><span class="_58cm">Bolsonaro</span></span></a> <a class="_58cn" data-ft="{"type":104,"tn":"*N"}" href="https://www.facebook.com/hashtag/moro?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARCOiKNdZ4x4Vys-ykOpNmuaIpTnifHbNxIB43c-_9imDfaVAYdCHr4Fo_Q1gIDZ5evzWMv_a5z0L_SLOhOnSZMyJpzhRzvGQjYBXzQzgaXa9PN1kDWbl-dd3Qt3WeYb9blC4RkpzKJcrNRRyzl3mvA_zS2qefFaXgIR0vrniDaJqZrMJTLhwnE47zqO99GPhLWX1bbwl67gejEODeZ0qTXe03lF0xqzDvTMpyxj0lnrsnnuKvM0NVuhVnaxYdPu5rjjlfSQ-CFPMoSpDpO0HWE-itJlW5DxKAp7&__tn__=%2ANK-R"><span class="_5afx"><span aria-label="hashtag" class="_58cl _5afz">#</span><span class="_58cm">Moro</span></span></a> @SF_moro<br /> <span class="_5mfr"><span class="_6qdm" style="background-image: url("https://www.facebook.com/images/emoji.php/v9/t9/1/16/1f1e7_1f1f7.png"); font-size: 16px; height: 16px; width: 16px;">🇧🇷</span></span><span class="_5mfr"><span class="_6qdm" style="background-image: url("https://www.facebook.com/images/emoji.php/v9/tb1/1/16/1f1ee_1f1f1.png"); font-size: 16px; height: 16px; width: 16px;">🇮🇱</span></span><span class="_5mfr"><span class="_6qdm" style="background-image: url("https://www.facebook.com/images/emoji.php/v9/t93/1/16/1f1fa_1f1f8.png"); font-size: 16px; height: 16px; width: 16px;">🇺🇸</span></span></span></div>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-21579027388496592542019-07-06T00:48:00.001-03:002019-07-06T01:06:19.035-03:00@SF_Moro #RT O BRASIL ESTÁ SOB ATAQUE !<div style="text-align: center;">
<a href="https://www.facebook.com/190201438538041/videos/2071556159805807/" target="_blank"><b>PRONUNCIAMENTO DO COMANDANTE SUPREMO DAS FFAA BRASILEIRAS</b></a><br />
<br />
<b>O Brasil tem seus heróis de ontem, de hoje, de sempre...
- Como Chefe Supremo das Forças Armadas minha continência e meu muito obrigado ao eterno Comandante, General Villas Bôas.</b><br />
<div class="_4ik3 _2k5d" style="bottom: 19px;">
…</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgM4ae2_nS_nmJ6574T3s5lnqpG3LM3IFWuo5PAAE-PqSffPQi-heJx9iK73CZZGYAR9XY1IZBcACCmMb4Rn8E3YTTwQnoVWHGQvwjVvgBBC6SayA-_vhvmoWvFFXBp-3FzU3D8ISVmNhs/s1600/GuardandoTesourosFundoPreto.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="400" data-original-width="386" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgM4ae2_nS_nmJ6574T3s5lnqpG3LM3IFWuo5PAAE-PqSffPQi-heJx9iK73CZZGYAR9XY1IZBcACCmMb4Rn8E3YTTwQnoVWHGQvwjVvgBBC6SayA-_vhvmoWvFFXBp-3FzU3D8ISVmNhs/s320/GuardandoTesourosFundoPreto.jpg" width="308" /></a></div>
<b> </b><span style="font-family: "verdana" , sans-serif;"><span style="background-color: yellow;"><span style="color: red;"><b> </b></span></span></span><br />
<h2>
<span style="font-family: "verdana" , sans-serif; font-size: x-large;"><span style="background-color: yellow;"><span style="color: red;"><b>O BRASIL ESTÁ SOB ATAQUE ! </b></span></span></span></h2>
</div>
<div style="text-align: center;">
<h2>
<span style="background-color: yellow;"><span style="color: red;"><b><span style="background-color: black;"></span> </b></span></span></h2>
</div>
As autoridades, a Imprensa e a Sociedade de um modo Geral não podem passar batidas por esse tema!<br />
Não é tão simplório assim: "Ah ! Mandaram nosso dinheiro pra fora !"<br />
-NÃO !<br />
A coisa é MUITO MAIS GRAVE !<br />
O caso BNDES tem potencial para gerar Guerra !<br />
Estrangeiros invadiram o Brasil e saquearam Banco Estatal acessando com Terroristas Nacionais que pavimentaram o acesso ao Dinheiro Subsidiado pelo Povo e evadiram as divisas, em escalas de CENTENAS DE BILHÕES DE DÓLARES !<br />
AGENTES USANDO CAMUFLAGENS, ARTIFÍCIOS, DISSIMULAÇÕES, EMPRESAS TERRORISTAS (ATÉ MESMO COM ORIGENS NAZISTAS ALEMÃS) TRAINDO A ECONOMIA, FRAUDANDO COM RESERVA MENTAL, COM FALSO IDEOLÓGICO FRANQUEARAM ACESSO AOS RECURSOS DO TESOURO NACIONAL EMPRESTANDO SEUS REGISTROS E CNPJ PARA OS INVASORES E AGRESSORES DA NOSSA NAÇÃO !<br />
ARROMBARAM OS COFRES DO TESOURO NACIONAL, ROUBARAM BILHÕES E EVADIRAM O BOTIM !<br />
***<br />
O BRASIL ESTÁ SOB ATAQUE DO TERRORISMO INTERNACIONAL COM MEMBROS NACIONAIS TRAIDORES DA PÁTRIA, COLABORACIONISTAS COM OS AGRESSORES!"<br />
O FORO DE SÃO PAULO REUNIU ESTA QUADRILHA !<br />
PRESTEM ATENÇÃO A AÇÃO DA ODEBRECHT NESTES ESCÂNDALOS DO BNDES E DO PT NA AMÉRICA LATINA, HÁ POUCOS DIAS O DITADOR MADURO E SEU REGIME COM O CARTEL NARCO DE LOS SOLES FOI DENUNCIADO ESTAR TRANSPORTANDO PARA A RÚSSIA LINGOTES DE OURO FUNDIDOS NA ALEMANHA NAZISTA, OURO EXPROPRIADO DE JUDEUS PERSEGUIDOS PELOS NAZISTAS QUE NA DÉCADA DE 1940 FORAM DERROTADOS E MUITOS EMPRESÁRIOS FUGIRAM PARA A AMÉRICA DO SUL !)<br />
ISSO É GRAVE POIS SE REUNIRAM (TERRORISTAS, GUERRILHEIROS, RADICAIS ISLÂMICOS, NARCOTRAFICANTES, SOCIALISTAS E REMANESCENTES NAZIFASCISTAS EUROPEUS ) EM UM BLOCO E AGEM EM ATAQUE CONTRA NOSSAS NAÇÕES LATINO AMERICANAS!<br />
***<br />
A INTELIGÊNCIA BRASILEIRA, AS FFAA E INSTITUIÇÕES DA SEGURANÇA TEM QUE ANALISAR MUITO BEM AS DELAÇÕES DO PALOCCI SOBRE O BNDES - É ATAQUE DIRETO TERRORISTA AO TESOURO NACIONAL CONDUZINDO O ESFORÇO PARA O DOMÍNIO DA PROTEÍNA ANIMAL ! <br />
***<br />
COM ESTES BILHÕES ROUBADOS ESTÃO FINANCIANDO AS AÇÕES TERRORISTAS CONTRA O ESTADO BRASILEIRO, nossa NAÇÃO E NOSSAS INSTITUIÇÕES.<br />
O <a href="https://www.facebook.com/hashtag/crime?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARBk3WuuME-UoDajYHTHI1ERtNaUV-Ks67brK8VnJP7STDyBDI09csNNtOYyLtWK9eL_nX4Y2U_IFHGNYz5jAhAsOCR9cfG97RIB3jvSEGu769UbQM_6lcJatapsh4inLH0bHSZmpsVmxLwBhbQykD7hzZroVKYBzeM7YyERZJwet1nV4z6ct2VpPm74gOXGID2U4-j6ZS7xZAcIVjIOqKPxjDQd4bhasX5G3qGTDCrmyyFiLPc7Vah5VRW5TsfAN5ego8_u5dl5JDOvoJI4WmfIsSyfFNyjK9JFSC9KSM_Z2Vs_zzzmNASMvFZEueU9Wrx_b4frFeyna7Zp50buSMMTaTL1TWZr_o0r_OkZDmGxmgLQNyGyXPoiyYboTNsbqPrBMGnUlH8rLJoY-5VyUwu3PXynNXEe-hS6&__tn__=%2ANK-R-R">#Crime</a> é GRAVÍSSIMO, UMA VERDADEIRA GUERRA E COM AÇÕES DE TERRORISTAS NACIONAIS QUE TRAEM A PÁTRIA !<br />
SÃO COLABORACIONISTAS COM O INIMIGO ESTRANGEIRO QUE ROUBOU NOSSO TESOURO NACIONAL E EVADIRAM NOSSAS DIVISAS !<br />
AS FFAA ATIVAS E NOSSAS INSTITUIÇÕES TÊM O DEVER DE DEFENDEREM A NAÇÃO, NOSSO TERRITÓRIO E NOSSAS INSTITUIÇÕES INVADIDAS !<br />
ISSO É MUITO GRAVE !<br />
Estrangeiros invadiram o Brasil e saquearam Banco Estatal acessando com Terroristas Nacionais que DERAM acesso ao Dinheiro Subsidiado pelo Povo e evadiram as divisas de CENTENAS DE BILHÕES DE DÓLARES !<br />
<a href="https://www.facebook.com/hashtag/bolsonaro?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARBk3WuuME-UoDajYHTHI1ERtNaUV-Ks67brK8VnJP7STDyBDI09csNNtOYyLtWK9eL_nX4Y2U_IFHGNYz5jAhAsOCR9cfG97RIB3jvSEGu769UbQM_6lcJatapsh4inLH0bHSZmpsVmxLwBhbQykD7hzZroVKYBzeM7YyERZJwet1nV4z6ct2VpPm74gOXGID2U4-j6ZS7xZAcIVjIOqKPxjDQd4bhasX5G3qGTDCrmyyFiLPc7Vah5VRW5TsfAN5ego8_u5dl5JDOvoJI4WmfIsSyfFNyjK9JFSC9KSM_Z2Vs_zzzmNASMvFZEueU9Wrx_b4frFeyna7Zp50buSMMTaTL1TWZr_o0r_OkZDmGxmgLQNyGyXPoiyYboTNsbqPrBMGnUlH8rLJoY-5VyUwu3PXynNXEe-hS6&__tn__=%2ANK-R-R">#Bolsonaro</a> <a href="https://www.facebook.com/hashtag/moro?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARBk3WuuME-UoDajYHTHI1ERtNaUV-Ks67brK8VnJP7STDyBDI09csNNtOYyLtWK9eL_nX4Y2U_IFHGNYz5jAhAsOCR9cfG97RIB3jvSEGu769UbQM_6lcJatapsh4inLH0bHSZmpsVmxLwBhbQykD7hzZroVKYBzeM7YyERZJwet1nV4z6ct2VpPm74gOXGID2U4-j6ZS7xZAcIVjIOqKPxjDQd4bhasX5G3qGTDCrmyyFiLPc7Vah5VRW5TsfAN5ego8_u5dl5JDOvoJI4WmfIsSyfFNyjK9JFSC9KSM_Z2Vs_zzzmNASMvFZEueU9Wrx_b4frFeyna7Zp50buSMMTaTL1TWZr_o0r_OkZDmGxmgLQNyGyXPoiyYboTNsbqPrBMGnUlH8rLJoY-5VyUwu3PXynNXEe-hS6&__tn__=%2ANK-R-R">#Moro</a> @SF_moro<br />
🇧🇷🇮🇱🇺🇸<br />
<h2 style="text-align: center;">
<span style="color: red;"><span style="background-color: yellow;"><span style="font-family: "verdana" , sans-serif;"><span style="font-size: large;">DEUS PROTEJA E DEFENDA A NOSSA NAÇÃO !</span></span></span></span></h2>
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi-QU8_pJsM9M01rYTJjZf2k1cMHs0KsX6XiBKz4Dg2CTL8CiCDnNg-mCneOCDgTLZNdWZKklPcsyoc2uk1fNPqsprC3t6QIOJ8bz_dhhK_EVTAb47KlV997b6DT_68GLyAR0yiZYYvZeI/s1600/ComandoMilitarLEgalmenteArmado.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="566" data-original-width="1209" height="297" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi-QU8_pJsM9M01rYTJjZf2k1cMHs0KsX6XiBKz4Dg2CTL8CiCDnNg-mCneOCDgTLZNdWZKklPcsyoc2uk1fNPqsprC3t6QIOJ8bz_dhhK_EVTAb47KlV997b6DT_68GLyAR0yiZYYvZeI/s640/ComandoMilitarLEgalmenteArmado.jpg" width="640" /></a></div>
<h2 style="text-align: center;">
<span style="color: red;"><span style="background-color: yellow;"><span style="font-family: "verdana" , sans-serif;"><span style="font-size: large;"> </span></span></span></span> </h2>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-20799128870549903232019-06-29T21:35:00.001-03:002019-06-29T22:39:24.966-03:00VEM PRA RUA / VIVA A LAVA JATO EM TODO O BRASIL E NO MUNDO !<div style="text-align: center;">
<br>
https://youtu.be/3rMX_rrv36w?t=45
#Dia30Ultimato <a href="https://youtu.be/3rMX_rrv36w?t=45 #Dia30Ultimato "></a>
</br>
<br>
<iframe src="https://ssl.twitcasting.tv/fmcmello1/embeddedplayer/live?auto_play=false&default_mute=true" width="640px" height="360px" frameborder="0" allowfullscreen></iframe>
<br /></div>
<br>
<br /><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com1tag:blogger.com,1999:blog-3644878695846633294.post-3947045242504300002019-06-29T01:25:00.001-03:002019-06-29T01:27:23.482-03:00MC115 NEWS: VITORIA E GRANDE REALIZAÇÃO NA POLITICA DAS RELA...<a href="https://mc115news.blogspot.com/2019/06/vitoria-e-grande-realizacao-na-politica.html?spref=bl">MC115 NEWS: <br />
<br />
VITORIA E GRANDE REALIZAÇÃO NA POLITICA DAS RELA...</a>: VITORIA E GRANDE REALIZAÇÃO NA POLITICA DAS RELAÇÕES INTERNACIONAIS MAS, SE NÃO RESOLVERMOS ESTA SITUAÇÃO DO CRIME ORGANIZADO NA PO...<br />
<br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">VITORIA E GRANDE REALIZAÇÃO NA POLITICA DAS RELAÇÕES INTERNACIONAIS </span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> MAS, SE NÃO RESOLVERMOS ESTA SITUAÇÃO DO CRIME ORGANIZADO NA POLITICA, TODAS ESTAS REALIZAÇÕES SERÃO BLOQUEADAS NO CONGRESSO ! </span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> O POVO NA RUA É QUE GOVERNA COM BOLSONARO ! </span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> SE SAIMOS DAS RUAS O CRIME DA QUADRILHA NO CONGRESSO CRIA OBSTACULO PARA TUDO ! </span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> SÃO MOVIDOS A PROPINAS ! </span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> BOLSONARO NÃO FOI ELEITO, FOI ACLAMADO E SE IMPÔS SOBRE A FRAUDE ELEITORAL E OS FRAUDADORES EM FUNÇÃO DA MASSIVA ACLAMAÇÃO ! </span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
Não é à toa que Bolsonaro tem mais de 87% de aprovação do povo <br />
brasileiro. Uma pessoa cheia de boa vontade para acertar e restraurar o <br />
Brasil para voltar a desenvolver a Nação ! </span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
Em breve será praticamente a unanimidade, quando o Povo no dia 30/06 <br />
neutralizar a quadrilha que recebeu cadeiras no Congresso para obstar as<br />
iniciativas do Executivo aclamado pelo Povo; </span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> Eleição sem auditoria dá nisso. </span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> Aparelharam o Parlamento, o Legislativo, com o que ha de pior da falta de Ética no contexto politico ! </span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
Nas sete milhões e duzentas mil apertadas de botão computadas pela Urna<br />
da Fé Cega como NULOS, sem qualquer possibilidade de verificação, nem <br />
mesmo para saber o que deu causa à nulidade, se foi erro de software ou <br />
de Hardware, o que torna mais provavel o crime de fraude eleitoral. </span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
Nos sete milhões e duzentas mil apertada de botões estão o equivalente a<br />
245 Deputados, maioria da Casa Legislativa , e bem podem ter sido <br />
varridos no Lixo Eletronico verdadeiros representantes do Povo <br />
Brasileiro alijados para dar assento a esta quadrilha ! </span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
MAS em 30/06 a Nação em Peso nas ruas do País, juntos vamos corrigir <br />
isto e RESOLVER essa situação do Crime Politico aboletado nas <br />
Instituições da Republica !</span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> * </span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
VAMOS DEFENDER NOSSAS INSTITUIÇÕES E FAXINA-LAS, REMOVENDO TODOS ESTES <br />
CRIMINOSOS COM O APOIO DAS FORÇAS ARMADAS QUE TEM O DEVER DE DEFENDER AS<br />
INSTITUIÇÕES !</span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> * </span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
O ART 5º da CF Garante nosso direto ao Livre Pensar e Expressar, <br />
garantindo nossa Manifestação e essa será a FORMA do POVO EXERCER O <br />
PODER DIRETAMENTE conforme ART 1º da CF, "O Poder emana do Povo que o <br />
Exe5rce por representantes OU DIRETAMENTE..."</span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> Somos O Poder Constituinte Originário !</span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> COMO POVO BRASILEIRO MASSIVAMENTE PRESENTE NAS RUAS, NÓS PODEMOS !</span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
Em prosseguimento, COMANDAREMOS ao PRESIDENTE E COMANDANTE SUPREMO DAS <br />
FORÇAS ARMADAS NOSSA INSTRUÇÕES DE QUE ATIVE O ARTIGO 142 DA <br />
CONSTITUIÇÃO E REALIZE A INTERVENÇÃO NAS INSTITUIÇÕES PARA DEFENDE-LAS <br />
DAS AÇÕES PERVERSAS DA ORGANIZAÇÃO CRIMINOSA QUE AS USURPARAM ! </span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
O COMANDO INTERPRETARÁ DEVIDAMNENTE A CONSTITUIÇÃO E A NOSSA ORDENAÇÃO <br />
PARA SUAS AÇÕES E DAS FORÇAS ARMADAS, NA DEFESA DO DIREITO DA NAÇÃO E <br />
NOSSAS INSTITUIÇÕES ! </span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> <a href="https://www.facebook.com/hashtag/30jun?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARBtr2Wdu_hiPsb7JechN1wfuD2NA6xsTflIo6s8iHRDa62V1Qi6JUgUeWNxKrkx1F9llFcrm2nuPOtVQuy5sePvHwA2byh1REqNRuMt9MncLVuOeOFG-aeJhI1i7QHFR0VubXXCgpN5cUOfdgCpzMKQ4y0vHcEGtsPuTDCj_qzUp0Me1JdEF8eBMq4mF4In9eXeihCr8ZhTsQmHlW-JXYlJWqUFc3Ss8NSe56FoNeaQ4LPjud_92FA-Mux_pmB0gYEEdfDWhaEuXsQ&__tn__=%2ANK-R-R">#30JUN</a> 30/06 DIA DA BASTILHA BRASILEIRA <a href="https://www.facebook.com/hashtag/bastilhabrasileira?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARBtr2Wdu_hiPsb7JechN1wfuD2NA6xsTflIo6s8iHRDa62V1Qi6JUgUeWNxKrkx1F9llFcrm2nuPOtVQuy5sePvHwA2byh1REqNRuMt9MncLVuOeOFG-aeJhI1i7QHFR0VubXXCgpN5cUOfdgCpzMKQ4y0vHcEGtsPuTDCj_qzUp0Me1JdEF8eBMq4mF4In9eXeihCr8ZhTsQmHlW-JXYlJWqUFc3Ss8NSe56FoNeaQ4LPjud_92FA-Mux_pmB0gYEEdfDWhaEuXsQ&__tn__=%2ANK-R-R">#BastilhaBrasileira</a> <a href="https://www.facebook.com/hashtag/povo?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARBtr2Wdu_hiPsb7JechN1wfuD2NA6xsTflIo6s8iHRDa62V1Qi6JUgUeWNxKrkx1F9llFcrm2nuPOtVQuy5sePvHwA2byh1REqNRuMt9MncLVuOeOFG-aeJhI1i7QHFR0VubXXCgpN5cUOfdgCpzMKQ4y0vHcEGtsPuTDCj_qzUp0Me1JdEF8eBMq4mF4In9eXeihCr8ZhTsQmHlW-JXYlJWqUFc3Ss8NSe56FoNeaQ4LPjud_92FA-Mux_pmB0gYEEdfDWhaEuXsQ&__tn__=%2ANK-R-R">#Povo</a>, <a href="https://www.facebook.com/hashtag/caminhoneiros?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARBtr2Wdu_hiPsb7JechN1wfuD2NA6xsTflIo6s8iHRDa62V1Qi6JUgUeWNxKrkx1F9llFcrm2nuPOtVQuy5sePvHwA2byh1REqNRuMt9MncLVuOeOFG-aeJhI1i7QHFR0VubXXCgpN5cUOfdgCpzMKQ4y0vHcEGtsPuTDCj_qzUp0Me1JdEF8eBMq4mF4In9eXeihCr8ZhTsQmHlW-JXYlJWqUFc3Ss8NSe56FoNeaQ4LPjud_92FA-Mux_pmB0gYEEdfDWhaEuXsQ&__tn__=%2ANK-R-R">#Caminhoneiros</a> e <a href="https://www.facebook.com/hashtag/soldadospatriotas?source=feed_text&epa=HASHTAG&__xts__%5B0%5D=68.ARBtr2Wdu_hiPsb7JechN1wfuD2NA6xsTflIo6s8iHRDa62V1Qi6JUgUeWNxKrkx1F9llFcrm2nuPOtVQuy5sePvHwA2byh1REqNRuMt9MncLVuOeOFG-aeJhI1i7QHFR0VubXXCgpN5cUOfdgCpzMKQ4y0vHcEGtsPuTDCj_qzUp0Me1JdEF8eBMq4mF4In9eXeihCr8ZhTsQmHlW-JXYlJWqUFc3Ss8NSe56FoNeaQ4LPjud_92FA-Mux_pmB0gYEEdfDWhaEuXsQ&__tn__=%2ANK-R-R">#SoldadosPatriotas</a>, </span></span><br />
<br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"> UNIDOS PARA DESTRAVAR O BRASIL !</span></span> <div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Tektonikehttp://www.blogger.com/profile/11170115271490637744noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-62992003726222718572019-06-25T05:18:00.004-03:002019-06-26T20:49:44.075-03:00TEKTONIKE ON VIMEO e Twitcasting TV-TEK Tektonike<center>
</center>
<center>
</center>
<center>
</center>
<center>
</center>
<center>
</center>
<center>
</center>
<center>
Uma Nova Moeda Vacina a Economia contra o que a Corrupção roubou pra fora do Sistema e força a lavagem ou a legalização !</center>
<center>
OTIMA SOLUÇÃO !</center>
<center>
A Ideia da Nova Moeda é Otima, precisamos desenvolver mais ideias sobre sua adoção ! <br />
Mas , sempre deveremos ter a Efigie de Marianne, representando a
Republica que é a Mensagem que a Nação Brasileira passa ao Mundo do
nosso Compromisso com o IMPÉRIO DAS LEIS na garantia de nossas moedas ! </center>
<center>
<iframe allow="autoplay; fullscreen" allowfullscreen="" frameborder="0" height="360" src="https://player.vimeo.com/video/344632529" width="640"></iframe></center>
<center>
</center>
<center>
</center>
<center>
Transmissões On Line e Tempo real pelo TwitCasting
</center>
<center>
<br />
<br />
<iframe allowfullscreen="" frameborder="0" height="360px" src="https://twitcasting.tv/fmcmello1/embeddedplayer/live?auto_play=true&default_mute=true" width="640px"></iframe>
<br />
<br />
</center>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Master Tektonikehttp://www.blogger.com/profile/16445303901402580247noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-13382457639510616622019-06-22T02:23:00.001-03:002019-06-22T02:29:54.644-03:00O Comportamento Ativista dos Membros da Suprema Corte que COMPROMETE A QUALIDADE DA JUSTIÇA NO BRASIL<div style="text-align: center;">
...<br />
É gravissimo o que acontece hoje em dia na Suprema Corte Brasileira e as consequencias do Ativismo de seus Membros !<br />
... </div>
<div style="text-align: center;">
<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/ChE5N-Rnmgk" width="560"></iframe>
</div>
<div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Master Tektonikehttp://www.blogger.com/profile/16445303901402580247noreply@blogger.com0tag:blogger.com,1999:blog-3644878695846633294.post-76423549762536613442019-06-20T13:11:00.001-03:002019-06-20T18:00:44.135-03:00A TEKTONIKE DO SER HUMANO<br>
<CENTER>
<BOLD>A TEKTONIKE DO SER HUMANO !
Quando a Tensão, o TONUS da Natureza Humana atinge ao Ponto de Transformação, quando as Energias Potenciais acumuladas se tornam Cinéticas e o Desenvolvimento do TAO prossegue seu curso de desenvolvimento rumo à PLENA MATURIDADE DO INDIVIDUO !
</BOLD>
</CENTER>
<br>
<CENTER>
<iframe width="560" height="315" src="https://www.youtube.com/embed/GxC-c2ysFoE" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
<br><BOLD><iframe width="560" height="315" src="https://www.youtube.com/embed/jf-nFPfkWro" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe></BOLD>
</CENTER>
<br>
<CENTER>
<br>
<br>
<iframe width="560" height="315" src="https://www.youtube.com/embed/fbAssT7rYQM" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
<br>
</CENTER><div class="blogger-post-footer">Tektonike copyright@2002_Fernando_C_de_Mello
Edificando as pessoas na Internet !
Visitem-nos e Adquiram nossos serviços !
https://go.hotmart.com/B64064148M?dp=1</div>Master Tektonikehttp://www.blogger.com/profile/16445303901402580247noreply@blogger.com0